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Abstract
An important role of cellular differentiation is to establish distinct and durable cell subsets that serve
different functions over the course of an immune response. Here, I investigate the problem of cellular
differentiation by considering 1) how epigenetic repression is overcome to establish unique preimmune
lymphocyte identity and 2) the durability of intraclonal and interclonal diversification resulting from an
immune response. The epigenetic states of hematopoietic cells contain cell-type specific accessible
chromatin structures which are developmentally constructed from repressive, compacted chromatin.
However, these structures feature binding sites for lineage-specific transcription factors, suggesting these
factors play a role in their generation. I used measurements of chromatin accessibility in sequential
stages of T cell development from bone-marrow derived progenitors alongside alternative lymphocyte
lineages to identify the central role that TCF-1 plays in creating T-cell specific chromatin during
differentiation. Genetic deficiency of TCF-1 reduced the accessible T cell chromatin state and the T cell
gene program, whereas the ectopic expression of TCF-1 in fibroblasts caused T cell chromatin to become
accessible and T cell genes to be expressed. These findings demonstrate that TCF-1 can overcome
repressive chromatin to establish a naïve T cell identity distinct from other lymphocyte lineages. Despite
our improved understanding of preimmune lymphocyte differentiation, much less is known about the
course of lymphocyte differentiation beyond the naïve stage. During immune responses, some activated B
lymphocytes express the transcription factor T-bet, but the clonal relationship to their T-bet- counterparts
and the durability of the T-bet+ phenotype is unclear. I found that T-bet+ B cells are generated early after
influenza infection and develop into a persistent memory pool. Immune repertoire profiling of influenza
hemagglutinin-specific T-bet+ and T-bet- memory B cells demonstrates that most clones are unique to
their respective subset, but lineage tree analysis of the remaining shared clones shows that T-bet+ clones
can stably bifurcate from T-bet- cells. Further, genetic fate-mapping indicates that T-bet expression in B
cells is stable. Together, these and other findings suggest that T-bet+ B cells are a distinct and durable
memory subset and uniquely contribute to the anti-viral humoral response.
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ABSTRACT
TRANSCRIPTIONAL LANDSCAPES IN LYMPHOCYTE DEVELOPMENT AND
DIFFERENTIATION: TCF-1 ENFORCES EPIGENETIC IDENTITY IN DEVELOPING T CELLS
AND T-BET RESOLVES FUNCTIONALLY DISTINCT MEMORY B CELLS
John L. Johnson
Michael P. Cancro

An important role of cellular differentiation is to establish distinct and durable cell
subsets that serve different functions over the course of an immune response. Here, I
investigate the problem of cellular differentiation by considering 1) how epigenetic
repression is overcome to establish unique preimmune lymphocyte identity and 2) the
durability of intraclonal and interclonal diversification resulting from an immune
response. The epigenetic states of hematopoietic cells contain cell-type specific
accessible chromatin structures which are developmentally constructed from repressive,
compacted chromatin. However, these structures feature binding sites for lineagespecific transcription factors, suggesting these factors play a role in their generation. I
used measurements of chromatin accessibility in sequential stages of T cell
development from bone-marrow derived progenitors alongside alternative lymphocyte
lineages to identify the central role that TCF-1 plays in creating T-cell specific chromatin
during differentiation. Genetic deficiency of TCF-1 reduced the accessible T cell
chromatin state and the T cell gene program, whereas the ectopic expression of TCF-1
in fibroblasts caused T cell chromatin to become accessible and T cell genes to be
expressed. These findings demonstrate that TCF-1 can overcome repressive chromatin
to establish a naïve T cell identity distinct from other lymphocyte lineages. Despite our
improved understanding of preimmune lymphocyte differentiation, much less is known
about the course of lymphocyte differentiation beyond the naïve stage. During immune
iv

responses, some activated B lymphocytes express the transcription factor T-bet, but the
clonal relationship to their T-bet- counterparts and the durability of the T-bet+ phenotype
is unclear. I found that T-bet+ B cells are generated early after influenza infection and
develop into a persistent memory pool. Immune repertoire profiling of influenza
hemagglutinin-specific T-bet+ and T-bet- memory B cells demonstrates that most clones
are unique to their respective subset, but lineage tree analysis of the remaining shared
clones shows that T-bet+ clones can stably bifurcate from T-bet- cells. Further, genetic
fate-mapping indicates that T-bet expression in B cells is stable. Together, these and
other findings suggest that T-bet+ B cells are a distinct and durable memory subset and
uniquely contribute to the anti-viral humoral response.
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CHAPTER 1: Overview of cellular differentiation

1.1 Cellular differentiation in the immune system and embryology

The theme of the 8th Midwinter Conference of Immunologists, held in California in
1969, was the Regulation of Cellular Differentiation in the Immune System. Seminal
discoveries made in the 1960s shed light on the importance of cooperation between two
distinct populations of lymphocytes, B and T cells, in the function of the adaptive immune
response. One can only speculate that the organizers felt it worthwhile to provoke new
patterns of thought on the matter by exploring connections to more established
disciplines. In fact, Ray Owen chaired the first session on “Principles of Cellular
Differentiation” with only two speakers: Clifford Grobstein (from UCSD) and Robert
Auerbach (from University of Wisconsin, Madison). The session was reported as
providing a “very fruitful interaction between two speakers disciplined in embryology and
an audience who were specialists in immunology (1).” These fruitful interactions included
discussion of the replication of the differentiated state, the different phases of cellular
development, and mechanisms of communication. Parallels were drawn between
embryonic development and the cellular interactions of thymus and bone marrow
derived lymphocytes as well as the stem cell concept in antibody formation; that is,
restrictive differentiation, environmental responsiveness, and cell multipotentiality. In his
closing remark, Grobstein noted, “both disciplines seek answers to similar questions of
differentiation, for example, the kind of regulation that occurs in cells … the nature of the
cue…and the steps in the instructive pathway (1).”
The intertwining of embryology and immunology has not faltered; it has instead
grown stronger with the continued discovery of important and distinct lymphocyte
1

subsets and the increasing appreciation for the epigenetic control of immune cell
differentiation, even serving at times as a model for metazoan development. Therefore,
the purpose of this overview is to accomplish a number of objectives: 1) to frame current
problems in lymphocyte differentiation in the time-tested framework of embryology 2) to
highlight the importance of studying lymphocyte differentiation, and 3) to describe the
systems I will use to investigate two aspects of lymphocyte differentiation.
The central theme of this dissertation is the cellular differentiation of the
lymphocytes of the adaptive immune system, both in their initial pre-immune
development and in their further antigen-experienced specialization. Comparisons will be
made in this overview to the developmental process occurring in embryogenesis, as this
is a tradition of thought extending back to Aristotle and greatly enhanced by brilliant
minds that followed. For both embryogenesis and the adaptive immune system, the
process of cellular differentiation is fundamental for the establishment of proper function
and form. In each process, a group of apparently homogenous cells becomes
permanently transformed in character and acquires a specialized function. In
gastrulation, the inner cell mass of the blastocyst forms the nervous system, the
notochord, the integument, and the gut. In hematopoiesis, stem cells form myeloid cells,
erythrocytes, granulocytes, and the T and B lymphocytes of the adaptive immune
system. In both cases, all of the parts contain specific types of cells, in the correct
proportions and position relative to one another, and carrying out the proper specialized
function. Therefore, the form of the question has remained the same in both processes
of development: to what extent and by what process do cells differentiate from their
progenitors and from each other?

2

1.2 Cellular differentiation, regional specification, and morphogenesis

Cell differentiation is the expression of gene products by a population of cells that
are different than those made by their progenitors and different from those made by
other populations of cells. Differentiation pervades nearly every aspect of multicellular
organisms occurring not only in the embryo, but also in the continual process of tissue
repair and homeostasis. Cell differentiation is a complex process requiring genetic and
epigenetic mechanisms of gene control, and embryonic development has laid the
conceptual groundwork, defined terms, and provided a framework for exploring these
mechanisms in all forms of differentiation.
Other developmental processes occur in the embryo but have more limited
parallels to lymphocyte differentiation. They are important, and I will touch on them
briefly. In early development, the core problem is regional specification. This is the
process whereby cells in certain regions of the embryo are turned onto certain pathways
of development. The most obvious parallel in the development of the adaptive immune
system is the regional specification that occurs when lymphocyte precursors enter the
thymus and are specified to become T lymphocytes. Whether a type of regional
specification occurs in the peripheral lymphatics during the lifetime of mature
lymphocytes is an interesting question, but not one that will be addressed in this
dissertation. Regional specification is not to be confused with cell differentiation, as
these are both important but distinct problems.
The developmental process of least concern to us, because it has the least
obvious parallel, is morphogenesis or the creation of form. This term is used to describe
the cell and tissue movements that shape the organism. However, leukocytes are unique
3

in that cells operate more or less as individual, mobile units. As such, comparisons made
of lymphocyte movements to the behavior of tissues would have to be made at an
abstract level. However, lymphocytes clearly demonstrate coordinated behaviors such
as the orderly trafficking of immature T lymphocytes through thymic structures during
development or the aggregation of mature B cells in follicles in peripheral lymphatics.
Although the mechanical and physical components of morphogenesis are not as directly
applicable to lymphocytes, the chemically directed components of this process are more
closely shared. Despite the importance of morphogenesis in embryonic development,
morphogenesis is largely the consequence of cellular differentiation.
1.3 Cellular differentiation is a developmental hierarchy

In embryogenesis, the parts to be developed in the basic body plan are not
specified all at once but are formed as a hierarchy of developmental choices. Perhaps
not surprisingly, a developmental hierarchy also exists in hematopoiesis. Figure 1
illustrates the subdivisions of the developmental choices made during hematopoiesis.
Setting aside discussions about details of the diagram, the familiar cell-types the
developed immune system are found at the bottom of the tree. These cell-types are
preceded by a series of prior commitment choices. At each of these a choice is made
between increasingly restricted alternative states arising from a subdivision of an earlier
less committed progenitor. Every decision is made among a small number of alternatives
and a new state of commitment is adopted with further restriction of potency. Upon
reaching terminal differentiation, potential has been exhausted, and the cell persists in
its final state until its death. The difficulty of deducing the arrangement of these fate
decisions lies in the largely covert nature of the cell state that can only be uncovered by
4

experimentally probing for remaining lineage potential. Despite this difficulty, the
organization of cell fate choices into a hierarchy has provided a useful framework for
understanding the gene control mechanisms of differentiation, and these molecular
mechanisms will be discussed below.
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MEP
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NK
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Figure 1. The hierarchy of development in hematopoiesis.
The formation of blood cells occurs by a process of progressive determination and fate
restriction. The property of self-renewal is lost at the onset of differentiation, but
hematopoietic progenitors initially maintain their pluripotency for all subsequent lineages.
As differentiation proceeds alternative fate choices are gradually lost as cells commit to
a lineage. The hematopoietic system is therefore built up as a result of a hierarchy of
decisions and several fate choices will be made before the cells differentiate into the
mature cell types shown at the bottom. The mechanisms underlying this process are
discussed in Chapter 2. For some cell-types, such as B and T cells, further differentiation
will occur after encountering antigen in an immune response and this will be discussed
in Chapter 3.
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1.4 Differentiation is organized at the genetic level by transcription factors

The process of restrictive differentiation that occurs during both embryogenesis
and hematopoiesis is the consequence of the regulatory system controlling gene
expression. Differentiation is the establishment of a new regulatory state that can be
thought of as the cumulative activity of particular sets of DNA-binding transcription
factors coordinating their activity at non-coding DNA and determining gene expression.
Regulatory states are interpreted by the DNA sequence elements composed of clusters
of transcription factor binding sites called cis-regulatory modules (CRM) or enhancers. It
is the binding of a transcription factor to a CRM that allows the transcription factor to
modulate the expression of nearby target genes, and the integration of all transcription
factors at the CRM produces a unique regulatory output. However, the availability of a
CRM for binding by the transcription factor, and therefore the contribution of the CRM to
the regulatory state, is controlled by the proteins that package DNA, collectively called
chromatin. The regulatory state encoding the prior cell identity can therefore be made
irrecoverable by two mechanisms: 1) transcription factors acting in the prior regulatory
state either cease to be expressed or 2) the previously available CRMs are made
inaccessible by the closing and compaction of chromatin. These mechanisms provide
directionality to differentiation, allowing signaling inputs to activate transcription factors
on the newly accessible chromatin and not at previously active chromatin. Thus,
restrictive differentiation is a consequence of the interplay between transcription factors,
DNA sequence elements known as CRMs, and the chromatin.
The hierarchical and ordered nature of development is also the consequence of
the integration of transcription factor activity at chromatin-controlled CRMs. The
6

interpretation of the current regulatory state at the available CRMs results in a regulatory
output that may induce new transcription factors or other regulatory genes. The addition
of transcription factors to a regulatory state specifies new modes of gene regulation that
can have multiple outcomes: 1) the process of differentiation continues by inducing the
expression of additional lineage-related regulatory genes or transcription factors, 2) the
cell is made competent for an alternative lineage by becoming receptive to new signal
inputs, or 3) the developmental process ends without inducing new transcription factors
and by expressing structural genes associated with terminal differentiation. Thus, the
contribution of transcription factors to differentiation is inextricable from the
developmental sequence because their activity is dependent on the developmental
history of the cell to establish a responsive regulatory state and to prime the chromatin
for action at appropriate CRMs.
However, cellular differentiation is rarely the result of the expression of a single
gene. Thomas Hunt Morgan used the term “gene battery” in 1934 to refer to the
functionally related effector genes that are coordinately expressed in a given cell type
upon differentiation. The CRMs regulating these gene batteries share lineage-specific
transcription factor binding sites, but the chromatin is often closed at these CRMs. How
is the cell-type specific accessibility at these gene batteries established during
development? Recent research has demonstrated that lineage-specific transcription
factors known as Pioneer Transcription Factors (PTFs) or Lineage-Determining
Transcription Factors (LDTFs) establish accessible chromatin at the CRMs of their
corresponding lineage through positive interactions with the normally repressive
chromatin (2, 3). LDTFs add new modes of regulation to the already existing regulatory
state by acting on the “tabula rasa” of the chromatin to create de novo accessibility and
7

establish competent and active CRMs. Because LDTFs are not inhibited by closed
chromatin they can reprogram cells or cause trans-determination when ectopically
expressed, and their identification has opened the door for new therapeutic options
involving cellular engineering through the manipulation of cell identity. Identifying the
LDTFs acting in T cell development will the focus of chapter 2.
Questions of mechanism have remained at the forefront of the field since the
advent of molecular biology in the 1980s, and for good reason. The models of genetic
control proposed by Jacob and Monod in 1961 (4) and Britten and Davidson in 1969 (5)
cannot be adequately tested at the cellular level. Advanced molecular techniques such
as microarrays and next generation sequencing have only intensified the investigation
into the molecular workings of differentiation. However, the questions being addressed
by these tools were the questions initially proposed by earlier embryologists. The basic
observation of development is the cell is the fundamental unit by which biological
systems are organized at the organismal level. As such, breaking down any cellular
system, such as the immune system, requires an understanding of the differentiative
events at the cellular level. Without this framework, making sense of the molecular
mechanisms driving differentiation would not be possible. For that reason, I will discuss
two additional embryological concepts, albeit familiar to an immunologist, that will be
explored in chapter 3.
1.5 Additional embryological concepts: the fate map and clonal analysis

The first of these concepts is the fate map. Fate mapping is fundamental to
embryology and just as important to immunology. Regional specification is the core
problem of embryonic development and the fate map is a diagram indicating what each
8

specified region of the early embryo will turn into. To create a fate map, the trajectory of
the cells must be tracked throughout development. For some organisms, the fate of each
individual cell can be tracked with great precision whereas other organisms tolerate
some degree of cell mixing between adjacent regions and thereby reducing the
resolution of the fate map. As long as the random mixing of cells is minimal, the fate map
tells you what organs and limbs each cell will become and allows faithful cell lineages to
be constructed. To the immunologist, fate mapping can establish critical lineage
relationships that are normally obscure for a number of reasons: 1) the longitudinal study
of immune cell differentiation, especially those located in tissues, is often not possible, 2)
a specific immune response does not develop in isolation as an embryo does but is
surrounded by cells differentiating at various stages from other immune responses, and
3) the terminal fate is normally indistinguishable even while differentiating cells take
different developmental trajectories to the terminal fate. The fate map can also help
determine whether a cell state is stable or merely represents a temporary phenotype,
and this is especially useful for studying lymphocyte differentiation. For both embryology
and immunology, the cell lineage established by fate mapping places the genetic and
epigenetic mechanisms of differentiation into the context of prior and future molecular
events. Thus, the interpretation of experiments on developmental decisions depends on
the fate map. However, fate mapping alone does not provide information on commitment
as it only reveals what will become of cells if left in place.
The second concept, clonal analysis, is related to the fate map, but differs
because it allows us to say something about commitment and determination.
Determination means that a cell is intrinsically committed to develop into a specific cell
type or a structure. To illustrate, a single cell may form cell type A or cell type B, or
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neither, but the undifferentiated cell could not have been determined if the clone
develops into both cell types. An important consideration to make concerns the inverse
of this principle: if the cell differentiates into one cell type, but not the other, then this
clonal restriction does not mean determination has occurred. However, not all
developmentally significant forms of clonal restriction need occur through an internal,
genetic mechanism of determination. Clonal restriction can also occur by the existence
of an extracellular barrier limiting mixing of unrestricted cells and thereby maintaining
stable and distinct cell identities. Moreover, fate mapping is often done in the embryo by
labelling groups of cells, but the analysis of a clone provides information about the
individual behavior, the resulting lineages, and the contribution of a cell to a particular
structure. This information is particularly important for studying lymphocyte immune
responses as they are typically polyclonal, and clonal analysis can distinguish which
clones contribute to certain effector or memory cell populations.
1.6 Cellular differentiation is central to adaptive immune system function

Why frame the lymphocytes of the adaptive immune system immunology in terms
of embryonic development? Given the importance of the immune system in protecting us
from pathogens, it’s no surprise the mammalian immune system relies on cellular
specialization through stable cellular differentiation as the basis of its functional
organization. Therefore, the study of differentiation itself and the mechanisms governing
differentiation, are of upmost concern to an immunologist. As encapsulated in the clonal
selection theory (6), the differentiation of lymphocytes occurs in two phases. The first
phase is the establishment of a preimmune pool of T and B cells bearing clonally
distributed receptors for antigen. At homeostasis, prior to antigen or pathogen exposure,
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the cells of the immune system develop from the progressive determination of postembryonic stem cells according to control principles similar to those in operation during
organismal development. The development of the embryo is a self-directed, hierarchical
process, and similarly the immune system differentiates according to an internally
regulated and genetically encoded developmental hierarchy. As such, both
developmental programs are conducted without much regard to the outside world. The
precise gene regulation necessary for this process of differentiation is supported by the
regulated packaging and post-translational modification of chromatin and histones
directed by lineage-specific transcription factors. In chapter 2, I explore the lineagespecific transcription factors guiding chromatin accessibility and chromatin modifications
in the context of the developmental sequence that transforms uncommitted
hematopoietic progenitors to mature, preimmune T cells.
In the second phase of lymphocyte differentiation, sufficient antigen receptor
occupancy causes the activation of the lymphocyte, initiates mitosis, and primes the cell
to receive differentiative signals. The response is not random; activated lymphocytes
differentiate according to the circumstances of the infectious challenge and the type of
pathogen encountered. Although stereotyped responses exist, new subsets of cells are
still discovered as techniques are developed that afford more precise resolution.
Accordingly, chapter 3 addresses the extent to which lymphocytes, particularly memory
B cells, develop into multiple subsets in response to infection, and interrogates the
differentiative relationship between these subsets.
The concepts discussed in this overview have been adapted from Jonathan Slack’s
From Egg to Embryo (7) and Eric Davidson’s The Regulatory Genome: Gene Regulatory
Networks in Development and Evolution (8).
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2.2 INTRODUCTION
2.2.1 The diversity of blood cells develops from hematopoietic progenitors
Eukaryotic organisms express genes in incredibly diverse patterns that are
necessary for biological complexity (10). This transcriptional diversity is largely controlled
by the interactions between transcription factors and their cognate DNA binding sites
within accessible chromatin regions. However, eukaryotic genomes are compacted to fit
over a meter of DNA within the limited volume of the nucleus and this compaction is
inherently repressive to processes that require access to the DNA sequence (11).
Despite the inherently repressive state of chromatin, a number of lineage-instructive
transcription factors alone or in cooperation with their partners can access a subset of
their binding sites even if it is partially occluded by nucleosomes, recruiting chromatinremodeling enzymes and exposing the underlying DNA. The distinctive collection of
such accessible sequences controls the transcriptional output of a cell type and
determines its functional characteristics (12).
Hematopoiesis is an excellent system for studying lineage-instructive
transcription factors and their roles in establishing chromatin accessibility as the
differentiation of the diverse and well-defined cell-types of the blood is continuous
throughout life. Hematopoiesis originates primarily in the fetal liver but is relocated to the
bone marrow at birth, serving as the source of hematopoiesis through adult life (13). The
process of hematopoiesis begins with the hematopoietic stem cell (HSC) (14) that is
subdivided by lifespan into two major cell subsets. Long-lived HSCs (LT-HSCs) are selfrenewing and can generate all the major lineages of the blood through asymmetric
division, whereas short-term HSCs (ST-HSCs) generate all blood lineages but self13

renew only for approximately eight weeks (15). A mixture of LT-HSCs and ST-HSCs can
be distinguished by the absence of surface markers expressed on mature cell types
(Lineage, or Lin), and the presence of Sca-1 and the cytokine receptor Kit (LSK, LinSca1+Kit+). Further, the SLAM marker CD150 more definitively identifies LT-HSCs within
the LSK compartment (16).
As in other developmental systems, hematopoiesis follows a developmental
hierarchy in which lineage potential and self-renewal is lost as cells differentiate. Thus,
LT-HSCs give rise to ST-HSCs with diminished capacity for self-renewal and ST-HSCs
in turn give rise to multipotent progenitors (MPPs) which have no capacity for selfrenewal but are multipotent (17). At this point, a fate choice is available, and the cell
either continues differentiation towards an erythrocyte lineage or the myeloid and
lymphoid lineage depending on cytokine cues. Cell that lose megakaryocyte potential
but retain lymphoid and myeloid potential are thus named lymphoid-primed MPPs
(LMPPs) (18). The LMPP subset expresses Flt3 and gives rise to the common lymphoid
progenitor (CLP) that was originally thought to be lymphoid restricted, but actually
retains significant myeloid cell potential (19). The cell surface marker Ly6D further
differentiates CLPs into those with restricted potential for the B lineage (LyD+ CLPs)
versus those with T, NK, B, and DC potential (20). However, many developmental
decisions at this early stage are still plastic and not yet fully determined. For instance, a
subset of common myeloid progenitors (CMP) expressing Flt3, but lacking CD150
expression possesses T cell potential that can be revealed using single cell assays in
vitro under T-inductive conditions (21). Despite possessing this T cell potential, this
subset does not have the ability to home to the thymus (21), the site of T cell
specification and development (22, 23). This clonal analysis is a good illustration that an
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apparent clonal restriction in vivo does not necessarily coincide with developmental
restriction as potential is determined by both intrinsic genetic mechanisms and external
instructive mechanisms. Therefore, progenitors must possess T lineage potential as well
as the ability to reach the organ of T cell specification to develop into T cells.
2.2.2 T cell development occurs in the thymus

T cell development is unique among the blood lineages because it is completed
in a specialized organ, the thymus, and homing to the thymus from blood-mobilized bone
marrow progenitors is necessary for T lineage specification (24). T cell development
begins when these rare progenitors settle the thymus, but very few are estimated to
reach the thymus each day (25). However, migration to the thymus appears to be a
regulated process and not a stochastic one as not all bone marrow progenitors are
equally capable of thymic settling. For instance, HSCs do not settle the thymus yet hold
profound T cell potential. Conversely, LMPPs and CLPs both settle the thymus and
possess T cell potential (26). However, it is unclear which, if either, are the true
progenitors. Unlike HSCs, both subsets express the chemokine receptors C-chemokine
receptor-7 (CCR7) and C-chemokine receptor-9 (CCR9) which are essential for thymic
settling (27, 28). P-selectin glycoprotein 1 (PSGL) is also necessary for thymic homing
and promotes homing when the thymic niche empties (29, 30).
The inception of T-lineage cells occurs when bone marrow-derived multipotent
precursors seed the thymus and give rise to early thymic progenitors (ETP) (31, 32).
ETPs reside within the CD4-CD8-CD44+CD25-Kithi double negative 1 (DN1) subset and
are defined by the absence of lineage-associated markers and CD25 while also
expressing Kit and CD44 (LinloKithiCD25-). ETPs are rare, making up 0.01% of
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thymocytes, but can generate all thymic lymphoid populations. However, ETPs are not
determined or developmentally restricted to the T lineage. ETPs must pass through
additional stages of differentiation before becoming mature T cells and they retain
differentiative potential for alternative fates, including NK and myeloid cells, which is
revealed when ETPs are removed from T-inductive signals (33-36).
The potential to develop into alternative fates is gradually lost as T cell
differentiation proceeds, and the process of development is associated with an orderly
trafficking through anatomic structures of the thymus. ETPs migrate from the
corticomedullary junction in the perimedullary cortex to the inner cortex while
differentiating into DN2 cells (CD44+Kit+CD25+) (37). However, DN2 cells are
heterogenous as was first demonstrated by examining the expression of the lymphocyterestricted kinase Lck using a GFP reporter (38). Lck- DN2 cells retain DC and NK
lineage potential that is revealed after removing Notch signals whereas Lck+ DN2 cells
do not, even if removed from Notch signals. Thus, a key regulatory event seems to occur
in the DN2 compartment. DN2 heterogeneity is further refined by using the level of Kit
expression with DN2a cells being Kithi and retaining alternative lineage potential whereas
DN2b cells are Kitint and are firmly committed to T cell development (39). Further, the
regulatory event occurring between DN2a and DN2b that enforces lineage commitment
is the initiation of Bcl11b expression through the combinatorial activity of transcription
factors at the Bcl11b locus (40).
DN2b cells then become DN3 cells, move to the subcapsular zone, and undergo
rearrangement of the T cell receptor (TCR) at the β, γ, and δ loci as these loci become
accessible and the recombination activating gene 1 (RAG1) and RAG2 are expressed
(41, 42). A small number of developing T cells will rearrange the γ and δ loci and
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become γδ T cells, but most DN3 cells (>95%) will rearrange the β locus and continue
development to become conventional αβ T cells (43, 44). Cells rearranging the β locus
are held at the β selection checkpoint until a productive, in-frame, recombination of the β
locus leads to expression of the β chain of the TCR that pairs with a surrogate α chain
(pre-T-α) for trafficking to the cell surface (45). The signaling accompanying this process
causes DN3 cells to downregulate RAG expression and enforce allelic exclusion of the
other β chain allele (46). DN3 cells passing β selection differentiate into DN4 cells and
undergo a burst of proliferation that replicates the successful β-chain rearrangement into
multiple daughter cells before the TCR co-receptors CD4 and CD8 are upregulated and
the DN4 cell becomes a CD4+CD8+ double positive (DP) cell and migrating back to the
cortex (47). The TCRs are tested for MHC binding in a process of positive selection
wherein DP cells that bind MHC II become CD4 single positive cells and MHC II
restricted whereas DP cells that bind MHC I become CD8 single positive cells and MHC
I restricted (48-50). Cells that fail to bind MHC will fail to receive survival signals from the
TCR and therefore ‘die by neglect.’ However, binding that is too strong to MHC will
cause the cell to undergo negative selection and undergo apoptosis or possibly
differentiate into regulatory T cells if MHC II restricted (51). Finally, T cell development
ends in the medulla and fully competent mature T cells emigrate from the thymus by
entering the blood stream (52).
2.2.3 Transcription factors acting in T cell development

Notch1, an evolutionarily conserved signaling pathway involved in multiple
developmental processes, initiates the T cell fate decision when Notch1 on the surface
of bone marrow progenitors settling the thymus interacts with Delta-like Notch ligands on
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the epithelial cells in the thymus (53). Mammals have four Notch homologues, Notch 14, and two families of ligands, Delta-like and Jagged, but the engagement of Notch1 with
Delta-like ligands in the thymus is critical for T cell development. DL-1 and DL-4 both
induce Notch1 signals and induce T cell development, but DL-4 is the most abundant
ligand in the thymus (54). Notch receptors that engage ligand undergo cleavage events
mediated by a metalloprotease and γ-secretase to release the intracellular domain of
Notch1 (ICN) for translocation to the nucleus. ICN binds the transcription factor CSL
(CBF1/Su(H)LAG1), also known as RBPJ (recombination signal combining protein-J),
and recruits mastermind-like (MAML) protein to act as a scaffold for the binding of coactivators such as p300 and the activation of the T cell gene program (55, 56). Notch
signals and transcriptional activation by ICN is crucial for generating ETPs and ectopic
expression of ICN is sufficient to induce T cell development in bone marrow progenitors
outside the thymus but is also oncogenic (57, 58). Notch1 also represses the
development of alternative fates. For instance, Notch1 inhibits B cell development in the
BM when ICN is ectopically expressed in bone marrow progenitors (59). Removing ETP
or DN2a cells from Notch1 signals allows non-T cell fates to develop indicating that
alternative fates are suppressed by Notch1 signals in early T cell progenitors (60).
The Ets family transcription factor PU.1 is a winged helix-turn-helix transcription
factor critical for establishing a gene regulatory program in bone marrow progenitors
conducive for T cell specification (61). The role of PU.1 in B and myeloid cell
development is well-established, and both lineages highly express PU.1 (62). However,
PU.1 is also expressed in early T cell progenitors in the DN stages but must decline for T
cell commitment to proceed (63). The dose of PU.1 in T cell progenitors strongly
influences fate commitment, and enforced PU.1 expression blocks commitment and
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diverts DN3 thymocytes to the myeloid lineage, but only when Notch1 signaling is
abrogated (63). Thus, while necessary for bone marrow progenitors to initiate T cell
specification, PU.1 must be precisely regulated to remove undue influence on pre-T cells
to develop into alternative fates (64). As such, PU.1 is downregulated at the DN2a and
DN2b transition, and TCF-1 and RUNX1 are important for this repression (65, 66).
However, the mechanisms of the timing of this downregulation are unclear as TCF-1 and
RUNX1 are both expressed highly in ETPs.
Other ubiquitous transcription factors, including E proteins, play an important role
in early T cell development (67). Members of the basic helix-loop-helix family (bHLH), E
proteins regulate transcription in many hematopoietic lineages and are suppressed by ID
proteins that dimerize with E proteins but lack a DNA-binding domain. Two splice
variants of the E2A gene, E12 and E47, are encoded by the Tcfe2a locus and are critical
for early B and T cell development (68). E2A regulates Notch1 transcription in early T
cell progenitors and synergizes with Notch to regulate key T cell genes (69). Another
bHLH member, HEB, is highly expressed in the thymus, but HEB deficiency manifests at
a later block in T cell development compared to E47 deficiency (70). ID3, an Id family
member, is induced by pre-TCR signals and inhibits E protein activity and Notch1
transcription (71). As such, E2A binding drops dramatically in β-selected thymocytes.
Zinc finger transcription factors, such as GATA3, also play important roles in T
development (72). GATA3-deficient hematopoietic progenitors generate normal numbers
of LMPPs and CLPs but show a deficiency in early T cell development (73). Conversely,
GATA3 does not enhance T cell development when overexpressed in bone marrow
progenitors unlike Notch and other key T cell transcription factors. Similar to PU.1,
GATA3 levels must be precisely controlled as overexpression of GATA3 diverts cells to
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the mast cell lineage when Notch signals are removed (74). Another zinc finger
transcription factor, Bcl11b, is likewise important for T-lineage commitment. Bcl11b is
expressed in DN2a cells at the point of T cell commitment and deletion of Bcl11b in DN
T cells causes an incomplete developmental block at the DN2a stage (75, 76).
Importantly, stem cell genes and alternative lineage fates such as myeloid and NK cells
increase when Bcl11b is deleted in DN2a progenitors (77). Deletion of Bcl11b later, in
DN3 and DP stages, causes diversion of T cells to the NK fate while also losing the T
cell gene program (77). Together, this indicates that the role Bcl11b plays in T cell
commitment is primarily in repressing alternative lineages and maintaining T cell identity
in a manner similar to PAX5 in the B lineage (78).
2.2.4 HMG Box transcription factors: TCF-1 and LEF-1

The High Mobility Group (HMG) Box transcription factors are a superfamily
dating back 1 billion years and can be divided into two major groups based on
sequence-dependent and sequence-independent DNA recognition, including the
TCF/SOX and HMG/UBF families, respectively (79). Members of the TCF/SOX family
have one HMG Box binding domain that binds the (A/T)(A/T)CAAAG motif whereas
HMG/UBF members contain multiple HMG Box domains and bind DNA non-specifically
(80). HMG Box domains bind unwound non-B-type DNA and alter DNA architecture by
inducing bends in the DNA backbone upon binding (81). This distortion of DNA is the
result of DNA contacts made between the HMG Box and the minor groove of the DNA
helix. HMG Box containing transcription factors have been proposed to play an
architectural role, bending the DNA backbone to allow binding of other transcriptional
regulators to the DNA and the formation of nucleoprotein complexes and occurs, for
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example, at the TCRα enhancer (82).
The two lymphoid-specific HMG Box transcription factors are T cell factor 1
(TCF-1) and lymphoid-enhancing factor-1 (LEF-1). TCF-1 is encoded by the gene Tcf7
and was identified in the early 1990s by Hans Clever who cloned TCF-1 from a human T
cell line as a transcription factor bound to the CD3ε enhancer (83). LEF-1 was also
identified in 1990 soon after at the human immunodeficiency virus (HIV) promoter and
was originally named TCF-1α while the mouse homologue was denoted as LEF-1 (84).
TCF-1 and LEF-1 are highly conserved in the HMG Box domain and share 98%
similarity and are believed to have arisen through gene duplication (85). High level of
TCF-1 expression is restricted to the T-lineage and LEF-1 is B and T-specific (86).
Genetic deletion of TCF-1 results in dramatically reduced thymic cellularity and multiple
blocks in T cell development (87). T cell development in LEF-1 deficient mice is largely
normal, but exhibit defects in B cell development (88). Moreover, LEF-1 may
compensate for TCF-1 as the genetic deficiency of both transcription factors causes an
absolute block in T cell development (89).
Canonically, TCF-1 and LEF-1 are the transcriptional effectors of the
evolutionarily conserved Wnt signaling pathway (90). The Wnt pathway regulates
numerous developmental systems including embryonic patterning, cell-fate decisions,
and tissue homeostasis (91). Wnt proteins are released and bind to Frizzled/low density
lipoprotein receptor related protein complex on the cell surface of target cells (92). In the
target cell, the transcriptional regulator β-catenin is maintained at low levels in the
cytoplasm through constant degradation. Degradation is lifted when Wnt signals are
received by the complex containing glycogen synthase kinase-3β (GSK-3), Axin,
Adenomatous Polyposis Coli. The accumulation of β-catenin allows for nuclear
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translocation and binding to TCF-1 and LEF-1 to activate transcription. In the absence of
nuclear β-catenin, TCF-1 and LEF-1 are believed to be transcriptionally repressive by
associating with the Groucho/TLE family of repressors (93). Thus, β-catenin displaces
Groucho/TLE and converts TCF-1 and LEF-1 to transcriptional activators (94). However,
loss-of-function studies for β-catenin does not diminish T cell development despite the
clear role of TCF-1 in activating target T cell genes (95, 96).
Finally, there are multiple isoforms for TCF-1 including multiple splice variants of
TCF-1 ranging from 25-55 kD. Further, TCF-1 has two promoters, 1 kb apart, that drive
transcription of two major isoforms (97). The upstream promoter transcribes the ‘fulllength’ TCF-1 isoform, called p45, and the downstream promoter transcribes the shorter,
p33, isoform of TCF-1. The 5’ coding region of the full-length isoform encodes the βcatenin interaction domain that the p33 isoform lacks. Thus, the p33 isoform is
speculated to be the repressive isoform of TCF-1. However, the mechanisms governing
the abundance of each isoforms is unclear.
The distinct phases of T cell development in the thymus are controlled by the
upregulation of transcription factors including TCF-1, GATA3, and Bcl11b as well as the
repression of alternative-lineage factors such as PU.1 and Bcl11a. Notch signaling is
indispensable in driving specification but is transient and only active up through the βselection checkpoint. The earliest T cell-specific transcription factor is TCF-1, encoded
by Tcf7, which is steeply upregulated in T cell progenitors by Notch1 signaling and
sustained until maturation. TCF-1 can positively regulate GATA3 in addition to Bcl11b,
which is necessary for T lineage commitment (40, 75). Transcription factors required in
other hematopoietic differentiation programs such as E2A and its relatives, Ikaros, Gfi1,
Myb, and RUNX1 are also essential in T cell development (98, 99). Despite the broad
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knowledge on the functions of these transcription factors at distinct developmental
stages, it remains unclear which ones shape the chromatin accessibility of mature T
cells in the thymus.
Numerous studies in macrophages and B cells illustrate the emergence of
accessible chromatin commanded by lineage-determining transcription factors (12, 100106). The pervasive patterns of PU.1 binding to thousands of genomic regions are
closely related to the permissive chromatin state in macrophages (101). EBF1 can
induce lineage-specific chromatin accessibility in B cell progenitors (103, 104). In
addition to instructing development, transcription factors can also play key roles in cell
reprogramming. For example, C/EBPα can induce transdifferentiation of B cells into
macrophages at high efficiency by activating regulatory elements of macrophages (105).
Despite numerous studies of CD4+ T helper cell differentiation (107-111) and
CD8+ T effector responses (112-117), and many reports on the dynamics of histone
modifications during T cell development (118-120), we have a limited understanding of
transcription factors shaping the chromatin accessibility of mature T cells in the thymus.
2.2.5 Scope

By mapping chromatin accessibility at eight stages of thymic T cell development
in mice, we found the significant enrichment of TCF-1 motif and binding events at
genomic regions that become accessible at the earliest stage of development and
persist until T cell maturation. While TCF-1-deficient mice show a severe reduction in
thymocyte numbers (87) and ectopic TCF-1 in bone marrow progenitors can drive the
expression of T-lineage genes (121), the mechanism through which TCF-1 controls T
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cell identity remains unclear. Some T-like cells continue to develop in the absence of
TCF-1 although they are functionally limited in terms of differentiation, and memory T
cells lacking TCF-1 are also defective (122). In line with these studies, we found that Tlike cells in TCF-1-deficient mice cannot establish the open chromatin landscape and
transcriptional profile of normal T cells. Moreover, TCF-1, but not RUNX1 or GATA3,
could dictate a coordinate chromatin opening in single cells that follow a T cell trajectory
amongst a vast landscape of possible states, suggesting a unique property for this
lineage-determining transcription factor. Gain of function experiments in fibroblasts
further revealed the ability of TCF-1 to bind to previously occupied nucleosomes,
generating de novo chromatin accessibility even at condensed chromatin regions and
inducing the expression of T cell-restricted genes ordinarily silenced in fibroblasts.
Remarkably, a subset of these binding events further erased the pre-existing repressive
marks in fibroblasts, highlighting the ability of this transcription factor to substantially
target closed chromatin. Collectively, our results identify the role of TCF-1 in the making
of chromatin accessibility at T cell genes and reveal an unprecedented means through
which this protein controls the epigenetic identity of T cells.

2.3 RESULTS

2.3.1 Three waves of chromatin remodeling during T cell development

To elucidate the developmental stages in which the open chromatin landscapes
of mature CD4+ and CD8+ T cells are established in the thymus, we assessed chromatin
accessibility at eight stages of development including ETP (also referred to as DN1),
DN2a, DN2b, DN3, DN4, DP, CD4+, and CD8+ T cells using ATAC-seq (STAR Method).
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To identify T cell-specific regulatory elements, we compared these maps with those of
progenitor cells including hematopoietic stem cells (HSC), multipotent progenitors
(MPP), and common lymphoid progenitors (CLP) in addition to B and NK cells. Initial
steps of the analysis led to the characterization of 35,869 open chromatin regions with
differential accessibility levels across cell states. Our unsupervised clustering of these
regulatory elements revealed patterns of gain and loss of chromatin accessibility as cells
progress from early to terminal stages of T cell fate determination (Figures 2A and S1AB). We aggregated patterns of gain and loss in chromatin accessibility into broader
meta-clusters capturing selective opening in early, intermediate, and late phases of
development. Our data show that the sustained accessibility of mature T cells is
established in three distinct waves: “early” at ETP (1,705 regulatory elements, cluster 9),
“intermediate” after commitment at DN2b (1,399 regulatory elements, cluster 19), and
“late” at the single-positive stage (1,917 regulatory elements, cluster 10) (Figure 2 A-B).
In addition, a set of genomic regions that became open early was shared between T and
NK cells (1,445 regulatory elements, cluster 7). Notably, our data revealed a pattern of
gain and loss of accessibility as 75% (9,071) of regulatory elements that became
accessible at the early ETP stage were dismantled before T cell maturation (“Open Early
in T” meta-cluster, Figure 2A). These results demonstrate an unexpected dynamic in the
remodeling of the regulatory landscape with distinct expansions and restrictions of
regulatory elements during T cell development.
2.3.2 TCF-1 is the top enriched transcription factor in mature T cell clusters

We reasoned that the transcription factors that can bind to nucleosomal DNA in
progenitors and create the chromatin accessibility landscape of terminally differentiated
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cells should be enriched within regulatory elements that selectively become open in that
lineage. To find transcription factors with such characteristics, we inferred their
occupancy in cell and stage-specific regulatory elements by performing motif analysis
(106). B-cell specific open chromatin regions were enriched with motifs of EBF1, a
transcription factor which has been previously reported to create the accessibility of
regulatory elements in B cells (Figure S1C) (103, 104). Furthermore, Tbox, ETS, and
GATA motifs were highly enriched among regulatory elements of NK and progenitorspecific cells (Figure S1C). In T cells, recognition sites for TCF, a high-mobility group
(HMG) family of proteins, were the top enriched motif in the early, intermediate, and late
waves of chromatin opening that persisted until T cell maturation (clusters 9, 19, 7, and
10) (Figure 2C-E). Notably, E2A, ETS and Runx recognition sites were among the
second and third motifs in these clusters (Figure S1C). Similar analysis on chromatin
accessibility maps of human T cells revealed the enrichment of TCF motifs within T cellspecific open chromatin of human naïve T cells, suggesting the conserved role of this
transcription factor in humans and mice (Figure S1D).
Among TCF family transcription factors, TCF-1 is induced early at the inception
of T lineage cells. To further substantiate direct binding of TCF-1 in comparison to other
T cell related transcription factors including GATA3, RUNX1, and PU.1, we calculated
the number of genomic regions within each cluster bound by these transcription factors
using ChIP-seq (STAR method). As predicted by the enrichment of its motif, TCF-1
bound to around 70% of the genomic regions within the early and intermediate T cell
specific clusters in addition to 24% of the late T cell cluster. This contrasts with RUNX1
and GATA3 binding events at less than 17% of the genomic regions within T cell-specific
clusters (Figure 2F). Moreover, the highest odds ratio was associated with TCF-1
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binding events in early and intermediate T cell clusters in particular clusters 9, 7, and 19
(Figure 2F). Of note, the early regulatory elements deactivated before maturation were
enriched with PU.1 binding, reminiscent of earlier findings that most active chromatin
features at PU.1 binding events are 'dismantled' as PU.1 is downregulated in early DN
stages (120). Together, the pervasive binding of TCF-1 corroborates the strong
enrichment of TCF motifs at accessible regulatory elements of mature T cells.
We further sought to explore the relationship between the activation of regulatory
elements and their associated genes. The ontology of genes proximal to T cell-specific
clusters was mostly related to T cell receptor signaling and naïve T cell development
with no ontology distinguishing different waves of chromatin opening (Figure S1E). The
gene expression levels proximal to dynamic regulatory elements did not present
significant differences during development, suggesting a larger transformation for the
regulatory landscape than the transcriptional output (Figure S1F). While the T cell
commitment factor Bcl11b has low expression levels in ETP, multiple T cell-specific
regulatory elements proximal to this gene became accessible at the earliest stage and
co-localized with TCF-1 binding (Figure 2G). The three waves of chromatin remodeling
during development is attested to the Bcl11b locus as the rightmost elements including
the Bcl11b promoter became accessible in the ETP and were retained until T cell
maturation. The middle of the locus was mostly accessible in intermediate stages, and
the leftmost elements of the locus gained accessibility late in the developmental process.
Collectively, these results demonstrate the dynamic of expansions and restrictions of
regulatory elements during T cell development and foreshadow the importance of TCF-1
in patterning the regulatory landscape from early thymic progenitors to mature T cells.

27

1

0.2
0

16
13

Open Early
in T

5
20
8
9
7
17

18
19
3
10
2

14
15
11

TTCCCCTTTT
T

C

13
5

20
8

C

CT ATT
TC
GT
AC

G
AA
A

C T

TA

C

A

A

G

AAA

A

G

PU.1 (ETS)

1e-25

25.8

17

32.4

18

G

C
G
A

PU.1 (ETS)

1e-109

A

GTC

C

CGT

CTC
TG
AT
G

AT

A

A

C

G
T

GC

TG
TCCAC

G

CTTTGATG

A
G

A
G
A

C

G

T

CA

C

TCA

TCF

AC
A

100 80 60 40 20 0

10

% TF binding

8

6

1e-32

42.6

1e-8
1e-29
1e-36
1e-31

45.6
55.3
23.9
44.0

4

2

Remains open
in mature T

19

E
Becomes open
in mature T

0

5
ATAC-seq

Early T
7
10

17

Remains open 18
in mature T
19

Intermediate T
65

13

16

16

5

13

16

24

11

14

4

1

11

14

3
10
Becomes open
2
in mature T
14

1

Late T
B/NK

15
Tcf-1
ChIP-seq

Tc
f

-1
PU DP
T
.1
PU DN
1
.1
D T
N
2a
G
T
at
a3
D
R
un P
x1
D
P
Tc
f-1
PU DP
T
.1
PU DN
1
.1
D T
N
2
a
G
T
at
a3
D
R
P
un
x1
D
P

11

28

TCCA
G

T

AACA

T

G

C

G

B

NK

CD8+ SP

DP

CD4+ SP

DN4

DN3

DN2b

G

0

motif

p-value

% of
targets

E2A

1e-27

38.4

E2A

1e-197

61.3

TCF

1e-56

42.4

RORC

1e-67

16.4

TCF

1e-51

54.3

G

TGACCTACTT
CTTTGATG
C

13

7

GTG
CTTTC
T
GATC
AC

T

16

14
17

T

A

1

44
52

G

A
CG

G

C
G

A

AC

CT

G

Odds ratio of TF binding

12

C

A

T
AA

A

10

Progenitors

37
44

TTG

GCA

A

GG

CC

0.5

Open Late in T
3

4

68
69

GGTGCAT
CAGGTGTC

GCA

C
G
AT

A

6

20
Remains open
8
in mature T
9

ETP

Open Intermediate in T
G
C

A

C

9

HSC

% of
targets

TGTGGTCT
RUNX
CATGGTCG
ESRRA (NR)
A
E2A
CAGGTGCT
CTTTGA CTT
TCF
T
G

C

7

F

p-value

G
TAT

CT

C

Remains open
in mature T

A

D

motif

Open Early in T
16

DN2b
DN3
DN4
DP
CD4+ SP
CD8+ SP
B
NK

HSC
MPP
CLP
ETP
DN2a

1

DN2a

Open
in B or NK

CLP

Open Late in T

MPP

Open Intermediate
in T

C

Open Early
in T

0.4

1

Open Intermediate
in T

0.6

Open Late
in T

0.8

12

ATAC-seq

Cluster 9
(1,705 elements)

Open
in Progenitors

B

FDR

Cluster 19
(1,399 elements)

ATAC-seq
6
4

Cluster 10
(1,917 elements)

A

T

Bcl11b
HSC

1

MPP

1

CLP

1

B

1

ETP T

1

DN2a T

1

DN2b T

1

DN3 T

1

DN4 T

1

DP T

1

CD4 T

1

CD8 T

1

late
DP T

intermediate

chr12:107893405-108032922

early

2

Figure 2. TCF-1 binding occurs at three waves of chromatin remodeling during T
cell development.
(A) A dynamic remodeling of the chromatin landscape with distinct expansions and
restrictions of regulatory elements at early, intermediate and late stages of T cell
development. Accessibility heatmap of 35,869 enhancers are measured by bulk ATACseq in HSC, MPP, CLP, ETP, DN2a-b, DN3, DN4, DP, SP, B and NK cells. Rows
represent regulatory loci and columns the significance of each element’s accessibility level
in every sample. Enhancers are organized in groups with k-means (k=20) clustering using
FDR as a proxy for signal enrichment. Lower values represent higher chromatin
accessibility. Number of clusters was chosen based on Average Silhouette Width statistic.
Clusters were further assembled into meta-clusters depending on their accessibility
pattern such as open in progenitor, early, intermediate and late in T as well as B or NK
cells. Clusters that are open in mature T cells and specific to T cell development are
highlighted in red.
(B) ATAC-seq profiles of normalized tag counts around enhancers (+/- 2kb window and
10bp bin size) in clusters 9, 19 and 10 across all 13 cell types.
(C-E) TCF is the top enriched motif at T cell-specific regions that become accessible at
early, intermediate and late waves of gain in chromatin accessibility during T cell
development. De novo motif discovery using HOMER in each group using remaining
elements in other clusters as background unveiled putative cell-type specific transcription
regulators.
(F) Widespread binding of TCF-1 at the open chromatin of T cells. Percentage of
enhancers in each cluster that are bound by TCF-1, PU.1, GATA3 and RUNX1 ChIP-seq
peaks (left) and their corresponding odds ratio (right). Contingency tables were calculated
using ChIP-seq data summarized in STAR Method.
(G) Example of the Bcl11b locus and several TCF-1 bound enhancers that exhibit diverse
accessibility levels during T cell development. The three waves of chromatin remodeling
during development is attested to at the Bcl11b gene as the rightmost elements including
the Bcl11b promoter became accessible in ETP and were retained until T cell maturation,
the middle elements were mostly accessible in intermediate stages, and the leftmost
elements gained accessibility late in the developmental process.
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2.3.3 TCF-1-deficient T cells cannot establish the open chromatin landscape of normal T
cells
Germline deletion of TCF-1 leads to a severe reduction in thymocyte numbers
(87). Although some T lineage-like cells continue to develop in the thymus of TCF-1deficient mice, they are functionally limited in terms of differentiation and persistence of
memory T cells during infection (87, 122). It remains unclear whether the chromatin
accessibility landscape and transcriptional outputs of these T-like cells is different from
those of normal T cells. Therefore, we next measured chromatin accessibility at TCF-1
binding events in wildtype and TCF-1-knockout DP T cells. Our data revealed the loss of
chromatin accessibility at 5,000 regulatory elements and the gain at 1,165 genomic loci
in TCF-1-deficient T cells (Figures 3A and S2A). We sought to elucidate the
relationship between regulatory elements that required TCF-1 for their accessibility and
the three waves of chromatin opening during T cell development (clusters in Figure 2A).
Regulatory elements that lost chromatin accessibility in the absence of TCF-1 were
strongly enriched within early or intermediate waves of chromatin opening during T cell
development, suggesting that this transcription factor is required for patterning the
chromatin at early stages (clusters 7, 9 and 19) (Figure 3B). Examples of affected
regions included the well-annotated Tcrb enhancer (123) and the distal Bcl11b
enhancers (124) (Figure 3C). Performing de novo motif analysis revealed TCF as the
top enriched motif in the lost sites supporting the notion that TCF-1 is directly
responsible for chromatin accessibility (Figure 3D). TCF-1-bound regions with gains in
accessibility in the knockout cells were also enriched with the TCF motif but were
associated with elements accessible in B and NK cells or T cell regulatory elements
deactivated in mature T cells, supporting the previously reported repressive role of TCF1 at some genomic locations (Figures 3B, 3D) (125). Together, these data demonstrate
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that TCF-1 is required for patterning the chromatin of T cells at early stages of
development in the thymus.
To elucidate how changes in chromatin accessibility relate to the dynamics of
gene expression, we evaluated the transcriptome of wildtype and TCF-1-deficient T cells
using RNA-seq (Figure S2B-C). We then interrogated changes in the expression of
genes proximal to TCF-1-dependent open chromatin regions using gene-set-enrichment
analysis. Genes proximal to regions that became less accessible in the absence of TCF1, such as Tcrb and Bcl11b, displayed reduced expression in cells lacking this
transcription factor (Figure 3E). Conversely, genes such as Adam19 that became more
accessible also showed an increase in transcription in TCF-1 deficient T cells (Figure
S2D). Together, these results indicate that while some T-like cells continue to develop in
the absence of TCF-1 in the thymus, they cannot establish the open chromatin
landscape and transcriptional profiles of normal T cells.
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Tcf-1 KO DP

Figure 3. TCF-1-deficient T cells cannot establish the open chromatin landscape
and transcriptional output of normal T cells.
(A) We generated three replicates of ATAC-seq in wildtype and TCF-1 germline deleted
DP T cells and evaluated the chromatin accessibility levels at TCF-1 binding sites based
on ChIP-seq. We applied variance stabilizing transformation and library size normalization
on the raw ATAC-seq counts and used DESeq2 to delineate differentially accessible
regions at TCF-1 binding sites(126) (fold-change > 1.5 and p-value < 1e-3). While 5,000
genomic regions were less accessible, 1,165 regions were more accessible in TCF-1
deficient T cells.
(B) Loss of TCF-1 selectively diminishes the accessibility of genomic regions that become
open at early or intermediate stages of development and sustain accessibility in mature T
cells. The overlapping genomic regions identified by DESeq in (A) and open chromatin
clusters in Figure 2 were found and used to measure the odds ratio.
(C) Representative examples included the well-established enhancers of Tcrb and Bcl11b.
(D) De novo motif analysis using HOMER unveiled TCF-1 as the most significantly
enriched motif in regions that both gained and lost accessibility.
(E) TCF-1 dependent changes in gene expression correlate with changes in chromatin
accessibility. We measured gene expression using RNA-seq in replicates for wildtype and
TCF-1 deficient T cells. We used DESeq2 to identify differentially expressed genes (foldchange > 1.5 and p-value < 1e-3). Our analysis unveiled 1,167 down- and 1,293 upregulated genes in TCF-1 deficient compared to wildtype T cells. Genes were ranked
based on log2 fold change estimated by DESeq2 and used as the pre-ranked gene list in
GSEA analysis. The GSEA gene sets were genes within 10kb of top 200 regions with
highest fold-change in chromatin accessibility between wildtype and KO cells.
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2.3.4 TCF-1 binding exerts a strong harmonizing impact on the chromatin of single T
cells

If a transcription factor is required for patterning the regulatory landscape of a
lineage, it may need to exert a harmonizing impact on the chromatin of individual cells
making the same fate decision. To interrogate which T cell transcription factor may have
such features, we first exploited maps of chromatin accessibility at the population level
and reasoned that at a given regulatory element, the strength of bulk ATAC-seq signal
reflects the fraction of cells in the population with open chromatin. We compared the
normalized intensity of chromatin accessibility in bulk ATAC-seq at genomic regions
uniquely bound by T lineage transcription factors TCF-1, GATA3, or RUNX1 (Figure
4A). Our analysis revealed that TCF-1 binding events rendered the highest average
level of chromatin opening in comparison to RUNX1 and GATA3, advancing the notion
that TCF-1 may unify chromatin accessibility across single T cells (Figure 4A).
While chromatin accessibility maps of bulk T cells measure the average patterns
of open regulatory elements at the population level, it remains unclear if Tn5 insertions
linearly reflected the fraction of individual cells with open chromatin. To address this
concern, we tested our hypothesis using single-cell (sc)ATAC-seq (127). In this
approach, individual cells stained for viability were captured and assayed using a
programmable microfluidics platform (Fluidigm) (Figure S3A-B). Collapsing reads from
single T cells to aggregate scATAC-seq data closely reproduced measures of
accessibility profiled by ATAC-seq generated from 50,000 T cells (Figure 4B). A
representative genomic region such as the Tcrb enhancer confirmed the strong
correlation between bulk and single-cell measurements (Figure 4C). Furthermore, data
from single T cells recapitulated several characteristics of bulk ATAC-seq data, including
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fragment-size periodicity corresponding to integer multiples of nucleosomes (Figure
S3C). Together, we performed three independent single-cell captures and 110 T cells at
the DP stage passed various quality control thresholds, suggesting high-confidence
single-cell chromatin accessibility maps in T cells (Figure S3D).
Single-cell chromatin accessibility data are sparse, binary, and high dimensional,
leading to unique computational challenges. To overcome these difficulties, we
developed a method using a geometric distance metric and quantified cell-to-cell
chromatin accessibility variation (Figure 4D, STAR Methods). To interrogate which T cell
transcription factor can create harmonizing effects, we exploited our method on
binarized scATAC-seq count data in every cell and calculated the average distance
between pairs of T cells at genomic regions uniquely bound by TCF-1, RUNX1 or
GATA3. We reasoned that binarizing scATAC-seq count data at transcription factor
binding events reflects the openness or closeness (1 or 0) of a locus in a single cell. Due
to biases in the number of observed fragment counts between cells based on the GC
content or mean accessibility of a given peak set, we normalized the distance between
individual cells at each set of transcription factor binding events to that of a background
set comprising an equal number of peaks with matching GC content and mean
accessibility. Our single-cell analysis revealed that TCF-1-bound regions were
associated with the least variability among individual T cells in comparison with GATA3
and RUNX1 (Figure 4E). We further applied another analytical technique called
“chromVAR” which was recently developed to address the same question (128). Unlike
our method in which the difference in accessibility of a genomic region between every
cell-pair contributes to the variability score, chromVAR relies on the aggregate of
accessibility signal across a genomic set. Despite differences in the inference of
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variability at transcription factor binding sites, chromVAR also identified TCF-1 as the
least variable transcription factor in exerting chromatin accessibility across single T cells
(Figure 4E). Together, two analytical strategies developed by us and others corroborate
the enrichment of TCF-1 binding at regulatory elements that their accessibility is
conserved across single T cells.
As an alternative strategy, we ranked T cell specific genomic regions in the early
T cell cluster (cluster 9) based on the fraction of cells harboring open chromatin and
evaluated whether they were bound by T cell transcription factors TCF-1, GATA3, and
RUNX1 (Figure 4F). The top regulatory elements open across majority of single cells
were bound consistently by TCF-1 in contrast with GATA3 and RUNX1 (Figure 4F). We
reasoned if TCF-1 indeed plays a role in creating accessibility at genomic regions with
the highest similarity across individual cells, its deletion should have a stronger effect on
the accessibility of these regions at the bulk level. Indeed, the most similar genomic
regions across individual T cells, i.e. being open at the highest fraction of cells, were
more affected by loss of TCF-1 compared to the least similar genomic regions (Figure
4F). In line with consistent TCF-1 binding and a stronger effect size in chromatin
accessibility in the absence of TCF-1, the TCF motif was selectively enriched within the
top 100 most similar genomic regions. Furthermore, the genes proximal to these
genomic regions with the highest similarity across individual T cells were associated with
T cell biology and included T cell relevant genes such as Bcl11b (Figure 4F). Together,
studying maps of chromatin accessibility at bulk and single cell levels with distinct
analytical strategies suggests that TCF-1 could dictate a harmonizing impact on the
chromatin of individual T cells.
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Figure 4. TCF-1 binding has the highest coordinate impact on open chromatin of
single T cells.
(A) TCF-1 binding events harbor the strongest chromatin accessibility measured by bulk
ATAC-seq in DP T cells. Genome-scale binding of TCF-1, RUNX1, and GATA3 in DP T
cells was measured by ChIP-seq. An equal number of genomic regions with unique
binding of each transcription factor were subsampled from ChIP-seq data sets. The
normalized tag count for ATAC-seq in DP T cells was calculated for each group of
transcription factor binding.
(B) The aggregate maps of scATAC-seq data closely reproduced measures of
accessibility profiled by ATAC-seq generated from 50,000 DP T cells. Open sites
identified from bulk ATAC-seq in 50,000 DP T cells were merged with peaks
characterized by aggregating the samples from 110 single DP T cells passing QC
measures. Normalized enrichment was subsequently calculated in downsampled bulk
ATAC-seq and aggregated scATAC-seq enabling the assessment of the correlation level
between the two assays.
(C) Aggregated single cell ATAC-seq profile recapitulates chromatin accessibility on the
bulk level at Tcrb enhancer.
(D) A novel method to infer transcription factor-associated chromatin accessibility
variation across single cells.
(E) Chromatin accessibility across individual T cells is the least variable at TCF-1 binding
events using our method (D) or chromVAR (128).
(F) Fraction of cells with binarized open chromatin was measured across all pairs of
elements to rank regulatory elements. TCF-1, GATA3 and RUNX1 ChIP-seq
enrichments were assessed in the same order as well as changes in chromatin
accessibility based on bulk ATAC-seq signal in wildtype and TCF-1 KO T cells. De novo
motif analysis using HOMER at the 100 enhancers exhibiting the highest similarity at the
single cell level revealed the enrichment of TCF while TCF was not enriched at 100 least
similar enhancers. T cell related genes were associated with the top enhancers.
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2.3.4 TCF-1 can create de novo chromatin accessibility in fibroblasts

It has been shown that when TCF-1 is forcibly expressed in bone marrow
progenitors, it can drive the expression of T-lineage genes (121). Yet, it is not clear
whether this alteration in the gene expression program of multipotent progenitors relates
to the ability of TCF-1 to bind to silent chromatin and/or drive the epigenetic commitment
to the T cell lineage. To examine if TCF-1 can create de novo open chromatin, we
assessed this transcription factor in a gain-of-function model in nonhematopoietic
somatic cells. We reasoned that fibroblasts could serve as an ideal model since the
chromatin state in fibroblasts is distinct from cells of the hematopoietic system and T
cell-specific genes are repressed in these somatic cells, allowing us to better evaluate
the role of TCF-1 in targeting condensed chromatin.
To evaluate the genome-scale binding of TCF-1, we ectopically expressed this
transcription factor in a fibroblast cell line using a retroviral transduction system and
performed TCF-1 ChIP-seq (Figure S4A). To define genome-scale TCF-1 binding
events, we used the irreproducible discovery rate (IDR) method with a threshold of 2%
(129) (Figure S4B). We further mapped the position of nucleosomes using microccocal
nuclease (MNase)-seq in pre-induced cells. The ectopic expression of TCF-1 led to
more than 40,000 TCF-1 binding events across the genome of fibroblasts where 73% of
these events colocalized with previously nucleosome-occupied DNA (Figures 5A and
S4C). The extent to which TCF-1 bound to nucleosome-occupied regions in fibroblasts
was comparable to reprogramming transcription factors such as Oct4 (85%), Sox2
(80%), and Klf4 (65%) (130). As an independent measure, we found that 67% of TCF-1
summits, the center of TCF-1 peak, were within 75bp of a nucleosome dyad in contrast
with CTCF binding which is favored towards nucleosome-free regions, suggesting that
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TCF-1 binding is selectively enriched at previously occupied nucleosomes (Figure 5B).
Furthermore, TCF was the strongest motif within TCF-1-bound sites with different levels
of nucleosome occupancy (p-value<1e-930) (Figure 5C). TCF recognition sites bound
by TCF-1 in fibroblasts were significantly closer to the nucleosome dyads compared to
random TCF sites not bound by this transcription factor, reminiscent of PU.1 binding
events being shielded by nucleosomes in cells that do not express this protein (131)
(Figure S4D). Together, the ectopic expression of TCF-1 in fibroblasts revealed the
widespread binding of TCF-1 at genomic regions previously occupied by nucleosomes
harboring TCF consensus binding sites.
To measure the impact of widespread TCF-1 binding on silent genomic loci, we
mapped the accessibility of chromatin by ATAC-seq post transduction with Empty or
TCF-1 vectors. Using differential enrichment analysis, we found that 6,888 genomic
regions previously occupied by nucleosomes gained accessibility while 1,618 sites
became less accessible after TCF-1 expression in fibroblasts (Figures 5D-E, S4E). We
further performed de novo motif analysis and observed that more than 80% of the
gained sites harbored a TCF motif while the lost sites were enriched with AP-1 and Runx
family motifs (Figure 5F). In concordance with motif presence, 80% of the gained sites
were also bound by TCF-1 based on the TCF-1 ChIP-seq while only 3% of lost sites
colocalized with TCF-1 binding (Figure 5G), suggesting an indirect role of TCF-1 on
sites losing chromatin accessibility. To infer nucleosome position and occupancy within
TCF-1 binding events, we further applied the NucleoATAC algorithm (132) to our
chromatin accessibility data and found 7,395 genomic regions with significant loss of
nucleosomes after TCF-1 expression (Figure S4F). A striking example of de novo
regulatory elements induced by TCF-1 includes the T cell receptor alpha locus where the
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binding of TCF-1 at previously occupied nucleosomes led to gains in chromatin
accessibility at multiple genomic regions (Figure 5H). Together, our data suggest that
TCF-1 can bind to thousands of previously nucleosome-occupied DNA and this binding
can lead to de novo chromatin accessibility.
We next sought to examine whether de novo chromatin accessibility in fibroblasts
has any relevance to T cell biology. Our data revealed that TCF-1 binding events in T
cells and fibroblasts are highly correlated (Figure S4G) and more than 800 de novo
regulatory elements in fibroblasts (~11%) overlapped with open chromatin in T cells
while only 40 regions (~0.5%) corresponded to the open chromatin in B cells (Figure
S4H). Furthermore, the de novo regulatory elements in fibroblasts were selectively
enriched for regions belonging to the early wave of chromatin opening during T cell
development (cluster 9) (Figure S4I). For example, the promoter of Ccr7, which is
among the regulatory elements that gain accessibility at the early cluster 9, is bound by
TCF-1 and becomes accessible in TCF-1-expressing fibroblasts (Figure 5I). Together,
TCF-1 can invoke a subset of T cell regulatory elements to become open in distant
somatic cells like fibroblasts.
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Figure 5. TCF-1 can bind to nucleosomes and create chromatin accessibility in
fibroblasts.
(A) TCF-1 ChIP-seq TCF-1 (p33) expressing NIH3T3 using retrovirus (RV) as well as in
Empty vector controls 48 hours post transduction resulting in the identification of 40,562
reproducible peaks. The region surrounding TCF-1 summits was segmented in three
non-overlapping 200bp windows centered around each summit. Normalized MNase-seq
enrichment was calculated for each window and summits were ordered from high to low
enrichment. (B) The majority of TCF-1 binding events occur within the boundaries of
DNA wrapped around nucleosome. The distance between TCF-1 as well as CTCF
(serving as control) and the closest nucleosome summits were calculated as an
alternative strategy of assessing the ability of TCF-1 to directly bind nucleosomes. The
vertical dashed red line is set to 75bp which is typically half the size of histone octamer
bound DNA denoting the edge of nucleosomes. (C) TCF-1 motif is equally preserved in
genomic loci presenting nucleosome high, medium and low enrichment. K-means
clustering (k=3) was applied on TCF-1 summits using the normalized MNase-seq
enrichment in the three non-overlapping 200bp windows centered around each summit.
We chose the open chromatin regions presenting no overlap with TCF-1 summits as
background in our de novo motif analysis using HOMER and found TCF as the only
motif significantly enriched in each cluster.
(D-I) TCF-1 can create de novo open chromatin in fibroblasts. (E) We performed ATACseq in triplicates in Empty and TCF-1 RV NIH3T3 cells. To identify differentially
accessible regions, TCF-1 ChIP-seq and ATAC-seq peaks were merged to facilitate
differential enrichment at both TCF-1 bound and unbound regions of the genome. We
used DESeq2 and based on fold-change > 1.5 and p-value < 1e-3, 6,888 regions gained
while 1,618 lost accessibility in TCF-1 RV cells. (F) De novo motif discovery unveiled
TCF-1 as the most significantly enriched motif in gained sites and AP-1 as well as Runx
motifs in lost sites. (G) TCF-1 bound to 5,575 (80%) gained sites in contrast to only 40
(3%) lost sites. (H) TCF-1 directly binds nucleosomes at Tcra related enhancers and
creates de novo open chromatin. (I) Example of the Ccr7 gene promoter that becomes
accessible at the earliest stage of T cell developmental and is naturally bound by TCF-1
in T and Tcf1-RV NIH3T3 cells with a corresponding increase in accessibility.
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2.3.5 TCF-1 binding at chromatin domains with H3K27me3 and H3K9me3 repressive
marks

The widespread binding of TCF-1 in fibroblasts led to thousands of de novo
open chromatin regions. Yet, it is not clear whether these TCF-1-dependent regulatory
elements were previously repressed or instead poised for activation with permissive
histone modifications in fibroblasts. To address this question, we examined the preexisting patterns of histone modifications in fibroblasts using maps of 5 histone
modifications including: H3K4me3, primarily associated with promoters; H3K4me1 and
H3K27ac characteristic of poised and active promoters and enhancers; and the
repressive marks H3K9me3 and H3K27me3. Correlation and principal component
analysis (PCA) at TCF-1 bound sites indicated a preferential colocalization of gained
sites with previously repressed domains containing H3K27me3 or H3K9me3
modifications (Figures 6A and S5A-B). To create a more quantitative picture of the
chromatin state prior to TCF-1 binding, we developed an unsupervised learning workflow
and partitioned TCF-1 binding events into 11 clusters corresponding to 7 distinct
chromatins states (Figures 6B, S5C-D, STAR Methods). Although less than half of TCF1 binding events associated with active and poised enhancers or promoters (~40%),
16,800 (~42%) occurred within repressed and heterochromatin genomic regions.
Strikingly, the gains in chromatin accessibility by TCF-1 were strongly enriched at these
repressed domains (Figures 6B and S5E).
The widespread binding of TCF-1 at genomic regions with pre-existing repressive
marks was unexpected. To further assess whether TCF-1 is also capable of erasing the
repressive histone modifications, we next mapped H3K27me3 and H3K9me3 repressive
marks in addition to the active enhancer mark H3K27ac in TCF-1 expressing cells. We
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found that more than 1,400 TCF-1 binding events overlapping de novo open chromatin
were associated with gain in H3K27ac and loss of H3K27me3 and H3K9me3 repressive
marks at the center of TCF-1 binding (Figure 6C-D). Together, the integration of
nucleosome mapping, chromatin accessibility, transcription factor binding, and histone
modifications in fibroblasts suggest a fundamental role of TCF-1 in creating de novo
chromatin accessibility because of its binding to previously repressed chromatin
domains.
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Figure 6. TCF-1 can bind to repressed chromatin and make it open.
(A-B) TCF-1 binds to repressed chromatin and promote accessibility. (A) The
enrichment of ATAC-seq in NIH3T3 TCF-1 RV versus Empty RV cells and vice versa
was also calculated around each summit for assessing different levels of chromatin
accessibility. Principal component analysis showed that gain in accessibility occurs at
TCF-1 binding sites located in repressed chromatin and loss in accessibility happens in
previously active regulatory regions. (B) K-means clustering (k=11, designated as the
optimal number of clusters by Average Silhouette Width coefficient) of TCF-1 summits
on the adjusted significance levels of the enrichment in each histone mark identified
chromatin states ranging from PRC (H3K27me3) (4,110, 10.2%), hetero/PRC
(H3K27me3 and H3K9me3) (8,957, 22%), hetero (H3K9me3) (4,242, 10.4%), trivalent
(H3K27ac, H3K4me1 and H3K9me3) (6,634, 16.4%), poised enhancers (H3K4me1)
(7,458, 18.3%), active enhancers (H3K4me1 and H3K27ac) (7,343, 18.2%) and
promoters (H3K4me3) (1,818, 4.5%). Normalized enrichment profiles of histone
modification using ChIP-seq as well as ATAC-seq were also calculated for 10bp nonoverlapping bins spanning the +/- 3kb region centered around TCF-1 summits.
(C-D) More than 1,400 TCF-1 binding events colocalize with a gain in both chromatin
accessibility and the active mark H3K27ac with a corresponding loss of
H3K27me3/H3K9me3 repressive marks. To assess differences in the enrichment of
H3K9me3, H3K27me3 and H3K27ac ChIP-seq signal around TCF-1 binding events
between pre-induced and TCF-1 RV NIH3T3 cells, we used the diffR function from
normR package using an FDR threshold of 5e-2. The average profiles for histone
modifications, chromatin accessibility and TCF-1 binding using ChIP-seq were
generated and demonstrated above each heatmap.
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2.3.6 T cell-restricted genes are actively transcribed after TCF-1 expression

To evaluate whether the ectopic expression of TCF-1 and its widespread binding
at over forty thousand genomic regions corresponds to any change in gene expression,
we measured the transcriptional changes in fibroblasts (Figure S6A). After TCF-1
transduction, we found that 1,478 genes were upregulated while 1,296 genes were
downregulated (Figure S6B). To further assess the identity of these up- and downregulated genes, we generated two gene sets containing top “T cell genes” and
“fibroblast genes” by performing differential expression analysis in DP T cells and preinduced fibroblasts. Using gene-set-enrichment analysis, we found that the fibroblast
gene-set was enriched within the down-regulated genes, suggesting the repression of
the fibroblast gene expression program by TCF-1 (Figure 7A). Conversely, the T cell
gene set was enriched within genes upregulated by TCF-1 (Figure 7B). The leading
edge in this enrichment analysis included genes essential for T cell commitment and
development including Bcl11b, Rorc, and Cd247 (Figure 7C). Together, TCF-1 can
initiate the reprogramming of fibroblasts towards T cells.
To examine whether TCF-1 upregulated genes in fibroblasts have any relevance
to transcriptional profiles during T cell development, we delineated ‘thymocyte-specific
genes’ as a group of genes that were selectively expressed in at least one stage of T cell
development but not in bone-marrow progenitors using the ImmGen expression data
(133) (Figure 7D). We found that TCF-1 was capable of upregulating 81 thymocytespecific genes with ontologies associated with tissue development, cell proliferation and
immune system processes (Figures 7D and S6C). Examples include Bcl11b, Ikzf4,
Il2rb, Klf4, and Rorc. Additional 597 genes upregulated by TCF-1 were expressed at
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multiple cellular states (Figures 7D left panel). It is well established that TCF-1 has
recurring roles in T cell development, peripheral T cells and cells with stem properties
(134, 135). We further evaluated the expression of the 1,478 genes up-regulated by
TCF-1 in fibroblasts for their expression in hematopoietic progenitors together with naïve
CD4+ and naïve, effector and memory CD8+ T cells using RNA-seq data (Figures S6DE). After performing unsupervised clustering, we found that 753 genes are ordinarily
expressed in one of these hematopoietic stages. Among these, 475 genes (63%)
including Ccr7, Il15ra, and Icosl are selectively expressed in the T cell program (Figures
S6D-E). In addition, 42 genes that were upregulated by TCF-1 in fibroblasts were
selectively downregulated in TCF-1-deficient DP T cells, suggesting that TCF-1 is
required and sufficient for the expression of these genes (Figure S6F). Together, our
data suggest that de novo open chromatin regions are invoked by TCF-1 to induce the T
cell-specific gene expression program in fibroblasts.
2.3.7 Genes up-regulated by TCF-1 reside in previously repressed chromatin domains in
fibroblast

Our data in TCF-1 expressing fibroblasts led to two unexpected observations: (a)
TCF-1 can generate chromatin accessibility at previously repressed domains and (b)
TCF-1 can induce the expression of thousands of genes. To relate the chromatin state at
the TCF-1 binding events to changes in transcriptional outputs in fibroblasts, we
calculated the enrichment of up- and down-regulated genes among genes whose 5kb
extended regions fell within TCF-1 binding events in different chromatin states. We
found that the genes up-regulated by TCF-1 were significantly enriched for TCF-1
binding events at chromatin domains with repressive chromatin marks (Figure 7E).
Conversely, genes downregulated by TCF-1 were mostly associated with promoters and
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the trivalent state with high H3K4me1 and H3K27ac surrounded by H3K9me3 (Figure
S6G). Of note, a statistically significant proportion of genes were proximal to TCF-1
binding events that led to gain in H3K27ac and loss of H3K27me3/H3K9me3
modifications in contrast to those that did not alter the chromatin state (Figure S6H).
Remarkably, genes of the T cell program were strongly enriched within genomic regions
previously within repressed chromatin domains or harboring high nucleosome
occupancy (Figures 7F and S6I). Examples of T cell genes ordinarily blanketed by
repressive H3K27me3 and H3K9me3 in fibroblasts and actively transcribed after TCF-1
expression included the receptor required for cell trafficking within and out of the thymus,
Ccr7, and an essential transcription factor for T cell development Rorc (Figures 7G and
S6J). Thus, TCF-1 can induce the expression of T cell genes in an unrelated nonhematopoietic cell type by accessing repressive chromatin domains and converting
these regions to open, transcriptionally active loci.
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Figure 7. T cell-specific genes innately repressed in fibroblasts are upregulated by
TCF-1.
(A-C) Ectopic expression of TCF-1 upregulates T cell genes and downregulates
fibroblast genes. Differential expression analysis between WT DP T cells and Empty RV
NIH3T3 cells delineated T cell and fibroblast gene sets (STAR methods). RNA-seq
between Empty and TCF-1 RV NIH3T3 cells (see Figure S6) and GSEA analysis on the
fibroblast gene set (A) and the T cell gene set (B). Leading edge analysis (C) in top T
cell genes included essential genes in T cell development and commitment such as
Bcl11b and Rorc.
(D) TCF-1 upregulates thymocyte-specific genes that are expressed at different stages
during normal T cell development. Thymocyte-specific genes were defined (STAR
methods) and the overlap tested between TCF-1 RV upregulated genes in NIH3T3 (see
Figure S6B) and thymocyte-specific genes. These genes were clustered using ImmGen
microarray expression profiles (middle and right). Gene expression profiles of genes not
overlapping thymocyte-specific genes but expressed in progenitors (597 genes) were
also plotted (left).
(E-F) TCF-1 can upregulate genes initially buried within repressed chromatin. TCF-1
summits assigned to chromatin states (see Figure 6B) were linked to proximal genes
(STAR methods). (E) Enrichment of upregulated genes by TCF-1 within each chromatin
state. (F) Enrichment of T cell genes upregulated by TCF-1 (B) in each chromatin state
was compared to fibroblast genes (A).
(G) Example of T cell genes ordinarily blanketed by H3K27me3 and H3K9me3 in
fibroblasts and induced after TCF-1 expression included Ccr7.
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2.4 DISCUSSION

It has been known for more than 2 decades that TCF-1 is a key transcription
factor in T cell development (87). As a major mediator of Notch signaling in the
specification of bone-marrow progenitors to a T cell fate, TCF-1 is required for the
expression of transcription factors essential for T cell commitment and specification such
as GATA3 and Bcl11b (121, 136). Yet, it has been unclear whether the mechanism by
which TCF-1 controls T cell fate is the specific transcriptional regulation of a small
number of genes or whether this protein has a more fundamental role shaping the global
epigenetic identity of T cells. Here, by reading between the ‘open’ lines of the genome
during thymocyte development, we found that TCF-1 is the most enriched transcription
factor at thousands of regulatory elements that become accessible at the earliest stage
and persist until T cell maturation. While it remains unclear whether all genomic regions
with H3K9me3 modifications comprise heterochromatin (137), we found that TCF-1
binding across the genome of fibroblasts leads to gains in chromatin accessibility at
genomic regions enriched with H3K27me3 and H3K9me3 repressive marks and lacking
H3K27ac and H3K4me1/3 activating marks. This unique ability of TCF-1 targeting
repressed chromatin might be attributed to the ability of HMG proteins to introduce a
strong bend into DNA (82). The de novo change in accessible elements caused by TCF1 coincided with transcription of hundreds of T cell genes. A subset of de novo open
chromatin regions was also associated with gain of the active enhancer mark H3K27ac
and loss of the repressive marks H3K27me3 and H3K9me3, corroborating the ability of
TCF-1 in targeting silent chromatin. Transcription of Ccr7, a gene that plays an essential
role in intrathymic migration and proper T cell development (138), was induced when
TCF-1 was ectopically expressed in fibroblasts. Notably, the promoter of Ccr7 that
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became accessible in TCF-1 expressing fibroblasts is among the first wave of chromatin
remodeling in T cell development. Similarly, the up-regulation of Bcl11b, a T-cell
restricted transcription factor essential for T cell commitment, highlights the role of TCF1 as an early inducer and stabilizer of T cell identity by promoting epigenetic changes
that drive key transcriptional regulators of the T cell program. Although TCF-1 has been
known to induce selected genes involved in T cell biology, these results reveal a
previously unappreciated broad mechanism by which TCF-1 controls T cell fate through
genome-wide programming of the epigenetic identity of T cells. Our integrative strategy
exploiting development and reprogramming in T cell progenitors may also provide a
foundation to delineate cell fate determining transcription factors shaping the
accessibility landscape of other cell types.
It has been recently shown that TCF-1 is essential for repressing CD4+ related
genes in CD8+ T cells through intrinsic HDAC activity (125). Of all TCF-1 binding events
that had differential accessibility in the absence of TCF-1 in T cells, we found that a
majority (80%) exerts an activating role (i.e., losing accessibility in knockout cells) with a
smaller number gaining accessibility, supporting this previously reported repressive role
of TCF-1. Strikingly, both gained and lost sites in our data were enriched with TCF-1
binding and TCF motif, suggesting the direct role of this transcription factor at
recognizing its binding sites across the genome. While further analysis is required to
examine the sequence features and epigenetic modifications classifying the activating
versus repressive TCF-1 binding events, our work reveals the pervasive role of TCF-1 at
establishing de novo open chromatin during development and reprogramming.
Conrad Waddington proposed a metaphor for cellular differentiation coining the
term “epigenetic landscape” and envisioning a cell rolling down a hill like a ball with
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successive bifurcations that resulted in irreversible cell fate` decisions (139). Exploiting
the single cell technology, we interrogated whether a lineage-determining transcription
factor can exert harmonizing and coordinate impact on the chromatin of single cells
following the T cell trajectory. To infer cell-to-cell variability on open chromatin
associated with transcription factors, we developed an analytical method and found that
TCF-1 target sites but not those of RUNX1 or GATA3 confer the lowest cell-to-cell
variability across individual T cells. Stated in a different way, open chromatin events that
are highly conserved across single cells (revealed by single cell ATAC-seq) are likely to
be causal to the identity of that cell type since, in this case, T cells appear not to function
effectively without TCF-1 driven epigenetic events (122). Despite the limitation that our
knowledge of transcription factor binding is still gathered from bulk assays such as ChIPseq, our data demonstrate a distinct pattern at genomic regions with TCF recognition
sites and TCF-1 binding, suggesting the role of this transcription factor at coordinating
the chromatin accessibility of individual cells.
Our data clearly demonstrate that the TCF motif and TCF-1 binding events are
strongly enriched at T-cell specific regulatory elements that become accessible early and
persist until T cell maturation. Furthermore, loss of TCF-1 selectively affected the
accessibility of the early regulatory elements. These findings together with the early upregulation of TCF-1 in T cell development and the ability of this protein to reprogram the
gene expression profile of fibroblasts may describe TCF-1 as a “pioneer” transcription
factor (140). Nonetheless, we propose that the epigenetic complexities and the
requirement for combinatoriality among transcription factors suggest that even ‘master
regulators’ or ‘pioneer factors’ may require additional events to fully enact the program of
cell lineage that they initiate (141-143). Here, we found that TCF-1 was endowed with an
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unprecedented ability to target chromatin regions with repressive marks and in this
manner, is more potent than the previously characterized pioneer factors in other
developmental settings which are often impeded by heterochromatin (130, 144).
Nevertheless, not the entire collection of ~1 million TCF recognition sites are bound by
TCF-1 in fibroblasts and only a fraction of the T cell-specific regulatory elements became
accessible in this context. It is worth noting that no other transcription factor including the
previously studied pioneer factors has been reported to bind to the entire set of possible
binding sites present in the genome (130, 145). We postulate that higher order
chromatin conformation and epigenetic modifications such as DNA methylation may
impede TCF-1 binding to the entire set of its cognate sites (146, 147). Moreover, the
three waves of chromatin remodeling during T cell development enriched with TCF-1
binding suggest multiple modes of action for this transcription factor. The regulatory
elements in the intermediate wave that remain closed at an earlier stage may indicate a
requirement for the cooperation between TCF-1 and its partners. Similarly, although
more than thousand TCF-1 binding events in fibroblasts abolished the pre-existing
repressive marks, the remaining TCF-1 binding events did not modify the chromatin
state, indicating the requirement of cooperating partners at these regulatory sequences.
The regulatory syntax that TCF-1 follows to read the genetic code may be ascertained
by machine learning techniques delineating rules of transcription factor engagement
from DNA sequence and shape, histone modification, chromatin conformation, and
transcription factor binding data during development and reprogramming. Collectively,
our integrative data highlight a widespread means by which TCF-1 initiates the T lineage
program through genome-wide epigenetic programming and induction of T cell identity
genes.
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2.5 MATERIALS AND METHODS

Mice: Mice used were C57BL/6J (CD45.2+) and B6.SJL-Ptprca Pepcb/BoyJ (CD45.1+)
purchased from the US National Cancer Institute animal facility. All mice analyzed were
6-12 weeks and were used without randomization or ‘blinding’ of researchers to mouse
or sample identity. Tcf7-/- (TCF-1-/- ΔVII) mice were kindly provided by A. Bhandoola (87).
All animal work was in accordance with the Institutional Animal Care and Use Committee
for the University of Pennsylvania in accordance with guidelines set forth by the NIH.
Cell culture: NIH3T3 cells were purchased from ATCC for this study and used at a low
passage number (<12) and were maintained in high glucose DMEM 1x medium with Lglutamine and sodium pyruvate (Corning) with 100 U mL-1 penicillin and 100 μg mL-1
streptomycin (Gibco) and 10% bovine serum (Gibco). 293T (ATCC) cells were
maintained in high glucose DMEM 1x medium with L-glutamine and sodium pyruvate
(Corning), and 100 U mL-1 penicillin and 100 μg mL-1 streptomycin (Gibco) with 10% fetal
calf serum (Gemini). All cells were grown at 37°C and 5% CO2.
Retroviral Transductions: Gateway compatible MSCV-IRES-VEX (MSCV-ccdB-VEX)
and empty vector controls (MSCV-VEX) retroviral vectors were obtained from A.
Bhandoola (121). Mouse Tcf7 cDNA (NM_009331) of the short isoform of TCF-1 (p33)
was obtained from Origene and cloned into MSCV-ccdB-VEX (MSCV-TCF7-VEX)
according to Gateway Clonase II instructions (Invitrogen). Sequences were verified
using MacVector v15.5.0. Cells were transduced by addition of virions to culture media
supplemented with polybrene at 8 μg mL-1 and 10 mM HEPES. As transduction
efficiency in NIH3T3 was >99%, all assays on transduced NIH3T3 cells were performed
without cell sorting.
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Retroviral Packaging: 293T cells were plated in 4 mL DMEM media in 10 cm dishes
prior to transfection. Immediately prior to transfection, chloroquine was added to a final
concentration of 25 μM. The retroviral construct and the pCL-Eco plasmid were
transiently co-transfected using Lipofectamine 3000 (Invitrogen). The cells were returned
to the incubator for 6 hours. Subsequently, the medium was changed to fresh media.
Virions were collected 24 and 48 hr after transfection, snap-frozen, and stored at -80°C
for future use.
Assay for Transposase-Accessible Chromatin (ATAC): ATAC-seq was performed as
previously described with minor modifications (148). Fifty thousand cells were pelleted at
550 x g and washed with 1 mL 1x PBS, followed by treatment with 50 μL lysis buffer
(10 mM Tris-HCl [pH 7.4], 10 mM NaCl, 3 mM MgCl2, 0.1% IGEPAL CA-630). After
pelleting nuclei, the pellets were resuspended in 50 μL transposition reaction with 2.5 μL
Tn5 transposase (FC-121-1030; Illumina) to tag and fragment accessible chromatin. The
reaction was incubated in a 37°C water bath for 45 minutes. Tagmented DNA was
purified using a MinElute Reaction Cleanup Kit (Qiagen) and amplified with 12 cycles of
PCR. Libraries were purified using a QIAQuick PCR Purification Kit (Qiagen). Libraries
were paired-end sequenced (38bp+37bp) on a NextSeq 550 (Illumina). For accessibility
in NIH3T3 cells, two biological replicates were performed at both 48 and 96 hr time
points after transduction. Three technical replicates were performed between WT and
TCF-1 KO DP T cells.
Single Cell ATAC: Single cell ATAC-seq was performed as previously described (127)
using the C1 Single-Cell Auto Prep System with the C1 Open AppTM program (Fluidigm).
Briefly, cells were FACS sorted to high viability and purity. Cells were then stained with
mammalian LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen) for 10 minutes on ice at a
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final concentration of 5 μM Ethidium homodimer-1 and 5 μM Calcein AM in 1x PBS.
After staining, cells were diluted in RPMI-1640 to a concentration of 400,000 cells mL-1.
C1 Cell Suspension Reagent (Fluidigm) was added to a final concentration of 20%.
Brightfield and fluorescent images of each capture site was taken with a Leica DMi8.
The Lysis/Tagmention step in the C1 protocol was lengthened to a duration of 60
minutes using the Open AppTM software (Fluidigm). After single cell ATAC-seq chemistry
was performed on the Fluidigm C1, tagmented DNA was harvested and amplified for 14
PCR cycles (Fluidigm). Libraries were paired-end sequenced (38bp+37bp) on a NextSeq
550. Three captures of DP T cells were performed over the course of this study.
Chromatin Immunoprecipitation (ChIP) assay: ChIP-seq was performed as previously
described (149). Briefly, chromatin samples prepared from fixed cells were
immunoprecipitated with antibodies recognizing mouse TCF-1 (C46C7; CST), H3K9me3
(AM39161; Active Motif), and H3K27me3 (07-449; EMD Millipore). Antibody-chromatin
complexes were captured with protein G–conjugated beads, washed, and eluted. After
reversal of cross-linking, RNase and proteinase K treatment were performed and DNA
was purified and quantified for library preparation. Input sample was prepared by the
same approach without immunoprecipitation. Libraries were then prepared using the
UltraTM DNA Library Prep Kit (NEB). Two replicates were performed for each condition.
Indexed libraries were validated for quality and size distribution using a TapeStation
2200 (Agilent). Single end sequencing (75 bp) was performed on a NextSeq 550.
RNA-seq: Cells were washed once with 1x PBS before resuspending pellet in 350 μL
Buffer RLT Plus (Qiagen) with 10% 2-Mercaptoethanol (Sigma), vortexed briefly, snapfrozen on dry ice, and stored at -80°C. Subsequently, total RNA was isolated using the
RNeasy Plus Micro Kit (Qiagen). RNA integrity numbers were determined using a
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TapeStation 2200 (Agilent), and all samples used for RNA-seq library preparation had
RIN numbers greater than 9.5. Libraries were prepared using the SMARTer® High-Input
Strand-Specific Total RNA-seq for Illumina kit (Clontech). Libraries were single-end
sequenced (75 bp) on a NextSeq 550. Three biological replicates were performed for
TCF-1 RV and Empty RV transduced NIH3T3 cells. Two technical replicates were
performed in WT and TCF-1 KO DP T cells.
Cell staining and flow cytometry: Single-cell suspensions were prepared from thymi of
mice by dissociation of tissue through 70 μM mesh filters (Falcon) in RPMI 1640
(Corning) +1% FBS (Gemini), and surfaces were stained following standard protocols.
The fluorochrome-conjugated, anti-mouse antibodies were as follows: PE CD4 (RM4-4),
APC CD8a (53-6.7), PE c-Kit (2B8), APC CD25 (PC61), and Streptavidin BV605. For
intracellular detection of TCF-1 in RV-transduced NIH3T3, cells were harvested after
trypsin dissociation (Gibco), fixed with 1% PFA for 10 minutes on ice to preserve VEX
signal, fixed and permeabilized with the FoxP3/Transcription Factor Staining Buffer Set
(eBioscience), and incubated with PE-conjugated anti-TCF-1 (S33-966). All antibodies
used for flow cytometry were purchased from BioLegend or BD Biosciences. Data were
collected on an LSRII running DIVA software (BD Biosciences) and were analyzed with
FlowJo software v10.2 (TreeStar).
Cell sorting: Antibodies used in the lineage cocktail (Lin) include biotinylated antibodies
against B220 (RA3-6B2), CD19 (1D3), CD11b/Mac1 (M1/70), Gr1 (8C5), CD11c (HL3),
NK1.1 (PK136), TER119 (TER-119), CD3ε (2C11), CD8α (53-6.7), CD8β (53-5.8), TCRβ
(H57), γδTCR (GL-3). After surface staining with the lineage cocktail, cells were
incubated with Streptavidin Microbeads (Miltenyi Biotec). DN cells were then negatively
isolated from total thymocytes using magnetic separation columns (Miltenyi Biotec).
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Negatively selected cells were then stained with c-Kit and CD25 followed by Strepavidin
BV605 to reveal escaping Lin+ cells. The DN3 population was defined and cell-sorted as
Lin– Kit– CD25+. Total thymocytes were stained with CD4+ CD8+ to define and sort the
DP population. Dead cells were excluded through 7-amino-actinomycin D (7-AAD)
uptake. Doublets were excluded through forward scatter–height by forward scatter–width
and side scatter–height by side scatter–width parameters. Purity was verified after
sorting, and all cell populations were sorted to a purity of >98%. Sorting was performed
on FACS Aria II (BD Biosciences) and were analyzed with FlowJo v10.2 (TreeStar).
High-throughput sequencing data pre-processing: Quality assessment of raw reads
was achieved with FastQC (150) and contaminants were removed using Trimgalore
(151) with parameters ‘-q 15 --length 20 --stringency 5’. For RNA-Seq samples, ‘-clip_R1 3’ was added to the Trimgalore parameters facilitating the removal of the 3nt
bias introduced to the 5’ end of reads. Human (GRCh37, November 17 2015) and
mouse (GRCm38, May 23 2014) reference genomes were downloaded from UCSC
repository (152) and mouse gene models were derived from Gencode vM11 (153).
Bulk ATAC-seq samples were mapped to the reference genomes using Bowtie2 v2.2.9
(154) with –X2000. STAR v2.5 (155) was used for aligning single-cell ATAC, RNA, ChIP
and MNase-seq reads with parameters specifically optimized based on the properties of
each protocol. RNA-seq samples were analyzed with parameters ‘-outFilterMultimapNmax 1 --outFilterScoreMinOverLread 0 -outFilterMatchNminOverLread 0 --alignEndsType Local’. On the other hand, ChIP-seq
raw reads were aligned with parameters ‘--alignSJDBoverhangMin 999 -alignSJoverhangMin 999 --alignIntronMax 1 --outFilterMultimapNmax 1 -outFilterScoreMinOverLread 0 --outFilterMatchNminOverLread 0 --alignEndsType Local’
61

to disable the usage of known and prevent calling novel splice junctions. The same
parameters were also applied for mapping scATAC-seq and MNase-seq data combined
with ‘--alignMatesGapMax 2000’ which limits the distance between aligned read mates
to 2,000bp.
Reads aligned to the mitochondrial genome as well as reads mapping to multiple
genomic loci were discarded from downstream analyses. Additionally, Picard (156)
minimized the PCR amplification bias in ATAC-, ChIP- and MNase-seq samples. In
cases of paired-end MNase-seq samples, fragments smaller than 75bp were also filtered
out.
ATAC-seq samples derived from single DP T cells were filtered using previously
described quality standards (127). In brief, libraries containing less than 10,000
fragments or libraries with less than 15% of their fragments falling in open chromatin (as
defined in the single cell accessibility section) were also removed from subsequent
analyses (Figure S3C-D).
Differential gene expression analysis: HTSeq v0.6.1 (157) facilitated counting RNAseq reads on Gencode vM11 (153) gene models with parameters ‘-s yes -t exon -m
intersection-nonempty’. DESeq2 (126) was subsequently applied on gene counts to
identify genes differentially expressed between DP WT and DP TCF-1 KO (Figure S2C),
NIH3T3 Empty RV and NIH3T3 TCF-1 RV (Figure S6B) as well as DP TCF-1 WT and
NIH3T3 Empty RV cells after removing entries that exhibited zero counts in all
replicates. The quality of replicates was assessed by calculating pairwise spearman
correlation coefficient (Figures S2B and S6A) as well as plotting the variability
explained by the first two principal components (data not shown).
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Additionally, gene expression levels were calculated in a variety of cell types ranging
from hematopoietic stem cells to effector and memory T cells and normalized using the
variance stabilizing transformation (VST) (126). K-means (k=12) clustering was then
applied on the VST expression values of genes upregulated by TCF-1 in NIH3T3 cells to
identify cell state specific patterns (i.e., clusters) of TCF-1 regulated gene expression.
For the same set of genes, we also calculated RPKM normalized expression values that
were used to filter out lowly expressed genes (RPKM < 0.5 in all samples) and
visualizing the clusters (Figure S6D-E). Cluster 1 was removed from the analysis due to
low expression levels in all hematopoietic lineages. Genes downregulated in the TCF-1
KO DP T cells were overlapped with the genes upregulated by TCF-1 RV in NIH3T3 and
the significance of the overlap was tested by Fisher’s exact test. (Figure S6F).
Defining thymocyte-specific gene program: Normalized microarray expression data
for bone marrow stem cell and thymocyte populations was downloaded from the
Immunological Genome Project Consortium (133). Microarray probe IDs (affy mogene
1.0st v1) were converted to Ensembl gene IDs using the Ensembl mouse gene mart
(GRCm38.p5) in biomaRt (158, 159). Genes were considered expressed in a population
if expression values were above 120 indicating >95% probability of true expression
(160). To define thymocyte-specific genes (Figure 7D), genes were filtered based on
expression values lower than 120 in all considered progenitor populations (LT-HSC, STHSC, MPP, CLP) and with expression values higher than 120 in at least 1 thymocyte
population (ETP, DN2a, DN2b, DN3a, DN3b, DN4, ISP, DP, CD4+, CD8+). Genes were
further filtered based on having at least a 2-fold increase in expression between any two
populations. The overlap of thymocyte-specific genes and genes upregulated by TCF-1
RV in NIH3T3 was determined using the GeneOverlap package (161). Genes
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upregulated by TCF-1 RV in NIH3T3, described in previous sections, but not overlapping
with thymocyte-specific genes were filtered based on expression >120 in at least one
progenitor population and plotted (Figure 7D). Thymocyte genes were grouped into
patterns of expression by combining thymocyte-specific genes with both overlapping and
non-overlapping with genes upregulated by TCF-1 RV in NIH3T3 and performing kmeans clustering using 5 centers. Gene ontology analysis (Figures S1E and S6C) was
performed using the Gene Ontology gene set collection in MSigDB database v6.1 (162,
163).
Peak calling: Following ENCODE guidelines, for the characterization of reproducible
TCF-1 peaks in NIH3T3 TCF-1 RV cells, macs2 v2.1.1 (164) was initially applied
separately on each of the two ChIP-seq replicates as well as after merging both
replicates with parameters ‘--nomodel --extsize 300 --keep-dup all --call-summits -q 0.9’
using the TCF-1 ChIP-seq on NIH3T3 Empty RV cells as control. The identified peaks
were filtered with Irreproducible Discovery Rate (IDR) v2.0.2 (165) using an IDR
threshold of 2e-2 resulting in a high-quality set of 40,562 reproducible peaks.
TCF-1, GATA3, RUNX1 and PU.1 binding sites in mouse thymocytes were identified by
applying macs2 with parameters ‘-p 1e-3 -q 0.05’ using the corresponding Input samples
as control resulting in 56,817 TCF-1 peaks, 54,475 GATA3, 67,915 RUNX1, 98,036
PU.1 in DN1 and 92,660 in DN2a.
A proximity-based strategy was adopted for linking genes to regulatory elements and
transcription factor binding sites. Gene models were downloaded from Gencode M11
and both ends of each gene were extended by 5kbp. Open chromatin sites identified by
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ATAC-seq as well as ChIP-seq derived transcription factor binding sites were assigned
to genes if they were found to overlap with their extended models.
Differentially accessible chromatin between DP WT and TCF-1 KO as well as
between NIH3T3 TCF-1 and Empty RV cells: Macs2 with ‘-p 1e-7 --nolambda -nomodel’ was applied on each DP WT and DP TCF-1 KO ATAC-seq replicate separately
to identify accessible chromatin. Peaks were subsequently merged using BEDTools
(166) and ATAC-seq read counts were calculated in the merged peaks for every
replicate. The resulting count table was used to identify 6,165 (1,165 presenting more
and 5,000 less enrichment in DP TCF-1 KO) loci differentially enriched in ATAC-seq
signal between DP WT and DP TCF-1 KO with DESeq2 after applying a 0.001 and 0.55
cutoff on p-value and logFC respectively (Figure 3A).
The same approach and cutoff were applied in NIH3T3 cells (Figure S4D) for identifying
8,506 genomic regions presenting differential ATAC-seq signal enrichment between
Empty and TCF-1 RV (6,888 presenting more and 1,618 less enrichment in TCF-1 RV).
Characterization of cell-state specific accessible chromatin: An IDR threshold of 5e2 was used, following the pipeline described in previous section, to identify accessible
chromatin for every murine ATAC-seq sample (HSC, MPP, CLP, B, NK and all stages of
T cell development from DN1 to naïve CD4+ and naïve CD8+ cells). Peaks were merged
and filtered based on their overlap with annotated promoters (Gencode M11 TSSs
extended by +4kb/-2kb) resulting in a collection of 55,481 distal regulatory elements.
The FDR value of each peak in every cell type was used as a proxy for the level of
accessibility.
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Each peak was assigned a 13-dimensional vector containing the ATAC-seq enrichment
proxy in every cell type. Average Silhouette Width (ASW) statistic was used for deciding
on the number of clusters prior to applying k-means. The initial set of regulatory regions
was reduced after removing the members of clusters 7, 8, 10, 11, 13, 17 and 23 (Figure
S1A). The remaining 35,869 loci were re-clustered after re-calculating ASW (data not
shown) to produce the final set of groups (Figure 2A). Normalized (TPM) ATAC-seq
profile for every regulatory element was calculated by segmenting a +/- 2,000bp window
around its center in 10bp bins and calculating the normalized overlapping ATAC-seq tag
counts (Figures 2B and S1B).
De novo motif analysis using Homer with ‘-size given -len 6,8,10’ was applied on each
cluster separately using the excluded set of clusters as background (Figure 2C-E,
Figure S1C). Additionally, odds ratio and percentage of binding of TCF-1, GATA3,
RUNX1 and PU.1 (DN1 and DN2a) was calculated for each cluster based on publicly
available ChIP-seq data (Figure 2F).
An alternative approach was used for identifying T cell specific accessible chromatin in
human cells (Figure S1D). The lack of replicates for certain cell types restricted the use
of IDR. Therefore, macs2 with parameters ‘-p 1e-7 --nolambda --nomodel’ was used for
every cell type (HSC, MPP, CLP, B, NK, Naïve CD4+ and Naïve CD8+ cells) on each
replicate separately. Peaks were merged with BEDTools and normalized ATAC-seq
enrichment for every cell type was calculated after merging the replicate samples within
each cell type. Gencode M11 gene models were used to separate the set of ATAC-seq
peaks into distal and promoter related loci after extending the annotated gene
transcription start sites by -4kb/+2kb.
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Each peak was assigned a 7-dimensional vector containing the normalized ATAC-seq
enrichment in every cell type. Within Sum of Squares (WSS) statistic was used (data not
shown) for deciding on the number of clusters prior to applying k-means (k=10 for the
distal sets and k=5 for the promoter sets). De novo motif analysis using Homer with ‘size given -len 6,8,10,12’ was applied on each cluster separately with remaining peaks
in other clusters as background (Figure S1D).
Querying chromatin accessibility at the single-cell level: To assess whether TCF-1
binding events harbor the strongest chromatin accessibility as measured by ATAC-seq
in DP T cells, we measured genome-wide binding of TCF-1, RUNX1 and GATA3 by
ChIP-seq as previously described. An equal number of genomic regions with unique
binding of each transcription factor were subsampled and the normalized tag count
enrichment from ATAC-seq in DP T cells facilitated the comparison of the 3 regulatory
proteins (Figure 4A).
Based on this analysis, TCF-1 bound open chromatin was found to exhibit the highest
levels of accessibility compared to RUNX1 and GATA3. This observation inspired us to
further investigate with a single cell analysis. ATAC-seq data from 110 single DP T cells
passing previously defined (127) quality standards (Figure S3D) were utilized to test the
hypothesis that TCF-1 exerts a deterministic effect on the chromatin, forcing T cell fate
commitment. Following pre-processing and alignment, DP single cell ATAC-seq reads
were merged and using macs2 with parameters ‘-p 1e-3’, 22,774 accessible sites were
identified.
To assess the correlation between aggregated single cell and bulk ATAC-seq enriched
sites identified from both experimental procedures were merged. Normalized enrichment
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was subsequently calculated in bulk (downsampled to 11.6 million reads using samtools)
and aggregated scATAC-seq with 11.6 million reads enabling the correlation level
quantification between the two assays (Figure 4B).
Our objective was to assess whether TCF-1-bound open chromatin had lower
accessibility variance than background noise and chromatin bound by RUNX1 or
GATA3. To this end, we generated 4 disjoint sets comprising of ATAC-seq peaks
uniquely bound by TCF-1, RUNX1, GATA3 as well as peaks not bound by any of these
three transcription factors. For each subset, binarized accessibility matrices were
calculated based on the overlap between the identified peaks and ATAC-seq reads from
each cell, thus 1 translates to accessible and 0 to inaccessible regions.
TCF-1 binding events overlapped with more ATAC-seq peaks than RUNX1 or GATA3,
therefore we subsampled 30 peaks from each TF-bound peak set. We repeated the
subsampling process 500 times to increase accuracy. We then calculated the
accessibility variance between cells at each subsample as follows. For each subsample,
the binary accessibility vector of each cell formed a 30-dimensional vector. To measure
cell to cell differences in accessibility levels, we calculated the pairwise Manhattan
distance between accessibility vectors, forming a distance matrix.
We subsequently centered the Manhattan distance matrix by subtracting column and
row means and adding the overall mean. Then we spectrally decomposed the centered
matrix to define principal coordinates and mapped all accessibility vectors to full principal
coordinate space. We identified the location that minimized the average distance to all
vectors, termed the spatial median (Figure 4D). Then, we calculated each vector’s
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distance from the spatial median. Finally, we calculated the average distance from
accessibility vectors to the spatial median using the R package vegan (167).
Correction for Technical Biases: Variation associated with technical factors such as
GC content and mean accessibility differences can often introduce obstacles in
interpreting NGS data. To overcome such limitations, for every original peak, we
selected 30 “technical control” ones. The set of peaks not bound by any TF were divided
into 2-percentiles based on GC content. Every original peak was subsequently placed
into a 2-percentile, and 30 technical control peaks within a 2-percentile of GC content
were randomly subsampled with replacement. All technical control peaks were also
within +/- 0.01 of the overall mean accessibility of the original 30 peaks.
Correction for Background Noise: To measure accessibility variation beyond
background noise, we calculated accessibility variation (with technical controls) for 500
randomly selected subsamples of peaks bound by no TF. This can be viewed as a
negative control.
A variability equal to 1 implied that a TF was associated with no more variation than
background noise. A variability below 1 implied that a TF was associated with less
variation than background noise, and a variability above 1 implied greater variation than
background noise.
In addition to the methodology described above, we also applied chromVAR (168) for
assessing the deterministic effect of TCF-1 on shaping the chromatin landscape during T
cell development (Figure 4E).
ChIP-seq oriented approach for assessing the deterministic effect of TCF-1 during
T cell development: An alternative, unbiased strategy was also adopted which, unlike
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the previous approach, was not formed on the basis of TCF-1 binding (Figure 4F). The
T cell specific sites in cluster 9 (Figure 2A) were ranked based on the sum of binary
counts across individual T cells. Using default parameters of bedtools intersect, the
overlap of regions with ChIP-seq signal from transcription factors known to be important
in T cell development such as TCF-1, GATA3 and RUNX1 was assessed. De novo motif
analysis was performed on the top and bottom 100 enhancers that exhibit the highest
and lowest homogeneity respectively at the single cell level using Homer with
parameters ‘-size given -len 6,8,10,12’. Background control in this motif analysis was
any other open chromatin sites in DP T cells. The top/bottom 100 enhancers were also
linked to genes based on proximity (<10kbp) in order to enable GO term enrichment
analysis using the GSEA software.
Identifying the nucleosome occupancy level on TCF-1 binding sites: MNase-seq in
mouse embryonic fibroblasts was used as a proxy for observing the nucleosome
enrichment surrounding TCF-1 binding sites. To this end, the region around TCF-1 peak
summits was divided into 3 windows of 200bp each; -300/-100, -100/+100 and
+100/+300 following a upstream-central-downstream rationale. The nucleosome
enrichment in every window was approximated by calculating the number of overlapping
MNase-seq reads after extending their 3’ end to 147bp and normalizing based on the
number of uniquely mapped reads in each sample. TCF-1 summits were subsequently
ranked from high to low enrichment by summing the values of left, central and right
windows. For visualization purposes, the normalized MNase-seq enrichment was also
calculated for 10bp non-overlapping bins spanning the +/- 3kb region centered around
TCF-1 summits (Figure 5A).
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In the case of mouse embryonic fibroblasts, visualizing the prior nucleosome enrichment
status on the genomic loci bound by TCF-1 after Tcf7 retroviral transduction clearly
suggests that TCF-1 binding occurs on: a) nucleosome dense, b) nucleosome free and
c) regions of intermediate nucleosome occupancy (Figure 5A). Instead of choosing an
arbitrary threshold on the ratio of central versus left and right window nucleosome
enrichment, k-means (k = 3) clustering was applied resulting in the formation of 3 TCF-1
summit groups and validating the previously described observation (Figure S4C). A total
of 29,661 (73.2%) TCF-1 binding events occur on sites with dense (10,593, 26.2%) or
intermediate (19,068, 47%) nucleosome enrichment and 10,901 (26.8%) on nucleosome
free regions.
Dpos module from Danpos2 (169) was applied on the MNase-seq data with default
settings to identify nucleosome positioning as well as calculate the nucleosome
enrichment profile on a genome-wide scale. Regions called as nucleosomes exhibiting
increased fuzziness (Dpos score less than 80) were removed from subsequent
analyses. The distance of 40,562 TCF-1 summits in mouse embryonic fibroblasts to the
closest nucleosome summit was calculated as an alternative strategy of assessing the
ability of TCF-1 to directly bind on nucleosomes (Figure 5B). The typical length of DNA
fragments wrapped around nucleosomes is 147bp. This allowed us to classify 27,145
TCF-1 summits (66.9%) located less than 75bp (vertical dashed red line) away from
nucleosome summits as bound to nucleosomes and 13,417 (33.1%) summits as
unbound. As a control, we applied the same bound/unbound to nucleosomes
classification scheme on CTCF summits derived from analyzing public ChIP-seq data,
resulting in 20,370 (56.6%) bound and 15,616 (43.4%) unbound summits.
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To assess the difference of nucleosome occupancy level around TCF-1 ChIP-seq peak
summits between Empty RV and TCF-1 RV NIH3T3 cells, TCF-1 summits (IDR less
than or equal to 0.02) were intersected with ATAC-seq enriched regions in both
conditions. Summits overlapping ATAC-seq peaks in either set (n=15,763) were
extended by +/- 500 bases and nucleosome occupancy in Empty and TCF-1 RV NIH3T3
cells was measured using NucleoATAC algorithm (132). NucleoATAC infers nucleosome
enrichment by integrating large and small ATAC-seq fragment positioning in accessible
chromatin. Therefore, to quantitate nucleosome enrichment around TCF-1 summits with
NucleoATAC algorithm, ATAC-seq signal from both Empty and TCF-1 RV NIH3T3
samples is required. Out of 15,763 queried summits 7,395 were found to exhibit at least
1.5 fold-change difference in nucleosome occupancy signal between Empty and TCF-1
RV NIH3T3 cells (Figure S4F).
T cell gene enrichment in nucleosome enriched based clusters of TCF-1 summits:
Based on the previously described analysis regarding the pre-induced nucleosome
enrichment levels around TCF-1 ChIP-seq derived binding events in TCF-1 RV NIH3T3
cells, we identified 3 clusters of TCF-1 summits (Figure S4C). TCF-1 summits with high
(n=10,593), intermediate (n=19,068) and low (n=10,901) nucleosome enrichment. In
parallel, the previously described differential gene expression analysis between Empty
RV NIH3T3 and DP T cells, identified 3,349 genes as DP T and 4,040 as NIH3T3 cellspecific. To calculate the enrichment of the 2 gene sets in the 3 nucleosome enrichment
clusters, TCF-1 peak summits were associated with genes, as described in previous
section, resulting in 27,794 interactions between 24,330 TCF-1 summits and 10,212
genes. To remove redundancy in the association between genes and nucleosome
clusters we filtered out genes associated to zero or more than one clusters. The
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remaining were used to calculate the enrichment of DP T cell-specific genes in high,
intermediate and low MNase clusters with Fisher’s exact test (Figure S6I).
Motif distances from nucleosome summit: MEME-FIMO (165) and TCF-1 position
probability matrix (MA0769.1) from JASPAR (170) facilitated the discovery of 1,102,896
putative TCF-1 binding sites (motifs) in the mouse genome using a p-value threshold of
1e-4. 17,816 motifs were found to overlap with TCF-1 ChIP-seq peaks specific to TCF-1
RV NIH3T3 and 7,782 with peaks specific to DP T cells. To avoid biases associated to
imbalanced number of motif occurrences in peaks, a one-to-one association between
motifs and summits was created by selecting the closest to summit motif per peak with a
maximum distance threshold of 100bp. This resulted in the finalized sets of motifs bound
in TCF-1 RV NIH3T3 (n=10,665) and DP T cells (n=6,115). The remaining unbound
putative TCF-1 sites were grouped into motif hotspots using a distance threshold of
500bp. For every hotspot the motif with the highest FIMO score was selected as its
representative (random selection for ties) resulting in the formation of the final ‘Random’
set of unbound motifs (n=862,733) that were used as control.
Nucleosome positions were called using Danpos2 (169) as previously described. The
distance between motifs from NIH3T3, DP T and Random sets to their closest
nucleosome dyad was calculated using BEDTools (166). The visual comparison of the
distribution of distances between each cell type specific set and the Random set was
achieved by randomly selecting 1,000 samples from each set with replacement, plotting
the density of distances and repeating this process 1,000 times (Figure S4D). To assess
whether there is a statistically significant difference in the median motif distance from the
nucleosome dyad between each cell-specific (target) set and the Random set, we
carried out two separate bootstrapping procedures, one for each target set. Distances
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from the target and Random set were combined into a pooled vector. Both target and
Random sets were transformed by subtracting each set’s mean from every member of
the relevant set and adding the mean of the pooled vector. This way, both sets are first
centered around their mean and then shifted by the pooled mean resulting in the proper
transformation for testing the null-hypothesis (no difference between median motif
distances from the nucleosome center of the two sets) without making any assumptions
about their variance. Subsequently, we randomly selected 1,000 samples (with
replacement) from each transformed set and compared the difference between median
distances. After repeating this process 100,000 times we divided the number of times we
observed a difference between the median distances larger than (or equal to) the raw
difference (no subsampling) to calculate the p-value (Figure S4D).
Characterization of the chromatin state in NIH3T3 cells prior to Tcf7 retroviral
transduction: In addition to having established the pre-Tcf7 overexpression
nucleosome occupancy environment in NIH3T3 cells, querying the chromatin state
landscape is a critical step towards unveiling the properties of TCF-1 binding in a
genome-wide, quantitative way. To this end, the enrichment of H3K4me3, H3K4me1,
H3K9me3, H3K27me3 and H3K27ac versus Input in the +/- 1kb (and +/- 250bp) region
surrounding TCF-1 summits has been calculated by modeling read counts with a
binomial mixture model of two components with normR (171). The first component
models the background and the second one the signal, independently for each histone
mark, resulting in a five-dimensional vector of p-values adjusted for multiple
comparisons for every summit. H3K27me3, H3K9me3, and H3K27ac enrichment in
TCF-1 RV NIH3T3 cells was calculated as well (Figure 6C-D). Furthermore, the
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enrichment of ATAC-seq in NIH3T3 TCF-1 RV versus Empty RV cells and vice versa
has also been calculated around summits.
These enrichment results facilitated the assessment of correlations between the
chromatin status and chromatin accessibility before and after Tcf7 overexpression
(Figure 6, Figure S5). Additionally, k-means clustering has been applied on TCF-1
summits based on the enrichment level of the 5 chromatin marks in pre-induced cells
resulting in the formation of 11 clusters (Figure 6B, Figure S5D, Table S6), following
silhouette coefficient analysis (Figure S5C). For visualization purposes, the normalized
histone mark ChIP-seq as well as ATAC-seq enrichment was also calculated for 10bp
non-overlapping bins spanning the +/- 3kb region centered around TCF-1 summits
separately for each cluster.
Deregulated genes in NIH3T3 TCF-1 RV cells were linked to TCF-1 binding sites based
on the proximity strategy described in previous sections. Consequently, genes were also
connected to chromatin states. This enabled the calculation of the significance of upand down-regulated genes enrichment in each chromatin state using Fisher’s exact test
(Figures 7E and S6G). To assess differences in the enrichment of H3K9me3,
H3K27me3 and H3K27ac ChIP-seq signal around TCF-1 binding events between preinduced and TCF-1 RV NIH3T3 cells, we used diffR function from normR package using
an FDR threshold of 5e-2.
Gene set enrichment analysis: Pre-ranked lists of genes were used by ranking genes
using estimated log2 fold-change in DESeq2. GSEA v2.2.4 with default parameters was
used to perform gene set enrichment analysis.
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Quantification and Statistical Analysis: All statistical analyses were performed from
packages from R’s basic installation.
Data and Software Availability: The accession number for the ChIP-seq, RNA-seq and
ATAC-seq reported in this study is NCBI GEO: GSE99149
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3.2: INTRODUCTION

3.2.1 The innate and adaptive immune responses

Protective immunity depends on selecting appropriate effector function and
perpetuating those choices in long-lived memory cells. While non-specialized effector
function may afford some degree of protection, the adaptive immune response is most
protective when effector function is pathogen-tailored and subsequent memory cells
develop sustained specialization. These fate choices are set early in the immune
response due to the interplay between the innate and adaptive immune systems (173).
The signals exchanged between these two systems are often classified as activating and
regulatory interactions but can also include interactions that specify effector cell identity
and function. Cells of the innate immune system are the first line of defense and can
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respond rapidly to the presence of a pathogen. Innate cells such as macrophages and
DCs express a variety of germ-line encoded PRRs that bind evolutionarily conserved
PAMPs (174). The engagement of PAMPs with PRRs transmits an activation signal that
triggers an immediate innate cell response. Once activated, the innate cell response
provides inductive signals to cells of the adaptive immune response to direct effector
choices (175, 176).
Unlike the innate immune response, the adaptive immune response is directed
by antigen-specific lymphocytes. T cells and B cells bear antigen receptors (TCRs and
BCRs, respectively) that are assembled by gene rearrangement during their
development in the thymus and bone marrow. According to the clonal selection theory
(6), these unique antigen receptors are clonally distributed throughout T and B cell
populations. The interactions of antigen receptor with antigens are reversible, but
receptor occupation needs to exceed a threshold for lymphocyte activation to occur. This
requirement provides selectivity, as only the antigens with the right stereochemical and
electrostatic configuration will bind the receptor with a high enough affinity to cross-link
receptors or engage co-receptors (177). Antigen binding to the receptor triggers a
cascade of intracellular signaling events that culminates in the activation of transcription
factors to induce mitosis. Activated T and B cell clones retain their antigen specificity as
they expand by 10- to 100-fold and gain effector function. A fraction of these cells
persists indefinitely as memory cells, sustaining ongoing effector functions and
participating in responses to subsequent pathogen challenges. Deleting cells with
antigen receptors that respond to self-antigens or the preventing their acquisition of
effector function sustains immunological tolerance. These four pillars of the adaptive
immune response—inducibility, specificity, memory, and non-responsiveness to self—
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are shared between the cell-mediated and humoral aspects of the immune response,
mediated by T and B cells, respectively.
The T cells of the cell-mediated immune response coordinate their effector
functions via interactions of their TCR with peptide:MHC complexes on antigen
presenting cells. T cells are subdivided based on the mutually exclusive expression of
either CD8 or CD4, co-receptors involved in the binding of TCR to MHC I or MHC II,
respectively. The distribution of MHC I and MHC II expression varies amongst cells.
Essentially all nucleated cells express MHC I and peptides derived from cytosolic protein
synthesis are presented on MHC I. The immune surveillance of intracellular activity is
therefore carried out by CD8+ cytotoxic T cells, or CTL, that lyse cells presenting nonself peptides on MHC I. Conversely, extracellular activity is monitored by CD4+ T cells
that bind peptides derived from the endocytic pathway presented on MHC II. Thus, MHC
II expression and presentation are limited to antigen presenting cells that regularly
internalize components of the extracellular environment, such as B cells, macrophages,
and DCs. CD4+ T cells, or helper T cells, produce membrane-associated proteins and
cytokines to orchestrate the immune response and are capable of differentiating into
effector subsets such as TH1, TH2, TH17, TFH, or Tregs (178-180). The differentiation
programs associated with these effector subsets are carried out by master
transcriptional regulators in response to certain cues shaped by the nature of the
pathogen and its PAMPs, the PRRs that are engaged, and the interactions between
innate and adaptive immune cells. TCR signal strength, costimulation, and cytokine
milieu guide CD4+ helper T cells to adopt effector fates (181-184).
3.2.2 B lymphocytes of the adaptive immune response: subsets and development
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The humoral response is mediated by B cells that, following activation and
differentiation to plasma cells, produce highly specific antibodies. Antibodies serve as
the antigen receptor of B cells, but their exacting specificity for the molecular
conformation of the antigen means that a highly diverse set of antibodies need to be
represented in the primary pool of B cells (185). To achieve this diversity, antibodies are
composed of two chains, the heavy and light chain, and gene rearrangement of V, D,
and J gene segments for the heavy chain and V, J segments for the light chain greatly
diversifies the coding sequence (186). When translated, the recombined VDJ and VJ
regions of the heavy and light chains fold and come together to create an antigen
binding region called the combining site. The junctional sequence spanning the
recombined segments, known as the complementarity defining region 3, or CDR3, is the
most variable sequence of the antibody and plays a major role in determining specificity
(187). Further, an antibody is bivalent being comprised of two pairs of heavy and light
chains joined together by disulfide bonds (188). For antigen binding, the heavy and light
chains are made up of a variable region and a constant region. The joining of the heavy
and light chain variable regions contacts the antigen and confers specificity whereas the
constant region of the heavy chain, but not the light chain, dictates effector function.
There are five Ig heavy chain constant region isotypes, μ, δ, α, γ, ε that combine
with λ or κ side chains to make an IgM, IgD, IgA, IgG, or IgE antibody, respectively. The
IgG isotypes can be further subdivided into IgG1, IgG2a/c (IgG2a in BALB/c and IgG2c
for C57Bl/6 (189)), IgG2b, or IgG3. The selection of the Ig heavy chain isotype has
profound implications for the response quality. Antibodies can protect through multiple
mechanisms such as neutralization, opsonization, complement deposition,
degranulation, and ADCC, and it is the heavy chain constant region that dictates this
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effector action. The heavy chain constant region links the adaptive immune system with
the innate immune system as innate and other cell types express isotype-specific Fc
receptors (FcR). FcRs can be activating or inhibitory and can modulate cell behavior
based on the FcR expression profile (190). Moreover, the selection of isotype is based
on the cytokine milieu and the expression of master transcriptional regulators.
Immunoglobulin class switching, also known as class switch recombination (CSR) or
isotype switching, is the process by which antibody heavy chain constant regions are
changed in an ongoing immune response, involves gene rearrangement and is thus
irreversible. Therefore, tight regulation of isotype switching is critical for effective
humoral immunity and to avoid effector mechanisms that cause autoimmune or
inflammatory disease. Generating a protective antibody response of the proper effector
isotype requires strict regulation of B cell development, commitment, and homeostasis.
There are two major types of mature B cells: B1 and B2 cells. B1 B cells develop
from fetal liver precursors during embryogenesis and contribute to the bulk of IgM titers
to “natural” antigens as an extension of the innate immune system (191-193). B2 B cells
are derived from bone marrow stem cells and are constantly produced throughout life
except during old age when lymphopoiesis declines (194, 195). Multiple transcription
factors coordinate the transcriptional network of B cell development. The transcription
factor PU.1 (196) is expressed in B cell precursors to establish a regulatory state for E2A
(197) and EBF (198) to carry out the transcriptional program of early B cell specification
with PAX5 (199, 200) maintaining B cell identity. As B cells develop in the bone marrow,
they migrate from the endosteum to the central sinus of the bone marrow and become
immature B cells when they acquire IgM. At this time, immature B cells exit the bone
marrow and become transitional B cells (201, 202). In the periphery, transitional B cells
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undergo the final stage of development into mature B cells and can differentiate into
either marginal zone B cells or follicular B cells which occupy different niches in the
peripheral lymphatics (203-205). The cues required to adopt the MZ instead of the FO B
cell fate are the strength of tonic BCR signals, transcriptional programs from Notch2
(206), and interactions with Delta-Like-1 (207).
Millions of B cells are produced every day, but a small proportion of them enter
into the mature pool. A tenth of developing B cells become immature B cells and only a
third of those immature B cells will make it through the transitional B cell stage and
become mature B cells (202). This loss is due to stringent selection based on BCR
specificity at the immature and transitional stages (208-210). Negative selection and
positive selection reduce the frequency of polyreactive and self-reactive specificities
(209-211) while also selecting for BCRs with near threshold signal strength (212-215).
Therefore, autoreactive specificities decrease with differentiation (216, 217), and even
among peripheral B cells, transitional B cells are a source of autoreactive BCR
specificities (218, 219).
3.2.3 Thymus dependent and independent B cell responses

The immunoglobulin constructed by recombination during development serves as
the extracellular B cell receptor (BCR) driving antigen-specific B cell responses. The
chemical structures recognized by the BCR include proteins, glycoproteins,
polysaccharides, viral particles, and bacterial cells. Cross-linking of BCRs through
binding to epitopes on these multivalent chemical structures leads to the internalization
of the BCR as well as the bound antigen and initiates intracellular signaling events that
culminate in the activation of nuclear transcription factors and gene expression for B cell
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activation (reviewed in (220)). B cells also express PRRs internally and externally and
can become activated by the binding of PRRs to PAMPs to produce an innate-like
immune response or to tune the adaptive response (221). Thus, the internalization of
antigen by BCR cross-linking serves two purposes: 1) to deliver antigen to the endocytic
compartment for protein degradation and the loading of peptides onto MHC II and 2) to
expose PAMPS to intracellular PRRs. The quality of the ensuing B cell response
depends on the mode of interaction of the antigen with the BCR and the chemical
composition of the antigen. The integration of these parameters follows the two-signal
model whereby the cross-linking of the BCR provides Signal 1 and additional activation
or survival signals delivered by other receptors provide Signal 2 (222). There are two
major types of B cell responses that are largely determined by the nature of Signal 2. In
thymus-dependent (TD) responses, Signal 2 is provided by antigen-specific CD4+ T
cells that bind peptide:MHC presented by B cells in the form of surface receptor
engagement or cytokine secretion. In thymus-independent (TI) responses, Signal 2 can
come from B cell engagement of PRRs with PAMPs (TI-1) or through extensive crosslinking of the BCR itself (TI-2) to foster a short-lived response composed of low affinity
antibodies to microbial antigens (223, 224).
There are substantial differences between TI and TD responses in terms of
antibody affinity, isotype production, effector differentiation, and memory cell generation,
and different subsets of B cells contribute differentially to each type of response. In the
B-2 lineage, follicular B cells make up the bulk of TD responses. Conversely, marginal
zone B cells of the B-2 lineage and B-1 B cells primarily give rise to TI responses (225)
likely because of the characteristics of their BCR signaling, their differentiative potential,
and their enhanced sensitivity to detect PAMPs. Activated B cells in TI responses rapidly
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differentiate into extrafollicular plasmablasts for the short-lived secretion of low-affinity
antibody, primarily of the IgM isotype (226, 227). Conversely, B cell activity in TD
responses is protracted and eventually produces IgG (228). Intriguingly, the antibody
affinity of a TD response is not static but gradually increases over time in a process
known as affinity maturation (229). As with TI responses, B cells in a TD response
differentiate into extrafollicular PCs, relatively long-lived antibody secreting cells, and
memory cell B cells (MBCs) (230-233). Some activated B cells in a TD response will
migrate to the border between the follicle and the T cell zone to seek out cognate help
from CD4 T cells primed by dendritic cells (234, 235). Once engaged, B cell proliferation
continues and forms a germinal center, a transient structure composed of proliferating B
cells, CD4 T cells, and other myeloid cells such as follicular dendritic cells.
The germinal center is a structure unique to TD responses and fosters the affinity
maturation of germinal center B (GCB) cells (236, 237) and their differentiation to MBCs
and LLPCs (238). The exchange of signals between B cells and T cells is limited to the
CD4 T cells with specificity for the peptide antigens derived from the antigen internalized
by the B cell (239, 240). Thus, cognate interactions are provided by the CD4 T cell and
includes the engagement of CD40/CD40L and the production of key cytokines. These
signals foster the upregulation of BCL6 in B cells to drive a germinal center
transcriptional program (241-244). Another critical gene to be upregulated in GCB cells
is activation-induced deaminase (AID), which creates point mutations in the variable (V)
regions of the Ig (245, 246). The process of accumulating these point mutations is
referred to as somatic hypermutation (SHM) and results in clonal variants with altered B
cell receptors (247). An altered receptor can change the affinity and specificity of the
receptor and thereby influence the fate of GCB cells. In the GC, clones compete for
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survival signals and those with high-affinity receptors are preserved to continue SHM or
to differentiate whereas the clones with low-affinity receptors die (248). SHM and affinity
maturation is thought to be more efficient in GCs, but instances of SHM occurring in
extrafollicular sites have been reported (249, 250). How selective competition is created
between clones of differing affinities is still a matter of intense investigation, but clearly
clones compete for antigen and the opportunity to present that antigen (251). In the
cyclic reentry model, somatic hypermutation is thought to occur in the proliferating B
cells of the dark zone of the GC before upregulating the altered BCR and migrating to
the light zone (251). In the light zone, B cells find FDCs bearing antigen and compete
with other clones for the antigen. Successful acquisition of antigen allows the B cell to
present antigen to nearby CD4 T cells to receive survival signals and instructive cues.
The CD4 T cell subset guiding the GC reaction is transcriptionally distinct from other T
helper cells (252) and are known as T follicular helper (TFH) cells, which migrate to the
border of the B cell follicle via CXCR5 (253) and select high affinity GC clones through
BLyS secretion (239).
3.2.4 Plasma cells and memory B cells in humoral immunity

Humoral immunity depends on the continual production of circulating antibody as
antibodies only have half-lives measured in days or weeks. Therefore, the differentiation
of activated B cells into LLPCs or the sustained differentiation of SLPCs due to
persistent antigen is critical for long term protective immunity (254-256). The
differentiation of activated B cells into plasma cells depends on the integration of various
instructive cues resulting in the upregulation of the transcription factor BLIMP-1 (257,
258) and extinguishing the B lineage transcription factor PAX5 (259, 260). These
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transcription factor dynamics facilitate a gene expression program that direct B cells to
terminally differentiate into plasma cells and acquire the specialized functions associated
with antibody production. The heterogeneity in the lifespan of PCs has been elucidated
in recent years as well. T cell independent PCs are longer lived than initially thought and
the turnover kinetics in BM PC pools is more complex than previously appreciated (261,
262). Moreover, PCs are heterogeneous and have additional functions beyond antibody
production including cytokine and antimicrobial secretion (263, 264).
Similarly, accumulating evidence shows that memory cells are not monolithic
populations, but instead consist of functionally distinct subsets that play different roles in
protective immunity. Thus, several subsets of memory T cells have been defined,
reflecting differences in phenotype, function, and migration patterns (265, 266). Memory
B cell (MBC) subsets have also been described based on differential expression of
CD73, CD80 and PD-L2 (267); MBCs expressing both CD80 and PD-L2 form plasma
cells upon re-challenge, whereas the double-negative cells join germinal centers (268).
Different memory fates can be determined by cytokine milieu, metabolic cues
and transcriptional programs. For example, reciprocal patterns of T-bet and
Eomesodermin expression underlie differentiation of T cells to effector versus memory
subsets (269, 270). While the demarcation of T cell memory subsets by transcription
factor expression is well established, analogous relationships have not been extensively
explored in MBCs.
3.2.5 A T-bet expressing B cell subset accumulates during aging

The discovery of a T-bet+ B cell subset in both mice and humans has piqued
interest in the origin and role of these cells in primary and secondary humoral immune
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responses. T-bet+ B cells were first described in the context of murine aging and were
thus termed “Age-associated B Cells,” or ABCs (271, 272). Subsequent analyses
revealed roles for cognate T cell help and antigen presentation in their development.
This, as well as a high frequency of somatically mutated immunoglobulin (Ig) genes in
these cells, suggested that T-bet+ ABCs are MBCs formed during T-dependent B cell
responses (273). Whether T-bet+ versus T-bet- MBCs differ in their origins, kinetics of
generation, trafficking patterns, and functional roles remains unclear. We previously
showed that T-bet+ B cells appear and persist following influenza immunization or
infection in mice (273, 274), providing a means to track T-bet+ and T-bet- MBCs in a
defined antigen system. Moreover, most humans have been exposed to influenza
through immunization and infection and thus have standing influenza hemagglutinin
(HA)-specific MBCs, enabling direct comparative analyses between human and murine
MBC subsets.
3.2.6 Scope

Our results reveal multiple MBC subsets distinguished by T-bet expression,
whose phenotypic and functional attributes are largely shared between mice and
humans. We show that T-bet expression divides influenza-specific MBCs into T-bet-, Tbetlo, and T-bethi populations with differing anatomic localization, residency patterns, and
antigenic specificity. Upon infection, all three subsets are initially observed in draining
lymph nodes, spleen, and infected tissues, whereas T-bethi MBCs are selectively
maintained in the spleen, remain resident, and are excluded from the lymphatics. In
addition, B cell receptor sequencing shows that HA-specific T-bet+ and T-bet- MBCs are
largely clonally distinct, with infrequent sharing of clones. Divergence within clonal
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lineages, in conjunction with genetic fate-mapping, demonstrates that T-bet expression
in T-bet+ MBCs is stable. Finally, we show in mice that T-bet expression in the B lineage
is required for the development of HA-specific IgG2c and nearly all HA stalk-specific
antibody. Together, these results establish T-bet expression as a distinguishing feature
of MBC subsets that have profoundly different homing and functional properties and
mediate distinct aspects of humoral immune memory.

3.3 RESULTS

3.3.1 T-bet expression distinguishes unique influenza-specific memory B cell populations

Prior studies suggested T-bet-expressing B cells are an antigen-experienced
population, but the functional differences between T-bet+ and T-bet- MBC subsets
remain unclear. Thus, we set out to define T-bet- and T-bet+ B cell generation and
persistence using influenza infection in a T-bet-ZsGreen reporter system (275). We
infected T-bet-ZsGreen reporter mice with 30 TCID50 of influenza A/Puerto Rico/8/1934
(PR8) and observed weight loss and recovery over a period of 4 weeks post infection,
with the nadir at 9 days post infection (dpi; Figure S7A). We harvested mediastinal,
mesenteric, and pooled peripheral (superficial cervical, axillary, brachial, and inguinal)
lymph nodes (LN), spleen, lungs, and blood from infected mice at multiple time points,
and identified influenza hemagglutinin (HA)-specific B cells using biotinylated PR8 HA
probes modified to prevent sialic acid binding (276). The HA probes were separately
conjugated to two streptavidin-fluorophore conjugates to exclude fluorophore-specific B
cells during flow cytometric analysis (Figure S7B).
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We identified low numbers of HA-specific B cells in lymphoid organs of naïve
mice, in agreement with previous estimates of the primary HA-responsive repertoire
(277); these were uniformly T-bet- (Figure S7B). To exclude this primary pool, we
focused subsequent analyses on IgD- B cells (Figure S7C). IgD- HA-specific B cells
were detected in spleen, mediastinal LN, and lungs of all mice at both acute infection
and memory time points (Figure 8A). Examination of T-bet-ZsGreen and CD11c
expression in HA-specific B cells indicated that T-bet+ B cells can be phenotypically
subdivided into T-bethi and T-betlo subsets with different tissues being variably comprised
of T-bet-, T-betlo, and T-bethi subsets across infection (Figure 8A). The T-bethi subset
contained both CD11c+ and CD11c- cells with a phenotype and level of T-bet expression
matching Age-associated B Cells (Figure S7C). Furthermore, we confirmed that T-betlo
B cells expressed increased T-bet mRNA transcripts versus T-bet- B cells (Figure S7D).
In agreement with prior studies (278, 279), HA-specific B cells were readily
identified in spleen and mediastinal LN by 7 days post infection (dpi), peaked in number
and frequency at 15 dpi in spleen and 22 dpi in mediastinal LNs, and then declined to
steady state numbers in both organs by 40 dpi (Figure 8B). HA-specific B cells were
occasionally detected in the lungs of some mice as early as day 7, but cell numbers
peaked in lungs of all mice by 15 dpi and displayed a gradual decline continuing at least
through 100 dpi (Figure 8B). Small numbers of HA+ B cells were also detected in
mesenteric and peripheral LNs, but these were dwarfed by spleen, mediastinal LN, and
lung responses (Figure S7E).
Our longitudinal analysis of the HA-specific B cell pool identified differential
induction and maintenance properties for the T-bet-, T-betlo, and T-bethi B cell subsets
across tissues. The lung HA-specific response was entirely comprised of T-bethi cells at
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7 dpi; however, HA-specific cells were not detected in lungs of all mice at this time
(Figure 8B). The lung HA-specific population remained T-bet-dominated throughout
acute infection but was primarily T-bet- by 100 dpi (Figures 8A and 8B). The majority of
mediastinal LN HA+ B cells also expressed T-bet at 7 dpi, but T-bethi cells rapidly
declined by 15 dpi, suggesting rapid tissue exit or differentiation. T-betlo B cells similarly
declined by 15 dpi, albeit more slowly, and were nearly undetectable by 100 dpi in this
tissue. In accord with possible tissue egress, blood T-bethi cells peaked in frequency by
22 dpi and rapidly declined to undetectable levels by 40 dpi. In contrast, T-betlo and Tbethi subsets were consistently maintained in the spleen from 7 to 100 dpi comprising
27% to 52% (with an average of 37%) of the splenic HA-specific B cell response
(Figures 8A and 8B). These findings identify early but transient T-bet+ B cell responses
in lungs and mediastinal LN and suggest T-bet+ HA-specific B cell memory is primarily
sustained in the spleen.
We also assessed germinal center B (GCB) cells and MBC marker expression in
splenic HA-specific cells at each time-point. T-betlo and T-bethi cells were pooled for
these analyses since they displayed similar memory marker expression throughout
infection (data not shown). We delineated GCB cells as CD38–GL7+ and presumptive
MBCs as CD38+GL7– (280) (Figure 8C). Notably, GL7 expression closely correlated
with other established GCB markers including CD95 and Peanut Agglutinin (PNA)
(Figure S7F; data not shown). At 7 dpi, GL7 was present primarily on T-bet+ cells
without concomitant CD38 downregulation (Figure 8C), suggesting a pre-GC phenotype
(281-283). Nearly all HA-specific cells exhibited a GCB phenotype by 15 dpi and
maintained this through 22 dpi, at which time an MBC population begins to emerge
(Figure 8C). At 40 dpi, the majority of T-bet+ cells have a memory phenotype, whereas
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nearly half of T-bet- cells still maintain GC markers (Figure 8C). Regardless of T-bet
expression, nearly all splenic HA-specific B cells acquired an MBC phenotype by 100
dpi. In contrast, GCB cells persisted in the mediastinal LN, and to a lesser extent in the
lung, out to 100 dpi; however, these were T-bet-. (Figure S7G). Further analyses of
splenic MBC-phenotype cells at each time point identified upregulation of the previously
characterized MBC markers CD80, PD-L2, and CD73 (268) beginning by 15-22 dpi and
increasing further by 100 dpi, suggesting formation of stable T-bet- and T-bet+ memory
pools by the latter time point (Figure 8D). We also observed early expression of CD80 in
CD38+GL7– cells as early as 7 dpi (Figure 8D); these may represent other non-GC cells
such as extrafollicular plasmablasts, since they were not omitted by our gating strategy.
These findings indicate that GC and MBC differentiation is similar between T-bet- and Tbet+ subsets during the influenza response, except the T-bet+ subset loses GC
characteristics and transitions to a memory phenotype earlier than the T-bet- population.
Moreover, T-bethi HA-specific MBCs appear to be spleen-compartmentalized upon
resolution of infection.
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Figure 8. T-bet expression identifies memory B cell populations with unique tissue
distribution.
T-bet-ZsGreen reporters were intranasally infected with 30 TCID50 influenza A/Puerto
Rico/8/1934 (PR8). (A) Fluorescently-conjugated PR8 hemagglutinin (HA) detects HAspecific (HA+) B cells, and T-bet-ZsGreen expression in HA+ B cells resolves T-bet-, Tbetlo, and T-bethi subsets across tissues at acute (day 15) and memory (day 100)
timepoints. (B) Number of HA+ B cells in spleen, pooled mediastinal lymph nodes
(medLN), lungs, and blood at different time points after infection (left column), and
proportions of HA+ B cells that are T-bet-, T-betlo, and T-bethi in each tissue (right
column). The number of HA+ B cells in blood was estimated by calculating their
frequency per 100,000 B cells, and proportions of T-bet-defined subsets in blood were
calculated after concatenation due to low cell number. (C) Gating scheme identifies
splenic HA+ GCB cell (GL7+CD38-), MBC (GL7-CD38+), and pre-GC cell (CD38+GL7+)
subsets; concatenated flow plots (bottom) depict CD38 and GL7 expression of T-bet+
(pooled T-betlo and T-bethi; green) and T-bet- (purple) HA+ B cells at each time point
(bottom). Line plots (top) depict number of HA+ GCB cells and MBCs separated by T-bet
expression phenotype over time. (D) Expression of memory markers (CD80, PD-L2,
CD73) in T-bet+ (green) and T-bet- (purple) splenic HA+ MBCs (GL7-CD38+) and naive
follicular B cells (IgD+; grey). Data in (B) and (C) are compiled from 2 independent
experiments with at least 3 mice per experiment. Data in (A) and (D) are representative
of 2 independent experiments with at least 3 mice per experiment. Data in (B) and (C)
are plotted as mean ± SEM. HA+ B cells were identified as live, singlet, DUMP-, B220+,
CD19+, IgD- cells, HA-BV421+, HA-AF647+ cells. DUMP gate includes CD4, CD8, Gr-1,
and F4/80.
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Table I: Number of hemagglutinin-specific B cells after influenza infection
subset by level of T-bet expression. Related to Figure 8.
Tissue

Spleen

medLN

Lungs

mesLN

pLN

Days
p.i.

T-bet–
Average

T-betlo

SEM

T-bethi

Average

SEM

Average

SEM

0
7
15
22
40
100
0
7
15
22
40
100
0
7
15
22
40
100
0
7
15
22
40
100
0
7

199
565
63,118
36,188
3,077
1,937
14
146
4,283
13,484
5,520
4,740
0
0
1,529
1,067
531
217
6
11
55
69
70
57
8
15

60
240
20,498
10,807
2,056
532
14
119
1,339
1,735
2,050
2,027
0
0
885
293
215
112
6
5
27
16
23
17
5
8

0
87
24,923
10,795
565
862
0
199
1,057
1,868
557
105
0
0
2,844
990
382
21
0
2
20
23
26
34
0
2

0
29
5,878
3,649
176
431
0
167
271
956
173
38
0
0
1,241
186
93
21
0
2
17
7
4
11
0
2

0
91
5,874
6,468
701
603
0
78
162
397
104
62
0
9
3,798
1,137
87
42
0
0
5
39
26
7
0
10

0
47
770
2,317
224
238
0
58
43
143
24
15
0
6
1,701
347
54
42
0
0
5
19
4
5
0
7

15
22
40
100

48
50
30
38

23
13
13
10

16
41
23
26

13
6
8
9

26
30
24
0

11
13
11
0
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3.3.2 Human T-bethi B cells are an anatomically compartmentalized component of
influenza-specific memory

The following section on the distribution of human B cell subsets is the work of
James J. Knox who acquired this data as a PhD student in Michael Bett’s lab and as a
post-doc in the lab of Michael P. Cancro.
Having identified discrete influenza-specific MBC subsets with differential tissue
localization properties in mice, we questioned whether analogous human T-betexpressing MBCs show a similar anatomical distribution. In humans, T-bet-expressing B
cells have been identified alongside T-bet- MBCs in peripheral blood during active viral
infections and vaccinations, malaria infection, and autoimmune disease (284-288). Since
T-bethi B cells (CD21-T-bethigh) display a unique trafficking receptor profile
(CD11c+CXCR3+/-CXCR5lowCD62Llow) compared to classical MBCs (287, 288), we
hypothesized, as in mice, human T-bethi B cells might have a distinct tissue distribution
pattern. To test this, we obtained peripheral blood, tonsil, iliac and mesenteric lymph
nodes, spleen, and bone marrow as donated or discarded surgical tissue and examined
B cell phenotypes in these tissues (gating in Figure S8A). In agreement with our
previous study (288), we observed T-bethi B cells in the peripheral blood of all subjects
(Figures 9A and 9B). We also readily identified T-bethi B cells within spleen and bone
marrow compartments (Figures 9A and 9B) and confirmed their antigen-experienced
phenotype in spleen (Figure S8B). Conversely, T-bethi B cells were largely absent from
tonsils and both iliac and mesenteric lymph nodes (Figures 9A and 9B).
These findings suggested restricted trafficking properties of the T-bethi B cell
subset. To determine whether human peripheral blood T-bethi B cells recirculate through
tissues, we obtained matched peripheral blood and thoracic duct fluid (chyle) samples
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from individuals undergoing thoracic duct cannulation. The thoracic duct is the body’s
largest lymphatic vessel that collects draining lymph from both lymphoid and nonlymphoid tissues for return to the blood; thus, its contents represent cells undergoing
lymphatic recirculation. Despite consistent identification of T-bethi B cells in the
peripheral blood of these individuals, these cells were essentially absent in matched
thoracic duct fluid (Figures 9C and 9D). In contrast, naïve B cells and various CD21+
MBC subsets (IgM+CD27+, IgM-CD27+, and IgM-CD27-) were detected at similar
frequencies in both peripheral blood and thoracic duct fluid of all subjects, suggesting
this anatomical compartmentalization is a feature specific to T-bethi B cells, analogous to
what we had observed in mice (Figures S8C-E).
We next asked whether T-bet expression per se is associated with tissue
restriction. We previously identified two distinct populations of T-bet-expressing B cells in
blood of healthy individuals: T-bethi B cells (CD21-T-bethigh) and T-betlo B cells (CD21+Tbetlow; (288)), which likely correspond to the observed T-bethi and T-betlo MBC pools in
mice (Figure 8). Here, we extended these findings to show that CXCR3 expression
enriches for T-betlo cells within the greater CD21+ memory population (Figure 9E). Using
the CD21+CXCR3+ phenotype, we find that T-betlo B cells are present in human blood,
thoracic duct fluid, and lymph nodes (Figure 9E), and at similar frequencies between
matched blood and thoracic duct fluid samples (Figure 9F). Thus, human T-betlo B cells
recirculate through all lymphoid tissues, while T-bethi B cells are restricted to the spleen,
blood, and bone marrow in healthy individuals. Further analyses will be necessary to
determine the relationship between T-betlo and T-bethi B cells; however, we propose that
these CD21+T-betlo cells represent the human equivalent of the T-betlo B cells observed
in T-bet-ZsGreen reporter mice (Figure 8). Taken together, these findings identify
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human T-bethi B cells as a unique, tissue-restricted subset that does not recirculate via
the lymphatic system.
Since murine T-bethi HA-specific B cells preferentially populate the spleen at
memory time points (Figure 8), we next asked whether the human spleen harbors an
HA-specific T-bethi MBC population. Using fluorophore-conjugated HA probes from two
distantly-related influenza strains, A/California/07/2009 (H1) and A/Wisconsin/67/2005
(H3) (276, 289), we assessed T-bet expression by HA-specific class-switched (IgD-IgM-)
B cells in the spleen (Figure 9G) and mesenteric lymph nodes (Figure S8F). Despite
our efforts, we were unable to obtain human mediastinal lymph node samples without
significant blood contamination for analysis of lung-draining lymphoid tissue. HA-specific
T-bethi B cells recognizing H1 or H3 strains were identified in the spleens of all donors
but were rarely detected in mesenteric lymph nodes, whereas T-betloCD21+ and T-betCD21+ HA-specific memory B cells were present in all assessed tissues (Figures 9H-J;
data not shown). The relative representation of T-bethi B cells within the splenic HAspecific population varied considerably (~3-80% of H1+ B cells and ~3-53% of H3+ B
cells; Figure 9I) and positively correlated with age (Figures S8G and S8H). Lastly, we
assessed the isotype distribution of the human splenic HA-specific MBC compartment
and found that human IgG1, the analog of murine IgG2a/c, dominated the classswitched memory response to influenza (Figure 9K; isotype gating in Figure S8I). IgG3+
and IgA+ HA-specific cells could be detected at low levels in some donors; however,
IgG2+ HA-specific B cells were rarely identified (Figure 9K, Figure S8I). Together, these
findings suggest T-bet expressing B cells are a critical component of human influenza
HA-specific B cell memory and, as in mice, identify the human T-bethi HA-specific MBC
pool as spleen-localized and absent from lymphatics.
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Figure 9. Human T-bethi B cells do not recirculate via the lymphatics and maintain
influenza-specific memory in the spleen.
(A) Identification of human CD21-T-bethi B cells within total CD19+ B cells from peripheral
blood (PB), tonsil, iliac lymph node (iLN), mesenteric lymph node (mesLN), spleen, and
bone marrow (BM) of representative donors. Different tissue types in (A) or (B) are not
matched. (B) Frequency of T-bethi B cells in various tissues (n=6 per tissue group).
Statistics represent comparisons between PB, spleen, or BM with tonsil, iLN, and mLN;
frequencies within PB, spleen, and BM are not statistically different from one another.
(C) Identification of T-bethi B cells in matched peripheral blood (PB) and thoracic duct
fluid (TD) samples from a representative donor. (D) Frequency of T-bethi B cells in
matched PB and TD samples (n=8). (E) Identification of CD21+CXCR3+T-betlo (blue) and
CD21+CXCR3-T-bet- (black) subsets of memory (IgD-/IgD+CD27+) B cells in matched PB
and TD from a representative donor, and mesLN from another donor; T-bet expression
by these populations is shown as a histogram. Blood T-bethi B cells are included for
comparison in grey. (F) Frequency of the CD21+CXCR3+ population within PB and TD
CD19+ B cell pools from an 8-donor cohort. (G) Identification of HA-specific, IgD-IgM- B
cells within CD19+CD38low splenic B cells using two fluorescently-labelled
A/California/07/2009 HA probes (H1 strain) or a single fluorescently-labelled
A/Wisconsin/67/2005 HA probe (H3 strain). (H) CD21 and T-bet expression in IgD-IgMHA+ B cells in spleens and mesLNs from representative donors using H1 or H3 probes.
(I) Frequency of T-bethi phenotype within IgD-IgM-H1+ or H3+ B cells in spleens from two
10-donor cohorts and mLN from a 6-donor cohort. (J) T-bet MFI of splenic naïve
(IgD+CD27-) B cells and switched (IgD-IgM-) H1-HA-specific CD21+ and CD21-T-bethi B
cells from a representative donor. (K) Frequency of isotype expression within human
splenic IgD-IgM-HA+ B cells (n=6). Statistical comparisons performed using one-way
ANOVA with Tukey post-test (B), paired t-test (D and F), unpaired t-test (I), and
repeated measures ANOVA with Tukey post-test (K). Lines depict mean ± SEM. N.S. =
not significant, *p<0.05; **p<0.01; ***p<0.001. Credit goes to James J. Knox for
generating this figure.
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3.3.3 T-bethi HA-specific memory B cells are resident in the spleen

The apparent splenic localization of T-bethi HA-specific MBCs in both mice and
humans led us to rigorously assess tissue residency using a parabiosis-based approach.
Thus, T-bet-ZsGreen reporter mice infected ≥ 40 days prior with PR8 were surgically
joined to naïve congenic B6.SJL partners. We reasoned that all HA-specific MBC will
originate in the T-bet-ZsGreen partner, so their presence in the B6.SJL partner would
indicate that they are a recirculating population. Conjoined mice were monitored by
serial bleeds to assess the portion of circulating CD45.2+ (T-bet-ZsGreen reporter origin)
versus CD45.1+ (B6.SJL origin) B cells in each partner. Both partners demonstrated
mixing of CD45.1+ and CD45.2+ B cells in the blood as early as day 7, achieving stable
proportions between the partners by day 14 (Figure 10A). Accordingly, parabiosed pairs
were euthanized ≥ 17 days post-surgery. We observed similar frequencies of
CD45.2+IgD+ B cells – a pool anticipated to circulate freely – in spleen, lungs, and
mediastinal lymph nodes of each partner (Figure 10B), suggesting equilibration of
recirculating B cells by day 17.
HA-specific MBCs were observed in the spleens of both partners, and virtually all
of these were CD45.2+ (Figure 10C), consistent with their origin in the previously
infected T-bet-ZsGreen partner. T-bet- and T-betlo HA-specific B cells were identified in
the spleens of both partners, suggesting these subsets recirculate (Figures 10D-F,
Figure S9A). In contrast, T-bethi HA-specific MBCs were absent from the naïve B6.SJL
partner spleens but remained in spleens of previously infected T-bet-ZsGreen mice
(Figures 10E, 10F, S9A), even when data were concatenated from 7 parabiotic pairs
(Figure 10D). To confirm that ZsGreen-expressing cells were not being rejected in the
B6.SJL mice, we measured frequencies of donor T-bet-ZsGreen+CXCR3+CD8+
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lymphocytes, which highly express the ZsGreen protein, and found similar frequencies of
these cells in both partners (Figure S9B). Moreover, T-betlo HA-specific B cells were
also present in spleens of both mice (Figures 10D and 10E). Thus, broad rejection of
ZsGreen+ cells is not occurring, consistent with previous studies (290). Taken together,
these findings identify splenic T-bethi HA+ MBCs as a tissue-resident memory pool.
We also investigated whether HA-specific B cells showed evidence of residency
in mediastinal LNs and lung, the other primary locations of influenza memory cells, as
others recently demonstrated (291). We identified significant HA-specific B cell numbers
in mediastinal LNs of the previously infected partner that were absent in the naïve
partner (Figure 10G). We suspect this reflects the extended maintenance of HA-specific
GCs in mediastinal LNs, as the local HA-specific B cell population retains a GC
phenotype at least through 100 dpi (Figure S7G). This phenomenon appears to be
mediastinal LN-specific, as HA-specific GC B cells were not identified at this late time
point in any other lymphoid tissues examined. We also identified HA-specific MBCs in
the lungs of the previously infected partner (Figure 10H), but these cells were absent in
the naïve partner. Notably, nearly all mediastinal LN- and lung-localized cells were T-bet(Figures 10I-J). Thus, HA-specific memory is anatomically compartmentalized,
encompassing tissue-resident T-bethi B cells in the spleen and circulating T-bet- and Tbetlo B cell populations.
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Figure 10. T-bet expression resolves spleen resident versus recirculating MBC
pools.
(A). T-bet-ZsGreen reporters (CD45.2+; ≥ 40 dpi) and naïve B6.SJL (CD45.1+) were
surgically conjoined and showed evidence of blood sharing by day 7, with equilibrium
reached by day 14. Parabionts were euthanized at ≥ 17 days post-surgery for analysis.
(B) Frequencies of naïve follicular (IgD+) B cells expressing CD45.2 in lymphoid and
non-lymphoid tissues from each parabiosis pair. (C) Identification of HA+IgD- B cells
expressing either CD45.1 or CD45.2 in parabiosis partners. (D) Identification of T-betZsGreen reporter-derived (CD45.2+) T-bet-, T-betlo, and T-bethi HA+ MBCs in spleens of
T-bet-ZsGreen and B6.SJL partners; data concatenated from 7 pairs. (E) Numbers of Tbet-, T-betlo, and T-bethi HA+ splenic MBCs in T-bet-ZsGreen (red) and B6.SJL (black)
partners. (F) Percentage of splenic HA+ MBCs that are T-bet-, T-betlo, or T-bethi in each
partner. (G and H) Number of HA+ MBCs in medLN (G) and lungs (H) of parabiosis
partners. (I and J) T-bet-ZsGreen expression in HA+ MBCs from medLN (I) and lungs (J)
of T-bet-ZsGreen partner. HA+ MBCs were not detected in the medLN or lung of the
B6.SJL partner. Data displayed are from 8 pairs across three independent experiments
for spleen and 4 pairs across two-independent experiments for medLN and lungs. HA+ B
cells were identified as live, singlet, DUMP-, B220+, CD19+, CD45.2+, IgD-, HA-BV421+,
HA-AF647+ cells. Data in (E), (F), (G), and (H) show individual points with the mean ±
SEM indicated. Statistical comparisons performed using paired two-tailed t-test. ns = not
significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.001
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3.3.4 Established T-bet+ and T-bet- memory B cells undergo minimal interconversion

The different residency and recirculation properties of T-bet- and T-bet+ MBCs
raised the question of how T-bet- and T-bet+ MBCs arise. We considered four
possibilities (Figure S10A): 1) T-bet- and T-bet+ MBCs arise independently and are
stable, separate subsets; 2) T-bet+ cells give rise to T-bet- cells (or vice versa); 3) T-bet+
and T-bet- cells undergo shared selection followed by stable commitment to either a Tbet+ or T-bet- long-lived MBC population; 4) T-bet+ and T-bet- MBCs interconvert by
modifying T-bet expression as needed to change localization or functional properties.
Immune repertoire profiling of antibody heavy chain variable region gene (VH)
rearrangements can be used to distinguish between these four models, as each model
makes distinct predictions regarding differences in VH usage (model 1), somatic
hypermutation (model 2) and clonal overlap (models 3 and 4; Figure S10A).
We therefore sequenced VH rearrangements of HA-specific MBCs separated by
T-bet expression (Figure S10B) in T-bet-ZsGreen reporter mice immunized
intradermally with 30 μg of lipid nano particles (LNP) loaded with HA mRNA (292). The
LNP platform generates both T-bet- and T-bet+ MBCs (Figure S10B), and we confirmed
an HA-antibody response by hemagglutination inhibition (Figure S10C). At 90 days post
immunization, all splenic IgD- HA-specific B cells were sorted based upon T-bet-ZsGreen
expression into T-bet- and T-bet+ memory subsets, and antibody VH rearrangements of
both subsets and IgD+ naïve follicular control B cells were sequenced. Similarly, we used
the CD21-CD85jhi surface phenotype, which specifically identifies human T-bethi B cells
(288), to sort human splenic HA-specific IgD-IgM- MBCs into CD21-CD85jhi and CD21+
subsets (Figure S10D) and sequenced the VH rearrangements of these populations
along with control bulk splenocytes.
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VH analysis revealed comparable VH usage (Figures S10E and S10F) and
CDR3 length distributions (Figures 11A and 11B) in T-bet+ and T-bet- populations, and
there was some clonal overlap between the two populations (Figures 11C and 11D),
ruling out a strict separate lineage model (model 1). T-bet+ and T-bet- MBCs harbored
similar levels of somatic hypermutation, suggesting that one population was not a
precursor to the other (model 2), and both populations showed significantly more
mutations than naïve B cells or unsorted splenocytes (Figures 11E and 11F).
Next, we scrutinized the lineage trees of clones that contained T-bet+ and T-betmembers. In mice, overlapping clones between T-bet+ and T-bet- populations were not
as frequent as they were within replicate sequencing libraries from the same subset
(Figure S10G), suggesting that many T-bet+ and T-bet- clones arise independently,
rather than being fully intermingled. The same clonal analysis in humans did not reach
statistical significance, likely due to our restricted sample size – we sampled a small
portion of the spleen and therefore missed many clonal members (Figure S10H). In
further support of this separation, analyses of mouse clonal lineages containing both Tbet+ and T-bet- cells revealed that nearly all exhibited segregation of T-bet+ and T-betsequences onto separate branches (Figure 11G). Taken together, these findings in mice
following immunization and in established HA+ MBCs in human spleen favor model 3, in
which T-bet+ and T-bet- MBC precursors undergo shared selection, subsequently commit
to a T-bet+ or T-bet- MBC population, and thereafter remain stable with respect to T-bet
expression status, with minimal, if any, interconversion between established T-bet+ and
T-bet- MBCs.
To further verify the stability of T-bet+ B cells, we used a combined reporter/fate
mapper mouse (293). These T-bet-sufficient mice contain the ZsGreen construct fused
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to creERT2 under control of the T-bet promoter, such that treatment with tamoxifen during
active T-bet transcription causes irreversible tdTomato expression. Using these mice,
one can delineate cells that expressed T-bet during the tamoxifen treatment period and
have subsequently lost expression (tdTomato+T-bet-ZsGreen-) from those that retained it
(tdTomato+ZsGreen+). We treated ≥ 20-week-old T-bet-ZsGreen/tdTomato mice with
tamoxifen on days 0, 2, and 4 and performed serial bleeds to assess stability of
tdTomato+ZsGreen+ B cells. All mice demonstrated tdTomato labeling at day 10, with Tbet+ cells outnumbering T-bet- cells 10:1 within the tdTomato+ B cell population (Figure
11H). The ratio of T-bet+ to T-bet- cells was maintained steadily in all mice (Figure 11H),
suggesting most B cells expressing T-bet at day 0 maintained expression for 40 days,
interconverting rarely if at all during this period. In combination with our clonal overlap
and lineage tree analyses, these data show that established T-bet+ MBCs represent a
separate, stable population.

107

108

Figure 11. T-bet+ and T-bet- MBCs are selected from a shared pre-immune lineage
but do not interconvert.
HA-specific splenic MBCs from T-bet-ZsGreen reporters (day 100 post immunization)
were sorted into T-bet- and T-bet+ subsets, with naïve follicular (IgD+) B cell controls, for
immunoglobulin heavy chain genomic sequencing. Human HA-specific splenic MBCs
were similarly sorted into CD21+ and CD21-CD85jhi subsets; CD21-CD85jhi phenotype
identifies human T-bethi B cells (288) subsets. (A) CDR3 lengths (in nucleotides) of inframe sequences from murine T-bet- and T-bet+ HA+ MBCs and naïve follicular (IgD+) B
cell controls after all replicates were pooled. (B) CDR3 lengths of in-frame sequences
from CD21+ and CD21-CD85jhi HA+ MBC subsets were quantified (in nucleotides). Bulk
splenocytes (largely naive follicular B cells) served as a control. (C) The number of
clones that overlap between T-bet- (blue) and T-bet+ (red) HA+ MBCs in mouse (M. mus,
MM). (D) The number of clones that overlap between CD21+ (blue) and CD21-CD85jhi
(red) HA+ MBCs in humans (H. sap; HS). (E) Percentages of clones binned by the level
of somatic mutation (expressed as the percent difference in nucleotide sequence to the
nearest germline VH gene) in mouse T-bet- and T-bet+ HA+ MBCs and naïve follicular B
cells. (F) Percent of the heavy chain V-gene that is mutated from germline in CD21+ and
CD21-CD85jhi HA+ MBCs and bulk splenocytes in humans. (G) Representative lineage
trees of shared clones between T-bet- and T-bet+ HA+ murine MBCs, with inferred nodes
(black), T-bet- nodes (blue), and T-bet+ nodes (red). Trees were generated in ImmuneDB
and visualized with ETE3 (see Methods). Lineages had to contain at least 10 copies of
T-bet+ and T-bet- and have at least 4 trunk mutations (shared SHMs) to be included.
Numbers indicate the number of mutations compared to the preceding vertical node. The
inferred node at the top of the tree indicates the nearest germline sequence. (H) T-betZsGreen fate-mapping mice (293) were treated with tamoxifen to mark T-bet expressing
cells with permanent, Rosa21-driven, tdTomato expression and the status of T-bet
expression of marked B cells in the blood was tracked over 40 days. For panels (A), (C),
(E), and (G), two independent experiments were carried out with at least 4 mice per
group. Each gave similar results, and the results for the more recent experiment are
shown. For panels (B), (D), and (F), the splenocytes from 4 adult subjects were sorted
and sequenced. For genetic fate mapping (H), two independent experiments were
carried out with at least 4 mice per group; one experiment is shown here.
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3.3.5 HA stalk-specific antibody is derived primarily from the T-bet-expressing B cell
compartment

The distinct localization and phenotypic stability of T-bet+ HA-specific MBCs led
us to assess the contribution of the T-bet-expressing B cell compartment to the influenza
humoral response. In mice, T-bet promotes antibody class-switching to IgG2a/c (294301), the dominant isotype in influenza and other anti-viral responses (298, 302). In
accordance with this, we observed a greater increase in PR8-specific and HA-specific
IgG2c (Figures 12A and 12B) compared to IgG1, evident by day 12 and 15,
respectively. This isotype bias confirmed previous studies (279) and suggested a key
role for T-bet in regulating influenza antibody production (303). Therefore, we tested the
contribution of T-bet in the B lineage to HA-specific humoral responses by infecting B
cell-specific conditional T-bet knockouts (T-betflox/flox CD19Cre/WT; hereafter referred to as
cKOs), CD19-Cre controls (CD19Cre/WTT-betWT/WT), and wild type mice with PR8 and
examined antibody levels and characteristics. All three groups showed similar weight
loss kinetics (Figure 12C), total HA-specific B cell numbers (Figure 12D), and HAspecific GCB cell numbers (Figure 12E), although CD19-cre controls recovered weight
more quickly (Figure 12C). As such, CD19 heterozygosity does not appear to
significantly impair the influenza response, and initiation of the humoral response does
not require T-bet expression in B cells.
To assess the functionality of antibodies generated in the absence of B lineage
T-bet expression, we performed hemagglutination inhibition (HAI) assays from serum. At
15 dpi, the majority of mice displayed HAI titers greater than 40, the level associated in
human studies with protection (304, 305), although one wild type and several cKO mice
had titers ranging from 20 to undetectable (Figure 12F). HAI titers declined in all groups
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by 40 dpi (Figure 12F), likely due to the loss of acute infection-generated IgM titers
(302). However, cKOs displayed significantly reduced HAI titers versus the wild type and
CD19-Cre groups at 40 dpi, with 70% of mice showing titers below 40 (Figure 12F).
These findings suggest T-bet expression in B cells may be necessary for the
development of sustained protective influenza-specific titers.
We hypothesized that decreased HAI titers in cKOs may reflect a loss of specific
components of the antibody response. We next assessed antibody titers and found a
significant reduction in total PR8-specific IgG2c in cKOs, as expected (Figure 12G). Low
IgG2c titers remained in cKOs at 15 dpi but were nearly absent by 40 dpi, suggesting Tbet-independent mechanisms can initiate a degree of IgG2c switching during acute
infection (Figure 12G). We focused subsequent analyses on the HA protein, the
antigenic target relevant for protective humoral immunity to influenza and identified
significantly reduced IgG2c titers to full-length HA in cKOs at both 15 and 40 dpi
compared to wild type and CD19-Cre control groups (Figure 12H). PR8- and HAspecific titers of IgG1, a T-bet-independent isotype, were unaffected in cKOs and did not
increase to compensate for IgG2c loss (Figures 12G and 12H). These findings confirm
that the majority of HA-specific IgG2c antibody is derived from T-bet-expressing B cells.
Lastly, we questioned whether T-bet expressing B cells are important for
influenza antibody responses to certain specificities. Recent studies highlight a critical
role for HA-specific IgG2a/c antibodies for in vivo influenza protection, which are
primarily skewed toward stalk recognition (306, 307). Thus, we assessed stalk reactivity
of IgG1 and IgG2c using a chimeric construct comprised of the PR8-related H1 stalk and
unrelated H6 head (308-310). This chimera is bound primarily by stalk-specific
antibodies since most PR8-generated HA head-binding antibodies are strain-specific
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and do not recognize H6 head. We found that the stalk response is dominated by IgG2c
in wild type mice at both 15 and 40 dpi, while IgG1 stalk titers were negligible (Figure
12I). Moreover, cKOs largely lost IgG2c stalk-reactive titers (Figure 12I), indicating that
the bulk of the influenza stalk-specific antibody response arises from T-bet-expressing B
cells.
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Figure 12. T-bet+ B cells are required for optimal influenza antibody responses and
HA stalk-specific antibody in mice.
(A and B) Total betapropiolactone (BPL)-inactvated PR8-specific IgG1 and IgG2c (A)
and PR8 hemagglutinin (HA)-specific IgG1 and IgG2c (B) in sera from infected T-betZsGreen mice over time. (C). Weight loss and recovery from influenza infection in wild
type C57Bl/6, CD19cre/WTT-betfl/fl, and CD19cre/WT mice compared to PBS-treated controls.
(D) Number of HA-specific splenic B cells at day 15 and 40 dpi. (E) Number of HAspecific splenic GCB cells at 15 dpi. (F) Hemagglutination inhibition (HAI) titers at 15 and
40 dpi. (G-I) Antibody titers to BPL-inactivated PR8 (G), full-length PR8-HA (H), or
chimeric construct comprised of H1 stalk and H6 head (I). Wild type C57Bl/6 were used
for naïve controls in (F-I). Data are represented as mean ± SEM from 3 independent
experiments with at least 3-5 mice in each group. Statistical comparisons performed
using two-sided t-test (G-I) and Wilcoxon rank-sum test (F). *p<0.05, **p<0.01,
***p<0.001. Cells in (D, E) were identified as DUMP-, CD19+, B220+, CD138-, IgD-, HAPE+, with the additional definition of GC cells in (E) as PNA+CD95+.
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Table II: Serum antibody titers to various influenza antigens after infection. Related to Figure 12.

Antigen

Day 15 p.i.

Isotype
(μg/mL)

cre/WT

cre/WT

cre/WT

IgG2c
IgG1

8.2 ± 0.7

4.8 ± 0.8

5.8 ± 0.7

11.7 ± 3.2

8.9 ± 2.4

14.7 ± 3.2

IgG2c
IgG1

13.6 ± 2.4
0.9 ± 0.3

2.8 ± 0.9
0.5 ± 0.2

8.5 ± 0.7
0.9 ± 0.2

8.5 ± 1.3
1.1 ± 0.3

0.8 ± 0.4
2.1 ± 0.7

8.3 ± 3.5
2.7 ± 0.5

IgG2c
IgG1
* note: values ± SEM

1.5 ± 0.4
0.1 ± 0.0

0.2 ± 0.1
0.0 ± 0.0

1.2 ± 0.3
0.0 ± 0.0

0.6 ± 0.2
0.1 ± 0.1

0.1 ± 0.0
0.1 ± 0.0

1.2 ± 0.5
0.0 ± 0.0

HA

HA-stalk

C57Bl/6
37.5 ± 2.6

CD19
12.7 ± 1.8

CD19cre/WTTbetfl/fl
2.6 ± 0.5

CD19
45.1 ± 8.7

BPL-PR8

CD19
Tbet
14.0 ± 5.4

Day 40 p.i.
fl/fl
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C57Bl/6
18.6 ± 6.5

3.4 DISCUSSION

Our study reveals multiple MBC subsets delineated by T-bet expression, whose
distinct phenotypic and functional attributes are shared by mice and humans. T-bet
expression status divides MBCs by anatomic localization and residency, as well as
effector function and epitope specificity. Thus, T-bet- and T-betlo MBCs originate in all
secondary lymphoid tissues and freely recirculate, whereas T-bethi MBCs reside in the
spleen and are excluded from the lymphatics. Further, clonal and in vivo lineage tracing
analyses show that while T-bet+ and T-bet- MBCs likely arise from common pre-immune
pools, they diverge after antigen encounter and thereafter remain as separate and stable
pools. Finally, we show that the development of mouse IgG2c HA- and HA stalk-specific
antibodies, as well as durable neutralizing titers, require T-bet expression in the B
lineage. Taken together, these findings show that T-bet expression is a conserved
feature of an MBC subset with differential circulatory properties, tissue-residency, and
epitope specificity.
Pathogen-driven responses generate both isotype-switched and unswitched Tbet expressing B cells (301, 311, 312), but detailed analyses of the generation, fate and
anatomic characteristics of T-bet+ B cells have not been conducted. Our results formally
demonstrate antigen-mediated and antigen-specific generation of T-bet+ GC B cells
during viral infection, followed by the establishment of somatically mutated, antigenspecific T-bet+ and T-bet- MBC pools whose numbers are maintained indefinitely.
Consistent with memory character, both T-bet+ and T-bet- HA-specific B cells express
the MBC markers CD73, CD80 and PD-L2 with kinetics similar to those in hapten-carrier
responses (280). Despite these surface phenotypic similarities, our clonal analyses and
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genetic fate-mapping experiments suggest it is unlikely that a progenitor-successor
relationship exists, or that frequent interconversion occurs, between T-bet+ and T-betMBCs. Thus, while T-bet+ and T-bet- MBCs both result from antigen-driven naïve B cell
activation, they most often arise independently and remain distinct, rather than
representing different stages in a common differentiation pathway. In addition, the role
for these HA-specific MBC subsets in recall responses remains an open question.
Rechallenge studies in multiple mouse models have found that both CD80+PD-L2+
MBCs and HA-specific MBCs preferentially differentiate into early antibody-secreting
cells (ASCs) as opposed to re-entering germinal centers following antigen encounter
(268). These studies suggest that T-bet+ MBCs are primed for ASC differentiation, but
what influence T-bet has on this fate decision compared to T-bet independent factors
such as receptor affinity remains to be determined.
Our tissue distribution analyses indicate that memory B cells are anatomically
compartmentalized: T-bet- and T-betlo MBCs are found in all secondary lymphoid
tissues, whereas T-bethi MBCs are primarily in the spleen, blood, and bone marrow.
Parabiosis experiments further confirmed that established influenza-specific T-bethi
MBCs neither exit the spleen to populate the lymphatic system, nor home to the spleen
from blood or other anatomical locations. However, T-bethi B cells were identified
transiently in mediastinal LN and lungs early after infection, suggesting T-bethi B cell
generation can occur outside the spleen. We have previously reported the critical role of
innate sensors, such as nucleic acid sensing Toll-like receptors (TLRs), and common
gamma chain cytokines in regulating T-bet+ B cell fate (274). Thus, the generative
signals for T-bet expressing B cells are not spleen-specific per se, and the differential

116

anatomic distribution of established T-bethi MBCs is not an immediate consequence of
early antigen encounter specifically within the spleen.
Chemokine receptors and integrins regulate the anatomic distribution of immune
cells and may contribute to T-bethi B cells’ characteristic localization properties. Studies
examining human peripheral blood samples found that T-bet+ B cells express the integrin
CD11c, the chemokine receptor CXCR3, and low levels of CXCR4, CXCR5, and CCR7,
chemokine receptors associated with homing to lymphoid organs (285, 287, 313). Thus,
the specific combination of these and other surface receptors may impede lymphatic
entry and help recruit T-bethi B cells to the spleen. Via mechanisms that are unclear, Tbethi B cells also appear to enter the blood following activation or recent tissue egress.
Consistent with this idea, we observed early loss of HA-specific T-bethi B cells in the
mediastinal LN and lungs in infected mice, coupled with a temporary wave of HA-specific
T-bethi B cells in blood, and we previously described an increase in peripheral blood HAspecific T-bethi B cells following influenza vaccination in humans (314). While they are
normally absent from the lymphatics, recent evidence suggests consistent viremia
and/or chronic immune activation may be able to override T-bethi MBC
compartmentalization: lymphoid tissue infections with pathogens such as HIV and
Toxoplasma gondii are associated with a local enrichment of T-bet-expressing B cells in
lymph nodes (315, 316).
The splenic residency associated with T-bethi MBCs leads to some intriguing
possibilities regarding the role of T-bet+ MBCs in immune surveillance. While tissue
residency may be critical to protect from local reinfection, this role seems unlikely for
spleen-resident HA-specific T-bethi MBCs, inasmuch as influenza is a respiratory
infection and the virus is not known to replicate in the spleen (317). Instead, T-bethi
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splenic resident MBCs may be uniquely positioned to support broad immune
surveillance and rapidly produce antibody for systemic dissemination upon reinfection. In
support of this notion, T-bet+ B cells express elevated quantities of BLIMP-1 (287) and,
when isolated from the blood of SLE patients, quickly differentiate into plasma cells upon
TLR7 stimulation without obligate division (318). It is tempting to speculate that
circulating T-betlo B cells are short-lived cells derived from a stationary, self-renewing Tbethi population; indeed, the possibility of self-renewal and multipotency of T-bet+ MBCs
has been reported by others (311), and our findings confirm that T-bet+ MBCs are a
persistent population. Alternatively, T-betlo B cells might be a stable and persistent
population with separate maintenance requirements from the T-bethi subset. These
possibilities are not mutually exclusive and resolving their relative merits and
contributions will require examination of the turnover rates and clonal composition of
these MBC subsets.
Given the striking parallels between human and mouse T-bet+ MBCs, we
propose that T-bet expression is a conserved divisor for memory B cell subsets, and that
the relative contributions of T-bet+ vs T-bet- memory B cells to various aspects of
humoral immunity merits detailed investigation. Importantly, in addition to their
differences in anatomic localization, T-bet+ and T-bet- B cells differ in the quality and
specificity of antibodies they generate. Our studies with conditional knockout mice show
that T-bet drives influenza-specific IgG2c production to HA and the HA stalk. It is
tempting to speculate that these subsets could differentially contribute to
immunodominance, cross-reactivity, or original antigenic sin, and may thus play distinct
roles in immune responses to heterologous challenges. The loss of the IgG2c
component of anti-influenza responses in cKOs suggests a link between T-bet+ MBCs
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and influenza-specific antibody production; however, the direct contribution of these
established memory cells to antibody titer maintenance is unclear, as are the
implications of tissue-restriction. T-bet+ B cells are known to arise post influenza
vaccination in humans (287, 314, 319); therefore, based on recent interest in developing
HA-stalk-reactive vaccines for broad protection against influenza, we posit that focusing
vaccine design efforts on driving T-bet expression in HA-specific B cells and maintaining
this population long-term might lead to the development of more effective prophylactic
agents and vaccination regimens for influenza.

3.5 MATERIALS AND METHODS

Mice: C57BL/6 and B6.SJL (10-12 weeks old, females, purchased from The Jackson
Laboratory) T-betflox/flox CD19Cre/WT (from the laboratory of E. John Wherry, University of
Pennsylvania) and T-bet-ZsGreen (as previously reported (275)) were maintained and
used in accordance with the University of Pennsylvania Institutional Animal Care and
Use Committee guidelines.
Infections: Mice were infected by intranasal infection with 30 tissue culture infectious
dose50 (TCID50) of influenza strain A/Puerto Rico/8/1934 (PR8; American Type Culture
Collection).
Human samples: All study participants provided written informed consent. Tissue
samples were collected with IRB approval at the University of Pennsylvania (809316;
815056; 822686) and Case Western Reserve University (10-09-12). Human peripheral
blood mononuclear cell samples were obtained from the University of Pennsylvania
Human Immunology core. Human bone marrow mononuclear cell samples were
obtained from the University of Pennsylvania Stem Cell and Xenograft core. Paired
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blood and thoracic duct fluid samples were obtained from individuals with idiopathic or
trauma-based chylopericardium or chylothorax requiring intervention at the Hospital of
the University of Pennsylvania. Lymphoid tissue samples (mesenteric lymph node, iliac
lymph node, tonsil, and spleen) were obtained at the Hospital of the University of
Pennsylvania and Case Western Reserve University: mesenteric and iliac lymph nodes
were obtained during abdominal surgery and kidney transplant surgery, respectively.
Non-enlarged tonsils were obtained from sleep apnea patients. Spleens were removed
and obtained due to trauma or surgical intervention. Additional spleen samples were
obtained from the Human Pancreas Analysis Program (HPAP) at the University of
Pennsylvania. Mononuclear cells were mechanically separated from solid tissues and
enriched using a ficoll gradient.
Parabiotic surgery: Age-matched T-bet-ZsGreen reporters and B6.SJL adult female
mice were conjoined as described previously (320). Briefly, a skin incision was made
from the olecranon to the knee of each of the mice to be joined. The elbows and knees
of the two paired mice were then tied together with surgical suture, followed by
connecting of the skin with surgical sutures and staples. For pain control, mice were
given buprenorphine (0.1 mg/kg every 6 hours for 36 hours) and meloxicam (5 mg/kg
every 12 hours for 72 hours) and provided with sulfamexathole (400mg/L) and
trimethoprim (800mg/L) antibiotics in their drinking water to prevent infection. Mice were
monitored for signs of pain, infection, or damage to sutures. Blood was periodically
drawn from the tail to check for anastomoses, which appeared complete by d14,
therefore, mice were euthanized at day 17. The spleen was harvested from both
partners for all pairs, and the lungs and mediastinal lymph nodes were also collected
from some pairs.
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Flow cytometry: Flow cytometry reagents were purchased from BioLegend (BL), BD
Biosciences (BD), eBioscience (eBio), Southern Biotech (SB), or Invitrogen (Inv). The
following antibodies were used for mouse studies: T-bet (4B10; BL), CD11c (N418; BL),
IgM (R6-60.2; BD), CD38 (90; eBio), CD73 (TY/11.8; BL), CD80 (16-10A1; BD or BL),
PD-L2 (TY25; BL), CD138 (281-2; BL), IgD (11–26c.2a; BL), B220 (RA3-6B2; BL or
eBio), CD19 (1D3; BD or eBio), CD19 (6D5; BL) peanut agglutinin–FITC (Sigma),
CD45.1 (A20; BL), CD45.2 (104; BL), CD183/CXCR3 (CXCR3-173; BL) and CD3 (17A2;
BL). DUMP gate comprised CD8 (53-6.7; eBio), CD4 (H129.19; BL), F4/80 (BM8; eBio),
Ly-6G/GR1 (RB6-8C5; eBio). The following antibodies were used for human studies:
CD38 (HIT2; BL), CD85j (GHI/75; BD; HP-F1; eBio), T-bet (4B10; eBio and BL), IgM
(MHM-88; BL), IgD (IA6-2; BD), CD10 (CB-CALLA; eBio), CD27 (O323; BL), CXCR3
(G025H7; BL), IgG (G18-145, BD), CD21 (Bu32, BL; B-ly4, BD), CD19 (HIB19, BL), CD3
(UCHT1, BL), CD14 (MÆP9, BD), CD16 (3G8, BD), CD11c (3.9, eBio), Bcl-6 (K112-91,
BD), Ki67 (56, BD), IgG1 (HP6069, Inv), IgG2 (HP6002, SB), IgG3 (HP6050, SB), and
IgA (polyclonal, Inv). For detection of murine influenza-binding B cells, recombinant HA
PR8 (276) was obtained from the laboratory of Dr. Barney Graham, National Institute of
Allergy and Infectious Disease, biotinylated, and conjugated to streptavidin-fluorophores
as previously described (276), or was directly conjugated using the R-phycoerythrin
conjugation kit from Abcam (catalog ab102918) as per manufacturer’s instruction.
Human HA-specific B cell staining was performed using A/California/07/2009 and
A/Wisconsin/67/2005 HA probes prepared as previously described (276, 289). Mouse
samples were prepared for flow cytometry as follows: Mouse Fc fragment (Jackson
ImmunoResearch; 015-000-008) was added to all staining cocktails at a final
concentration of 1:200. Mouse spleens were homogenized, on ice, in staining buffer
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(PBS + 0.5%BSA + 2mM EDTA) and passed through nylon mesh (50μM) to obtain
single cell suspension. Red blood cells were lysed using ACK lysing buffer (Lonza, cat
10-548E) as per manufacturer’s instructions. Cells were washed with PBS and stained
as described previously(271, 274). Live/dead discrimination was done using Zombie
Aqua fixable viability kit (BL). Prior to T-bet staining, cells were fixed and permeabilized
using eBioscience™ Foxp3 / Transcription Factor Staining Buffer Set, at 4°C for 45min1hr. Human samples were prepared for flow cytometry as previously described (288).
Data were acquired on BD LSR II flow cytometer and FACS analyses were performed
using FlowJo v9 and v10 (Becton Dickinson Co., Ashland, OR).

Serum antibody titers: Serum was harvested by spinning whole blood at 13000g for 10
minutes and stored at -20°C until use. Antibody titers were assessed using ELISA as
previously described(271, 274) with the following modifications: 96-well medium-binding
plates were coated with either 20HAU/well of BPL-inactivated PR8, 2 μg/mL of PR8 HA,
or 2 μg/mL of H6/H1 chimeric constructs (expressed in baculovirus system as previously
described (321)). HA-specific monoclonal antibodies (from Dr. Jonathan Yewdell,
National Institute of Allergy and Infectious Diseases) were used as standards to
determine concentration of IgG1 and IgG2a/c. Standards were used at a starting
concentration of 100 ng/mL for IgG2a and 10 ng/mL for IgG1 and diluted 2-fold across.

HAU (hemagglutination unit) and HAI assays: Viral HAU titers were determined
before every HAI assay. All dilutions were prepared in PBS. 50 μL diluted virus, 50 μL
heat-inactivated sera and 12.5 μL of 2% turkey erythrocytes were used per well for all
assays, which were performed in round-bottom plates.
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Starting with a 1:100 dilution of live virus, 2-fold dilutions were mixed with 2% turkey
erythrocytes (Lampire biologicals) and incubated for 1 hour at room temperature.
Agglutination dose (AD) was determined at the end of the incubation period, and
confirmed by repeating the process with a 2-fold dilution series of virus, ranging from
4AD to 0.25 AD. This dose was subsequently used for the HAI assay.

Sera were heat-treated at 55°C for 30 minutes, diluted 2-fold in PBS (staring dilution
1:20), mixed with 4AD and 2% turkey erythrocytes, and incubated as for HAU assay.
HAI titers are expressed as inverse of the highest dilution that inhibited agglutination.

mRNA production: The sequence of the Puerto Rico/8/1934 influenza virus
hemagglutinin (pTEV-PR8 HA-A101) was codon-optimized, synthetized and cloned to
the mRNA production plasmid. The mRNA was produced using T7 RNA polymerase
(Megascript, Ambion) on linearized plasmids. The mRNA was transcribed to contain 101
nucleotide-long poly(A) tails. One-methylpseudouridine (m1Ψ)-5’-triphosphate (TriLink)
instead of UTP was used to generate modified nucleoside-containing mRNA. Capping of
the in vitro transcribed mRNAs was performed co-transcriptionally using the trinucleotide
cap1 analog, CleanCap (TriLink). mRNA was purified by cellulose purification, as
described (322). All mRNAs were analyzed by denaturing or native agarose gel
electrophoresis and were stored frozen at -20°C.
LNP formulation of the mRNA: Cellulose-purified m1Ψ-containing RNAs were
encapsulated in LNPs using a self-assembly process as previously described wherein
an ethanolic lipid mixture of ionizable cationic lipid, phosphatidylcholine, cholesterol and
polyethylene glycol-lipid was rapidly mixed with an aqueous solution containing mRNA at
123

acidic pH (323). The RNA-loaded particles were characterized and subsequently stored
at -80°C at a concentration of 1 µg µl-1. The mean hydrodynamic diameter of these
mRNA-LNP was ~80 nm with a polydispersity index of 0.02-0.06 and an encapsulation
efficiency of ~95%.
Mouse B cell receptor sequencing: Genomic DNA was extracted from sorted cells
using the Qiagen Gentra DNA purification kit (Qiagen, Germantown, MD, Cat.
No.158689). Primers used were adapted from Wang et al. (324) at the beginning of the
FW1 region of VH and were modified to include adaptor sequences for the Illumina
NexteraXT kit (sequences are provided below). Samples were amplified in duplicate (2
biological replicates per sample).
Primers:
VHmix (MH1) 5’- GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGSARGTNMAGCTGSAGSAGTC-3’
JH1,JH4 mix 5’- TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCTANTGAGGAGACGGTGAC-3’
JH2 5’ -TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGAGGAGACTGTGAGAGTGG-3’.

The mouse IgH library was generated with one VH primer and a cocktail of JH1,2,4
primers. The VH and JH primer mixes were used at 0.6 µM in a reaction volume of 25 µL
using a Multiplex PCR kit (Qiagen, Valencia, CA, Cat. No. 158388). Amplification
conditions for the PCR were: primary denaturation at 95oC for 10 minutes, cycling at
95°C 45s, 60°C 45s, and 72°C for 90s for 35 cycles, and a final extension step at 72°C
for 10 minutes.
Amplicons were purified using the Agencourt AMPure XP beads system (Beckman
Coulter, Inc., Indianapolis, IN), and second-round PCRs were performed as described
(325) to add Illumina NexteraXT adaptors to the IgH library. Final sequencing libraries
were quantified by Qubit Fluorometric Quantitation (Thermo Fisher Scientific, Grand
124

Island, NY) and loaded onto an Illumina MiSeq instrument in the Human Immunology
Core facility at the University of Pennsylvania and sequenced using 2x300 bp paired end
kits (Illumina MiSeq Reagent Kit v3, 600 cycle, Illumina Inc., San Diego, Cat. No. MS102-3003).
Human B cell receptor sequencing: Genomic DNA was extracted from sorted cells
using the Qiagen Gentra DNA purification kit. Sequences were generated from genomic
DNA using primers that were situated at FR1 and JH (BIOMED2) for IgH V region
sequencing. Samples were amplified in duplicate (2 biological replicates per sample).
Second-round amplification to generate sequencing libraries used Illumina Nextera XT
kit as previously described (325, 326). Sequencing were performed on an Illumina
MiSeq instrument in the Human Immunology Core facility at the University of
Pennsylvania using a 2x300 bp paired end kit.

Sequencing data analysis: Raw sequence data (FASTQ files) were processed through
pRESTO version 0.5.10 (327). First, paired reads (R1 & R2) were aligned. Then
sequences with an average Phred quality score of less than 30 (an error rate of 1 in
1000 bases) were removed. Of the remaining sequences, the 5’ and 3’ ends were
trimmed until a window of 20 nucleotides had an average quality score of at least 30.
Short reads of less than 100 bases were discarded after the trimming. Finally,
nucleotides with a quality score of less than 30 were masked with an “N,” and any
sequence with more than 10 such N’s were discarded.
Code 1 shows a script performing these filtering steps.
PairSeq.py -1 *R1* *R2*
AssemblePairs.py align -1 *R1_pair-pass* -2 *R2_pair-pass* --coord illumina --rc tail
FilterSeq.py quality -s *assemble-pass* -q 30
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FilterSeq.py trimqual -s *quality-pass* -q 30 --win 20
FilterSeq.py length -s *trimqual-pass* -n 100
FilterSeq.py maskqual -s *length-pass* -q 30
FilterSeq.py missing -s *maskqual-pass* -n 10

ImmuneDB (328) was used for gene identification and clonal inference of heavy chain
sequencing data in both humans (using v0.26.0) and mice (using v0.28.0). Sequences
were trimmed to IMGT position 20 in mice and 80 in humans to remove 5’ primer
sequences. Clones were assembled by grouping sequences with the same V-gene, Jgene, and 85% CDR3 amino-acid similarity as described in (326).
In the murine dataset, all mice contained a common CDR3 amino-acid string,
CARGNRYWYFDVW (or a truncated variant of CARGNRYWYFDV or
CARGNRYWYFD), possibly due to contamination, and were excluded from further
analysis. Further excluded were two clones that had over 20% mutation in the V-region,
due to incorrect V-gene assignment.
For all further analysis of both human and murine data, clones in each subject/subset
combination were only included if they contained more than half the mean frequency of
copies in that subject/subset.
Quantification and statistical analyses: All p values were determined using one of the
following as mentioned in figure legends: unpaired non-parametric t-test or one-way
ANOVA with Tukey post hoc test, paired t-test or repeated measures ANOVA with Tukey
post hoc test, or Spearman correlation, using GraphPad Prism version 7 or version 8
(GraphPad Software, La Jolla, CA 92037 USA). *p < 0.05, **p < 0.01, ***p < 0.001. Data
are represented as mean ± SEM. The number of mice and human subjects used in each
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experiment, as well as the exact number of times an experiment was repeated, is
mentioned in the figure legends
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CHAPTER 4: PERSPECTIVE

4.1 Investigating cellular differentiation in the immune system
Cellular differentiation is the principle problem in metazoan biology, and in my
graduate work I have tried to address the question of how and to what extent
lymphocytes differentiate in the establishment and functioning of the adaptive immune
system. In order to function properly, the immune system requires the establishment of
diverse cell-types. These cell-types result from the continual differentiation of
hematopoietic stem cells throughout life, but the mechanisms that forge unique cell
identity are still unclear. Despite the diversity, this range of cell-types alone is not
sufficient to ensure functional immune responses to the wide variety of pathogenic
insults encountered. As such, further differentiation and specialization of effector and
memory immune cells is required to carry out the type of immune response best suited
to the specifics of the pathogen challenge. However, extending the hematopoietic tree
beyond the naïve lymphocyte stage to the mature subsets of an ongoing immune
response cannot be done without firmly understanding their differentiative relationships
and the stability of their identity. The problem of differentiation in the immune system is
then two-fold: 1) to uncover the mechanisms leading to unique and stable cell identity
and 2) to identify new subsets and define the developmental relationships between the
diverse cell-types.
Questions about the control of cell identity have been long on the minds of
embryologists and seeking answers to these questions has led to the understanding that
chromatin acts as a biochemical filter for developmental cell-types by determining which
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genes are transcribed into RNA (329). The application of genome-wide techniques such
as ChIP-seq and ATAC-seq to differentiated cell-types in the hematopoietic system
reveal that chromatin states vary profoundly between hematopoietic lineages and are
more closely tied to cell identity than gene expression (119, 330). However, the
chromatin states of mature cell-types are not pre-established in progenitors, begging the
question of how they are established. Therefore, I first set out to address the question of
how the chromatin state of a cell identity is shaped during development. Significant work
had been done on erythrocyte (331, 332), macrophage (106), and B cell development
(104, 333), but comparatively little work had been done on T cell development. As such,
I focused my attention on T lymphopoiesis. As the proteins that modify histones are nonspecific, they must be guided by sequence-specific transcription factors to cell-specific
loci (334, 335). However, sequence-specific transcription factors are occluded by
nucleosomes and cell-specific loci are not accessible in progenitors (119, 336-338). We
hypothesized that a special class of transcription factors, uninhibited by nucleosomal
DNA, acts during T cell development to create chromatin accessibility for the
establishment of a T cell chromatin state and the activation of a T cell program.
Therefore, we set out to examine the DNA sequences of developmentally regulated T
cell chromatin to identify this mystery transcription factor.
4.2 Mechanisms of shaping epigenetic cellular identity in T cell development
By investigating genome-wide measurements of accessibility at multiple T cell
developmental stages we found that T cell-specific accessible chromatin defining T cell
identity is more enriched for TCF motifs compared to the motifs of other developmentally
important transcription factors. Further, T cell-specific chromatin was highly bound by
TCF-1 and deletion of TCF-1 severely abrogated the accessibility of T cell chromatin in
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the few surviving DP T cells. The chromatin accessibility mediated by TCF-1 regulated
components of the T cell gene program and changes to accessibility were reflected by a
compromised transcriptome including downregulation of important T cell genes such as
Bcl11b and others. At the single cell level, TCF-1 enforced a coordinate accessibility
among individual cells whereas sites bound by other transcription factors were more
heterogeneous in the population. Finally, ectopic expression of TCF-1 in fibroblasts
converted inaccessible T cell-specific heterochromatin into active and accessible
chromatin and induced expression of T cell-specific genes.
Previously, TCF-1 was shown to induce the gene program of T cell specification
in bone marrow progenitors even in the absence of Notch signaling (121). The question
then arises of whether TCF-1 initiates a T cell gene program that has been primed in the
chromatin of bone marrow progenitors prior to settling in the thymus. Our results indicate
the opposite. Inasmuch as we could measure it, chromatin accessibility in bone marrow
progenitors (as measured in CLPs in this study) was devoid of most T cell accessible
chromatin. Thus, it is likely that the T cell specification events mediated by TCF-1 is the
result of sweeping changes to chromatin that make the T cell gene program possible.
Consistent with this notion, we observed a profound increase in accessibility between
the CLP and ETP stage where TCF-1 is first induced to high levels of expression from
Notch1 signaling (136).
Together, our results indicate that TCF-1 acts as a lineage-determining
transcription factor to create accessible T cell chromatin and shape the epigenetic
identity of T cells. More broadly, our results suggest that the adoption of cell identity
during hematopoiesis is more than just the adoption of a specific gene program but is
established through extensive chromatin changes outnumbering even gene expression
changes. Similar conclusions have been drawn in other developmental contexts in
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hematopoiesis and embryogenesis (330, 338, 339). Moreover, our results indicate that
this process of development is carried out by lineage-specific transcription factors that
make lineage-specific chromatin accessible to organize the more ubiquitous transcription
factors to function at lineage-specific gene loci.
Transcription factors that mediate the selection and accessibility of chromatin
have been termed ‘pioneer transcription factors’ (PTFs) (2) or ‘lineage-determining
transcription factors’ (LDTFs) (3). Both labels describe transcription factors that act
before other transcription factors to establish lineage-specific accessible chromatin. The
difference between them is that PTFs have been shown to have an intrinsic biochemical
affinity to nucleosomal DNA (340), usually mediated through a special protein domain
(341), whereas LDTFs have not. The activity of TCF-1 during T cell development is
consistent with these descriptions, especially of the LDTF class. Although we have not
yet shown the binding of purified TCF-1 to nucleosomal DNA arrays in vitro, our results
in the fibroblast model demonstrated that almost half of TCF-1 binding events occurred
at a known nucleosome position, near the dyad. Thus, it is likely that TCF-1 will be
classified as a PTF in the future. In fact, a recent publication by Howard Xue’s group
demonstrated a vestigial, but functional histone deacetylase (HDAC) domain in TCF-1
(125), providing evidence of a biochemical link to the histone proteins comprising the
nucleosome. Whether this HDAC domain is required for TCF-1 to create de novo
chromatin accessibility remains to be determined.
Surprisingly, we found that β-catenin and Wnt signaling was not required for
TCF-1 to create accessible chromatin in the fibroblast model because we used the p33
isoform that does not bind β-catenin (97). The Wnt/TCF pathway is an evolutionarily
ancient signaling pathway used in multiple developmental contexts (91). The role of βcatenin in T cell development is a complex one with conflicting reports. One study found
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that β-catenin was essential for T cell development (342) whereas others show that T
cell development is largely intact in the absence of β-catenin (95, 96). Moreover, the p33
isoform has been assumed to be transcriptionally repressive because β-catenin is not
able to displace the recruitment of the Groucho/TLE family of transcriptional repressors
(93). Again, our results conflicted with this classification. We found that expression of the
p33 isoform in fibroblasts was able to create de novo chromatin accessibility and
activate T cell genes suggesting that β-catenin is not required for either function. Another
study by Howard Xue’s group suggests the role of β-catenin is limited to the regulation of
cell survival signals during positive selection but is dispensable for T cell differentiation
(343). Thus, it is possible that the effect of TCF-1 on shaping T cell chromatin and
activating T cell gene expression is largely independent from β-catenin except to
regulate a small suite of survival genes at a specific stage of development.
Because we utilized an unbiased, genome-wide approach, our analysis turned up
other unexpected findings. We found the chromatin that becomes accessible during T
cell development is dynamically regulated and becomes accessible in waves, occurring
at the ETP stage, the DN3-DN4 stage, and the mature single positive stage. The timing
corresponds to important developmental events occurring at these stages including T
cell specification, β-selection, and MHC restriction, respectively (45, 50, 121).
Importantly, TCF-1 binding events and motifs were enriched in all three waves of
accessible chromatin. Although this observation seems incongruous with the role of
TCF-1 in creating accessible chromatin, PTFs and LDTFs are known to require
additional regulatory events to specify their activity as even PTFs bind only a fraction of
their total binding sites (344). Such events could include the cooperation of other
transcription factors functioning in a combinatorial manner with TCF-1 (3). PTFs are
repelled by highly condensed heterochromatin (144), but we found that TCF-1 could
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overcome the repressive heterochromatin and establish accessibility. However, other
epigenetic factors including DNA methylation and chromatin folding could be responsible
in limiting the ability of TCF-1 to create accessible chromatin. In support of this idea, a
paper published in the same issue of Immunity by Keji Zhao’s group showed that the 3dimensional organization of the chromatin is dynamically regulated at key stages of T
cell development suggesting that the coordinated accessibility of these waves could be
the result of positive changes to the higher-order chromatin architecture (345).
4.3 TCF-1 establishes T cell chromatin during T cell development
In summary, my studies on the transcription factor TCF-1 in T cell development
has strengthened our understanding of how cell identity is managed at the chromatin
level during development. The role of TCF-1 in activating the gene program of T cell
specification has been known for several years, but our work has expanded the role of
TCF-1 beyond a simple model of gene activation. Our expanded model argues that TCF1 opens unprimed or repressed chromatin in progenitor cells to establish an accessible
and active chromatin state for the execution of a T cell gene program, and a graphical
depiction of our model is shown in Figure 13. Although our work sheds light on the
factors involved in creating a cell-specific chromatin state, it also raises additional
questions.
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Figure 13: Current working model: Forging T cell epigenetic identity using TCF-1.
In the thymus, Notch signals induce TCF-1 expression in thymic settling progenitors
such as CLP or LMPP. TCF-1 carries out T lineage specification by finding T cell-specific
CRMs buried in closed chromatin by binding its motif on nucleosome wrapped DNA.
Through an uncharacterized mechanism, TCF-1 establishes accessible chromatin at T
cell-specific CRMs, allowing the binding of additional transcription factors that are
normally repelled by the chromatin. The addition of new CRMs transforms the gene
program to induce the expression of Bcl11b for T cell commitment and Gata3 for further
T cell development. TCF-1 guides individual cells along the T cell trajectory by reducing
heterogeneity of accessibility at T cell specific CRMs and the germline removal of TCF-1
severely abrogates chromatin accessibility, reduces the T cell gene program, and
negatively impacts mature T cell function. TCF-1 is sufficient to create de novo
accessibility even in unrelated cell types such as fibroblasts suggesting that modulation
of TCF-1 levels could be used to tune the T cell chromatin state.
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4.4 Perspective on epigenetic engineering to control differentiation in immune responses
The T cell chromatin state is dependent on TCF-1, and the requirement of TCF-1
expression for robust memory CD8+ T cell responses suggests cell function beyond the
naïve stage is a function of the chromatin state established during development (122).
Recent work demonstrates that naïve, memory, effector, and exhausted CD8+ T cells
have unique chromatin identities, but the epigenetic profile of naïve and memory CD8+ T
cells share many features including enrichment for TCF motifs (113-115). Conversely,
the accessible chromatin of effector and exhausted CD8+ T cells, which do not express
TCF-1, lack TCF motifs suggesting that restoring TCF-1 expression could revert the
chromatin state of these cells to a naïve or memory state and restore immune function
and durability. The epigenetic reprogramming of immune cells to modulate aspects of
their function and survival has major therapeutic potential.
However, the transcription factors and regulatory events responsible for creating
different chromatin states between effector and memory subsets are not fully elucidated.
Unique chromatin states are established in a stepwise fashion through the hierarchical
activity of transcription factors to induce a distinct and stable gene program. Thus,
identifying the transcription factors that define cell identity requires an understanding of
the developmental sequence and the relationship between subsets. Generally, there is
much less acceptance over the developmental relationships of effector and memory cell
subsets beyond the naïve stage for both T and B cells. Part of the reason for this is the
many different types of effector and memory cells that can develop from the different
types of pathogens that can be encountered, Therefore, defining the developmental
trajectory of these subsets is a major open-ended question. In the second half of my
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graduate work I set to work on defining the differentiative relationships between subsets
of memory B cells resolved by the transcription factor T-bet.
4.4 Cellular differentiation in the memory B cell response
We used a Tbx21 transcriptional reporter to track T-bet expression in influenza
hemagglutinin (HA)-specific B cells at various time-points after PR8 infection. We
determined that T-bet- and T-bet+ HA-specific B cells arose early, acquired a germinal
center phenotype, and persisted long-term where both subsets acquired the memory B
cell markers CD73, PD-L2, and CD80. We also noted that the T-bet+ population was
composed of T-bethi and T-betlo subsets with T-bethi memory B cells (MBCs) having a
different anatomic distribution and recirculation properties in mice and humans
compared to T-betlo and T-bet- MBCs. Thus, we found that T-bethi MBCs were restricted
to the spleen while T-betlo and T-bet- MBCs circulated throughout all secondary lymphoid
organs. Through parabiosis, we determined that T-bethi MBCs were spleen-resident
whereas T-betlo and T-bet- MBCs circulated freely. To assess the differentiative
relationship between T-bet+ and T-bet- MBCs we performed a clonal analysis by IgH
sequencing and found that most clones were not shared between the subsets. In the
instances where we found clonal sharing, lineage tree analysis revealed that clonal
daughters eventually adopted either T-bet+ or a T-bet- fate. Further fate-mapping using
an inducible Tbx21 fate-mapping mouse confirmed the stability of the T-bet+ fate. Finally,
B cell expression of T-bet was important for the humoral response to influenza and B
lineage deletion of T-bet caused a reduction in influenza-specific antibody titers,
especially to the HA stalk.
Previously, Naradikian et al. (274) determined that the signals necessary to
engender a T-bet+ B cell phenotype include BCR signaling, B cell intrinsic nucleic-acid
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detection through TLR engagement, and TH1 inflammatory cytokine signals. Moreover, a
TH2-mediated response does not produce T-bet+ B cells. Influenza is an RNA virus that
produces a TH1-mediated response (346), and our results confirm that influenza infection
meets the conditions necessary to generate T-bet+ B cells. In the presence of IFNγ and
TLR7/9 agonists, T-bet expression occurs within 48 hours of B cell activation in vitro
suggesting that T-bet expression is an effector phenotype linked to the events of B cell
activation. Analogously, B cells in vivo adopt an activated T-bet+ effector phenotype
likely driven by BCR cross-linking with TLR7/9 signals and induced by IFNγ or IL-21
produced by TFH during a TH1-type response (274). The events of signaling, and not an
intrinsic activation program, drive the differentiation of T-bet+ B cells, and the adoption of
a T-bet+ effector phenotype does not appear to be confined to a certain pre-immune or
antigen-experienced subset of B cells. Thus, the differentiation of T-bet+ effector B cells
result from the integration of innate and adaptive activation signals with inflammatory
cytokines in unrestricted B cell populations.
By tracking antigen-specific B cells, our results extend previous findings by
demonstrating that T-bet+ B cells that arise during infection persist as a stable memory
pool. Therefore, the description of T-bet+ B cells is not confined to recently activated
effector B cells but also encompasses bona fide memory cells in both mice and humans.
Although definitive MBC markers in mice are lacking, expression of CD73, CD80, and
PD-L2 have been demonstrated on MBCs generated with an alum-adjuvanted haptencarrier response (267, 268). In mice, we found that nearly all HA-specific T-bet+ and Tbet- B cells express these MBC markers by day 100 post infection and are maintained at
a steady state, consistent with memory cell identity. Our results indicate MBCs are not a
monolithic population but are composed of discrete subsets that reflect fate choices
shaped by the events of early infection and differentiate according to pathogen-driven
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cues. However, our results also indicate that T-bet+ and T-bet- memory pools are distinct
and do not interchange, and T-bet+ MBCs do not arise from T-bet- MBCs or vice versa.
Thus, the effector functions selected during the humoral response are perpetuated by
the differentiation of distinct pools of long-lived memory cells.
B cells expressing T-bet have been described as “Age-associated B cells”
(ABCs) and are driven by similar innate and adaptive signals in both normal and
autoimmune humoral responses (347). Moreover, ABCs require cognate help from
CD40/CD40L interactions to form, suggesting they are the product of T dependent B cell
responses. Confirming this notion, we observed that T-bet+ B cells had a GC phenotype,
formed long-lived memory cells, and were hypermutated—processes that require T cell
help. Using the immune response to influenza, our results suggest that ABCs,
regardless of their setting of generation, are a durable MBC population. Moreover, we
found that T-bethi MBCs were spleen-resident in mice and increased in proportion with
age in human spleens suggesting that studies on T-bethi B cells isolated from the blood
alone may not be an accurate representation of the ABC pool in either settings of normal
immune responses or autoimmunity. Indeed, some have noted that T-bethi ABCs
isolated from the blood reflect an activated, effector phenotype rather than a memory
phenotype and, when isolated from the blood, do not demonstrate a proportional
increase with age in humans (348). Thus, studies on this critical population underlying
normal and autoimmune humoral responses need to be conducted in the tissues such
as the spleen rather than the circulation where possible.
The function of the T-bet+ MBC subset is unknown as of yet. The role of memory
B cells in humoral immunity may appear redundant alongside established plasma cells
and elevated antibody titers. However, memory B cells act as a second line of defense
through rapid reactivation and differentiation into plasma cells (349-351). Thus, the
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secondary humoral response is typically faster, of greater magnitude, and consists of
isotype-switched antibodies of higher affinity. The characteristics of the secondary
response are thought to be the consequence of the activity of MBCs, although some
aspects have been challenged recently (352). Nonetheless, MBCs make up a large
proportion of the peripheral B cell pool in adults. Moreover, the role of MBCs in recall
responses may contribute to the phenomenon of Original Antigenic Sin (OAS) or the reemergence of autoimmune antibodies after B cell depletion (353-356). Thus, the role of
T-bet+ MBCs in these aspects of the recall response needs to be addressed.
We show that MBC subsets are functionally divided by their anatomic distribution
and recirculation properties with T-bet- and T-betlo MBCs recirculating freely and T-bethi
MBCs residing in the spleen. The functional significance of T-bethi tissue residency is
unknown. Tissue-resident memory T cells, which survey intracellular environments, are
thought to mediate rapid effector responses to local antigen reencounter (357).
Presumably, soluble antigen recirculates more rapidly than the migration of cells and
antibodies freely diffuse through the blood. Therefore, the significance of resident
memory B cells is unclear, but is an emerging and active area of research (291).
However, the residency of T-bethi MBCs in the spleen may be related to their function.
The spleen is a unique secondary lymphoid organ that surveys both the circulatory and
lymphatic systems. Thus, we speculate the splenic-residency of T-bethi MBCs may
function to support rapid recall and differentiation to antibody secreting cells, especially
when antigens are mobilized in circulating lymph and/or blood in a manner similar to the
function of marginal zone B cells. Indeed, a study by Shlomchik’s group has
demonstrated that T-bet+ MBCs reside in the marginal sinus and appear to displace
marginal zone B cells (358). Degradation of the marginal sinus structure with age has
been reported previously, and we speculate the accumulation of ABCs may be at least
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partially responsible for this decline (359, 360). Experiments addressing the tissue
localization and the plasma cell potential of T-bethi MBCs can help answer these
questions.
4.5 T-bet+ memory B cells arise independently from T-bet- memory B cells
A clear function for B cell expression of T-bet in the humoral response is to
facilitate isotype-switching to IgG2c (294-301), and our results were consistent with this
function. Importantly, we did not see an increase in IgG1 titers, a T-bet independent
isotype, in the absence of B lineage T-bet expression. Moreover, nearly all of the
antibodies specific to the HA-stalk were IgG2c. In conjunction with the clonal and fatemapping analysis, these results suggest that T-bet+ B cells do not develop from the Tbet- pool. Instead, we propose that T-bet+ and T-bet- B cells mostly arise independently,
and our model is described in Figure 14. In a linear model of differentiation, cells adopt
an alternative identity from the accumulation of, or increased exposure to, a
differentiative factor. In the absence of the differentiative factor, cells do not differentiate
but remain, nonetheless. Our results indicate that the development of T-bet+ MBCs does
not follow a linear differentiation model but instead follows an ‘all-or-none’ model. Thus,
when T-bet is deleted in the B lineage, most HA-specific titers are absent and are not
produced by a T-bet independent subset of MBCs.
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Figure 14: Current working model: The differentiation of T-bet+ memory B cell
subsets
T-bet+ B cells differentiate early as a distinct pool from T-bet- B cells after influenza
infection. T-bet+ B cells possess unique specificities including the stalk of influenza
hemagglutinin, and the expression of T-bet facilitates isotype switching to IgG2a/c. Both
T-bet+ and T-bet- pools enter germinal centers, undergo somatic hypermutation, and
persist indefinitely as memory B cells. However, they possess different recirculation
properties and tissue distributions in mice and humans. T-betlo and T-bet- memory B
cells recirculate through the blood and lymphatics whereas T-bethi memory B cells are
spleen resident. Without B cell expression of T-bet, neutralizing titers to influenza fail to
be maintained and the bulk of the influenza-specific antibody response is absent.
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4.6 Perspective on the future research of T-bet+ B cells
An alternative explanation to the reduced HA-specific titers in the absence of B
lineage T-bet expression is a potential role of T-bet+ MBCs in generating or maintaining
plasma cells (318). In the humoral response, pathogen-specific titers can remain
elevated and provide protection either through the establishment of LLPCs or the
continual differentiation of SLPCs from an effector or memory pool (256). No T-bet+
plasma cell subset has been identified and it is well accepted that plasma cells do not
express T-bet. Thus, T-bet dependent antibody responses depend on the differentiation
of T-bet+ B cells into plasma cells while losing T-bet expression in the process. We
identified T-betlo and T-bethi subsets with different circulatory properties and hypothesize
that T-bethi B cells are a tissue-resident stem-like pool that populate the circulating Tbetlo pool on the way to plasma cell differentiation. A recent study by the Winslow group
demonstrates that T-bet+ memory B cells are multipotent, supporting this hypothesis
(311). Indeed, preliminary results in the lab indicate established T-bethi MBCs turnover
and differentiate into T-betlo MBCs and eventually plasma cells when adoptively
transferred. A progenitor-successor relationship between T-bethi MBCs, T-betlo MBCs,
and plasma cells suggests that supporting or reducing antibody production from T-bet+ B
cell populations requires targeting the spleen-resident T-bethi MBC pool.
Finally, what is the nuclear role of T-bet? As a transcription factor, T-bet binds to
the DNA in a sequence-specific manner to regulate the expression of genes (361).
However, transcription factor activity is filtered by the chromatin state and T-bet does not
appear to be sufficient or necessary to alter the chromatin state (111). A recent study by
the Lund group (362) has demonstrated that the chromatin state of T-bet+ B cells is
considerably different from the chromatin state of T-bet- B cells in an influenza response
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suggesting that unique modes of gene regulation operate in T-bet+ cells. Identifying the
transcription factors that act in the T-bet+ chromatin landscape and the gene loci
regulated by unique T-bet+ B cell CRMs will provide insight into their regulatory program
as well their function.
Naturally, future research will likely focus on the mechanisms that establish the
unique T-bet+ chromatin state. However, when setting out to understand the regulatory
events leading to the divergent chromatin states of T-bet+ and T-bet- B cells, it must be
noted that our results demonstrate that T-bet+ MBCs do not develop from T-bet- MBCs.
Epigenetic cell identity is built progressively by the incremental activity of transcription
factors on the chromatin. Therefore, an in-depth analysis of the establishment of T-bet+
cells should not focus primarily on the chromatin differences between T-bet+ and T-betMBCs, but on the events leading to the adoption of a T-bet+ fate. The transcriptional
events downstream of TLR signaling and/or inflammatory cytokine signaling are a good
place to start because STATs can shape the chromatin landscape (111). As suggested
by my investigation on immune cell identity at the chromatin level and the differentiative
relationships between immune cell subsets as outlined in this thesis, the establishment
of unique chromatin identity is best decoded when the fate choices and lineage
relationships between subsets are properly understood.
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Figure S1. TCF-1 binding occurs at three waves of chromatin remodeling during T
cell development, Related to Figure 2
(A) Accessible regulatory elements were identified in mouse across multiple cell types
including progenitors (HSC, MPP and CLP), T cell development (ETP, DN2a, DN2b,
DN3, DN4, DP, CD4+ and CD8+ SP) and non-T cell lineages (B and NK) using bulk
ATAC-seq data. Peaks were called with macs2 and their reproducibility was assessed
using IDR. Accessible regions were filtered based on annotated gene promoters (see
STAR methods) into distal and proximal regulatory elements. Proximal elements were
filtered out and the remaining 55,481 regions were clustered into 24 groups with kmeans using the FDR value in each sample as a proxy of ATAC-seq enrichment. Black
arrows indicate clusters that have been filtered out from the final set of regions shown in
Figure 2A.
(B) ATAC-seq profiles (+/- 2kb window) around summits of all 20 k-means clusters
identified in mouse from Figure 2A.
(C) Top three enriched motifs from de novo motif analysis using HOMER on all clusters
in Figure 2A.
(D) Clustering of accessible regulatory elements based on public ATAC-seq data in
human HSC, MPP, CLP, B, NK, CD4+ and CD8+ T cells. Peaks were called with macs2.
Due to the lack of replicates, IDR assessment of peak reproducibility was not feasible.
Normalized tag counts were used as a proxy of ATAC-seq enrichment to identify clusters
(see STAR methods). HOMER facilitated the de novo motif discovery in different
clusters.
(E) Pathway analysis for genes proximal to clusters 9, 19, and 10 (see Figure 2A).
(F) Distribution of the expression levels for genes proximal to clusters 9, 19, and 10
using microarray data from ImmGen.
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Figure S2
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Figure S2. TCF-1-deficient DP T cells cannot establish the open chromatin
landscape and transcriptional output of normal DP T cells, Related to Figure 3
(A-B) Pairwise Pearson correlation plots for replicates in (A) ATAC-seq and (B) RNAseq experiments in WT and Tcf7–/– DP T cells.
(C) Volcano plot demonstrating differentially regulated gene expression in WT and Tcf7–
/–

DP T cells. DESeq2 was used to identify 1,167 down- and 1,293 up-regulated (fold-

change > 1.5 and p-value < 1e-3) in Tcf7–/– DP T cells.
(D) Example of ATAC- and RNA-seq profiles from WT and Tcf7–/– DP T cells in Adam19
locus.
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Figure S3
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Figure S3. TCF-1 binding coordinates open chromatin between single DP T cells,
Related to Figure 4
(A-B) Examples of live/dead stained cells captured with Fluidigm C1 platform.
(C) Fragment size periodicity from scATAC-seq data derived from single DP T cells.
(D) Single DP T cells plotted based on two quality assessment metrics derived from
scATAC-seq samples. Single cell libraries containing less than 10,000 fragments or with
less than 15% of their fragments falling in open chromatin did not reach the minimum
quality criteria. Together, we performed three independent single-cell captures and 110
T cells at the DP stage passed various quality control thresholds.
147

148

Figure S4. TCF-1 can bind to nucleosomes and create chromatin accessibility in
fibroblasts, Related to Figure 5
(A) Ectopic expression of TCF-1 in NIH3T3 using retroviral transduction and subsequent
verification of expression by intracellular staining and flow cytometry.
(B) Log10 TCF-1 peak score as defined by the IDR package in replicates of ChIP-seq in
TCF-1 RV NIHT3T3. Red signifies peaks that fail to pass the IDR cutoff while black
reflects the reproducible subset of TCF-1 peaks in multiple thresholds.
(C) K-means clustering (k=3) of TCF-1 summits based on the normalized MNase-seq
enrichment in three non-overlapping 200bp windows centered around summits (see
Figure 5).
(D) Distribution of distance between TCF motifs unbound by TCF-1 (red) and uniquely
bound by TCF-1 ChIP-seq (green) in TCF-1 RV NIH3T3 cells (upper panel) or DP T cells
(lower panel). Nucleosome summits were identified using Danpos2 on public MNase-seq
data in fibroblasts (see STAR methods). TCF motif occurrences were identified genomewide using FIMO and the TCF-1 PWM derived from JASPAR database. Statistical
significance of the difference between the TCF-1 bound and unbound motifs to the
nucleosome summits was calculated using a bootstrap approach (see STAR methods).
(E) Pairwise Pearson correlation plots between ATAC-seq replicates in Empty and TCF1 RV NIH3T3 cells.
(F) Nucleosome enrichment profile around TCF-1 ChIP-seq binding summits assessed
using the NucleoATAC algorithm in Empty and TCF-1 RV NIH3T3 cells (see STAR
methods).
(G) Normalized TCF-1 ChIP-seq enrichment profile around merged TCF-1 binding
events in TCF-1 RV NIH3T3 and DP T cells with a Pearson correlation coefficient of 0.3.
(H) Regions that gained accessibility in TCF-1 RV NIH3T3 were overlapped with ATACseq peaks specific to HSC, MPP, CLP, B, NK, naïve CD4+, naïve CD8+, effector CD8+
and memory CD8+ cells. “Union T cells” was generated by merging the open chromatin
regions of all T cell datasets.
(I) Enrichment analysis of TCF-1 ChIP-seq binding events in: (1) DP T cells, (2) genomic
loci that lose accessibility in Tcf7-/- DP T cells and (3) regions that gained accessibility in
TCF-1 RV NIH3T3 cells at the clusters shown in Figure 2A.
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Figure S5
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Figure S5. TCF-1 can bind to repressed chromatin and promote accessibility,
Related to Figure 6
(A) Two replicates of H3K9me3 and H3K27me3 ChIP-seq from NIH3T3 cells were
generated as well as an input control (see STAR methods) and combined with public
H3K4me3, H3K4me1 and H3K27ac in NIH3T3 and their corresponding control input.
The enrichment of histone mark signal was calculated in a window (+/- 250bp) around
TCF-1 ChIP-seq summits from TCF-1 RV NIH3T3 cells with normR algorithm and used
as input for the Principal component analysis (see Figure 6A). The enrichment of ATACseq in TCF-1 RV vs Empty RV NIH3T3 and vice versa was also calculated and used in
the same analysis.
(B) Pairwise Spearman correlation coefficient between the enrichment (A) of different
histone marks and chromatin accessibility surrounding TCF-1 ChIP-seq binding sites.
(C) Average silhouette width plot for the identification of the optimal number of clusters
when applying k-means on the adjusted significance level of enrichment of H3K4me1,
H3K4me3, H3K9me3, H3K27me3 and H3K27ac ChIP-seq signal in the 2kbp window
centered on TCF-1 ChIP-seq summits.
(D) Heatmap of the adjusted significance level of histone mark enrichment around TCF-1
summits separated into the identified 11 clusters (C). Chromatin states were defined
based on the enrichment level of each histone mark in each cluster.
(E) Wilcoxon rank-sum test to assess the statistical significance of the difference in
ATAC-seq signal enrichment between Empty and TCF-1 RV NIH3T3 in the chromatin
states from (D).
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Figure S6. T cell-specific genes innately repressed in fibroblasts are upregulated
by TCF-1, Related to Figure 7
(A) Pearson correlation plots between RNA-seq replicates in Empty RV NIH3T3 and
TCF-1 RV NIH3T3 cells for assessing the reproducibility of the data.
(B) Volcano plot demonstrating differential gene expression using DEseq2 in three RNAseq replicates of Empty RV and TCF-1 RV NIH3T3 cells with the upregulation of 1,477
genes and the downregulation of 1,295 genes (fold-change > 1.5 and p-value < 1e-3).
(C) Gene ontology analysis for thymocyte-specific genes (see Figure 7D) overlapping
TCF-1 upregulated genes in NIH3T3 (top) and thymocyte-specific genes not upregulated
by TCF-1 in TCF-1 RV NIH3T3 (bottom).
(D) RNA-seq counts on gene exons from HSC, MPP, CLP, DP, naïve CD4+ SP, naïve
CD8+ SP, effector CD8+ and memory CD8+ T cells were calculated for genes
upregulated by TCF-1 in TCF-1 RV NIH3T3 cells (B). Genes were clustered in 12 groups
using k-means after reducing the heteroskedasticity of the data by applying variancestabilizing transformation with DESeq2. We subsequently calculated normalized
expression values (RPKM) for filtering lowly expressed genes (RPKM < 0.5 in all
hematopoietic cell types) and visualizing the results. Cluster 1 was excluded from any
further analysis due to low expression levels.
(E) Boxplots of the normalized gene expression levels (D) with representative examples
for each cluster.
(F) TCF-1 is sufficient to upregulate TCF-1 dependent T cell genes in fibroblasts. Genes
downregulated in Tcf7-/- DP T cells (see Figure S2) were overlapped with genes
upregulated by TCF-1 RV in NIH3T3 and the statistical significance of the enrichment
was calculated with Fisher’s exact test.
(G) TCF-1 ChIP-seq summits (see Figure 5A) were assigned to chromatin states (see
Figure 6B) and linked to proximal genes (STAR methods). The enrichment of
downregulated genes by TCF-1 within each chromatin state was assessed with Fisher’s
exact test.
(H) A statistically significant (tested with Fisher’s exact test) higher proportion of genes
were proximal to TCF-1 binding events that led to gain in H3K27ac and loss of
H3K27me3/H3K9me3 modifications (Figure 6D) in contrast to those binding events that
did not alter the chromatin state.
(I) The enrichment of T cell genes in different levels of nucleosome occupancy (see
Figure 7B, S4C, and STAR methods) was calculated using Fisher’s exact test.
(J) ATAC-, RNA- and ChIP-seq (histones and TCF-1) profiles in Empty and TCF-1 RV
NIH3T3 cells in Rorc locus as an example of a key T cell gene that is innately not
expressed in fibroblasts.
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Figure S7. Characterization of HA-specific B cells after influenza infection, Related
to Figure 8.
(A) Weight loss and recovery from PR8 influenza infection in T-bet-ZsGreen mice
compared to PBS-treated controls. (B) Fluorescently-conjugated PR8 hemagglutinin
(HA) detects the precursor frequency of HA-specific B cells in naïve T-bet-ZsGreen
mice, which are uniformly T-bet-. The naïve precursor frequency per 100,000 B cells is
plotted. (C) Gating scheme for the identification of T-bet-ZsGreen mouse HA+ B cells
and subsetting into T-bet-, T-betlo, and T-bethi populations via flow cytometry. C57Bl/6
mice are included in the T-bet-ZsGreen expression plot as a control. An identical gating
scheme was used for all tissues in Figure 8. (D) Tbx21 expression in sorted T-bet-, Tbetlo, and T-bethi B cell subsets via qPCR. CD19+ B cells were sorted into the
corresponding subsets according to ZsGreen expression (C), and RNA was isolated and
cDNA prepared for qRT-PCR analysis. (E) Number of HA+ B cells in peripheral and
mesenteric lymph nodes by T-bet expression phenotype at different time points after
infection; mice are the same as in Figure 8B. (F) Expression of GL7 and CD95 on T-betand T-bet+ splenic HA+ B cells at the indicated time points post PR8 infection. (G) The
percentage of HA+ B cells that are GL7+CD38- in the mediastinal LN and lungs of T-betZsGreen mice 100 days post PR8 infection, and the percentage that are T-bet+ in each
tissue (top). Data in (D) are plotted as mean ± SEM. HA+ B cells were identified as live,
singlet, DUMP-, B220+, CD19+, IgD-, HA-AF647+, HA-BV421+ cells. DUMP gate includes
CD4, CD8, Gr-1, and F4/80.
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Figure S8. Characterization of human B cell subsets, Related to Figure 9.
(A) Gating scheme for the identification of human peripheral blood CD19+ B cells via
flow cytometry. An identical gating scheme and identical gates were used for all tissues
in Figure 9. (B) Memory (IgD-/IgD+CD27+) phenotype of total CD19+ and T-bethi B cells
from spleen of a representative donor. (C) Identification of naïve (CD21+IgD+CD27-) and
CD21+ memory (IgD-/IgD+CD27+) B cells in paired peripheral blood (PB) and thoracic
duct fluid (TD) from a representative donor. Memory cells are further subsetted into
IgM+CD27+, IgM-CD27+, and IgM-CD27-. (D and E) Frequency of naive B cells (D) and
CD21+ memory subsets (E) gated in (C) within paired PB and TD sample cohort (n=8).
(F) Identification of HA-specific, class-switched (IgD-IgM-) B cells within CD19+CD38low
mesLN B cells using fluorescently-labelled A/California/07/2009 HA probe (H1 strain) or
a A/Wisconsin/67/2005 HA probe (H3 strain). (G and H) Correlation between frequency
of T-bethi phenotype within class-switched H1-binding (G) or H3-binding (H) B cells and
subject age. Subjects are the same as in Figure 9I; those without age information were
omitted from this analysis. (I) IgG1, IgG2, IgG3, and IgA expression profile by classswitched H1-HA+ splenic B cells from a representative human donor. Statistical
comparisons performed using paired t-test (D and E) and Spearman correlation (G and
H). N.S. = not significant, **p<0.01. Credit goes to James J. Knox for generating this
figure.
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Figure S9

# HA+ MBCs (x103)

3

*

CD45.2+CD8+

**

2

B

Spleen
ZsGreen
B6.SJL

**

1

%Tbet+CXCR3+

A

10

ns

5
0

0
Tbet–

Tbetlo

Tbethi

Spleen

Figure S9. Enumeration of HA-specific B cells in parabiotic partners, Related to
Figure 10.
(A) Absolute numbers of T-bet-, T-betlo and T-bethi HA+ splenic MBCs in ZSGreen (red)
and B6.SJL (black) parabiosis partners from Figure 10. (B) The percent of splenic donorderived CD8+ T cells that are T-bet-ZsGreen+CXCR3+ in each partner ≥17 days of
parabiosis from 8 parabiotic pairs. Statistical comparisons performed using paired twotailed t-test. ns = not significant, *p<0.05, **p<0.01
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Figure S10. Immune repertoire analysis by IgH sequencing, Related to Figure 11.
(A) Models regarding the possible origin of T-bet+ and T-bet- MBCs and their
distinguishing characteristics. (B) Scheme for sorting T-bet+ and T-bet- HA-specific
MBCs from negatively depleted, CD19+IgD-HA+ splenocytes 90 days post HA mRNA
LNP immunization. (C) HAI titers at 21 days post immunization. (D) Gating scheme for
the sorting of human splenic IgD-IgM-HA+ memory B cell subsets, defined by CD21 and
CD85j expression. (E and F) VH gene usage in mice (E) and humans (F) computed
based upon clonal usage (each clone is only counted once). Sequencing libraries from
the same subject (human or mouse) and subset were pooled. Clones having less than
half the mean copy number frequency within that subject/subset sequencing library were
excluded from the analysis. Clones from the same species and subset were then pooled.
Gray cells indicate no data and the VH usage was normalized by subset in both panels.
Clone counts for mice (E) are HA+T-bet+ 1,605; HA+T-bet- 1,993; and IgD+ 21,889. Clone
counts for humans (F) are HA+CD21+ 5,739; HA+CD21-CD85jhi 2,018; HA-CD21+ 31,396;
HA-CD21-CD85jhi 21,442; and SPL 10,125. (G and H) Cosine similarity between
sequencing replicates of each subset and between subsets in mice (G) and humans (H).
Statistical comparisons in (G) and (H) performed using paired t-test, *p<0.05.
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